0001858685
false
--12-31
0001858685
2024-02-19
2024-02-19
0001858685
BFRI:CommonStockParValue0.001PerShareMember
2024-02-19
2024-02-19
0001858685
BFRI:PreferredStockPurchaseRightsMember
2024-02-19
2024-02-19
0001858685
BFRI:WarrantsToPurchaseCommonStockMember
2024-02-19
2024-02-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): February
19, 2024
Biofrontera
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40943 |
|
47-3765675 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
120
Presidential Way,
Suite
330
Woburn,
Massachusetts |
|
01801 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (781)
245-1325
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, par value $0.001 per share |
|
BFRI |
|
The
Nasdaq Stock Market LLC |
Preferred
Stock Purchase Rights |
|
|
|
The
Nasdaq Stock Market LLC |
Warrants
to purchase common stock |
|
BFRIW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01 |
Entry
into a Material Definitive Agreement. |
On
February 19, 2024, the Company entered into a securities purchase agreement (the
“Purchase Agreement”) with certain accredited investors (the
“Preferred Investors”), pursuant to which the Company agreed to issue
and sell, in a private placement (the “Offering”), (i) 6,586 shares of
Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “Series B-1
Preferred Stock”), and (iii) warrants (the “Preferred
Warrant”) to purchase shares of Series B-3 Convertible Preferred Stock, par value $0.001 per share (the “Series
B-3 Preferred Stock”) for an aggregate offering price of $8.0 million. Each share of Series B-1 Preferred Stock was
sold for $1,000 per share and the consideration for each Preferred Warrant was $0.125 per share of common stock that each share of
Series B-3 Preferred Stock may be converted into.
Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock, which is filed
as Exhibit 3.1 to this Current Report on Form 8-K (the “Certificate of Designation”), each share of Series B-1 Preferred
Stock is, subject to the Stockholder Approval (as defined below), automatically convertible into shares of the Company’s common
stock, par value $0.001 per share (the “Common Stock”) and/or, if applicable, shares of Series B-2 Preferred Stock,
par value $0.001 per share, of the Company (the “Series B-2 Preferred Stock” and together with the Series B-1 Preferred
Stock, the “Issued Preferred Stock”), in lieu of Common Stock.
The
aggregate exercise price of the Preferred Warrants is approximately $8.0 million, exercisable for an aggregate of 8,000 shares of
Series B-3 Preferred Stock commencing on the Exercisability Date (as defined in the Form of Preferred Warrant) until the earlier of
(i) 5 days following the date of completion of (A) the Company’s public announcement of
(I) at least 95% of the Company’s territory managers, medical science liaisons, and reimbursement employees are using
the Company’s customer relationship management system routinely or on a performance improvement plan and (II) the
Company’s revenue for the period starting on January 1, 2024 and ending no earlier than April 30, 2024 excluding revenue from
related parties (including Biofrontera AG) is at least 5% higher than the Company’s revenue excluding revenue from related
parties (including Biofrontera AG) for the corresponding period of the same length, starting on January 1, 2023, which
announcement shall be made promptly after certification by the Company’s board of directors that such targets have been
completed, and (B) the Stockholder Approval, and (C) the effectiveness of a registration statement with the U.S. Securities and
Exchange Commission covering the resale of the Common Stock underlying all shares of Series B-3 Preferred Stock (as defined below)
and (ii) February 22, 2027
Subject
to the terms and limitations contained in the Certificate of Designation, the shares of the Series B-1 Preferred Stock issued in the
Offering are immediately convertible and the Series B-3 Preferred Stock issuable upon exercise of the Warrants issued in the
Offering will not become convertible until the Company’s stockholders approve (i) the issuance of all Common Stock issuable
upon conversion of the Issued Preferred Stock and the Series B-3 Preferred Stock or the Series B-3 Preferred Stock upon exercise of
the Preferred Warrants to the extent required under the Nasdaq listing rules, (iii) an increase to the Company’s authorized
share capital (collectively, the “Stockholder Approval”). Each share of Series B-1 Preferred Stock shall automatically
convert into Common Stock, at the conversion price of $0.7074 per share, subject to the terms and limitations contained in the
Certificate of Designation. Subject to the limitations set forth in the Certificate of Designation, at the option of the holder,
each share of Series B-2 Preferred Stock or Series B-3 Preferred Stock shall also be convertible into Common Stock, at the
conversion price of $0.7074 per share, rounded down to the nearest whole share, and in each case
subject to the terms and limitations contained in the Certificate of Designation.
The Offering closed on February 22, 2024.
The gross proceeds of the Offering were approximately $8.0 million, before deducting fees paid to the placement agent
of the Offering and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering
for working capital purposes and other general corporate purposes and ongoing activities related to expediting the development and approval of additional indications for Ameluz®.
Pursuant
to the Purchase Agreement and as soon as practicable following the date of the Stockholder Approval, the Company shall appoint two independent
director to the Company’s board of directors who are designated by Rosalind Advisors, Inc.
Pursuant
to the Purchase Agreement, as soon as practicable following the closing (a “Filing Date”) (and in any event no later
than 15 days thereafter), the Company shall file a registration statement providing for the resale by the Preferred Investors of the
Common Stock issuable upon conversion of the Series B-1 Preferred Stock and to use commercially reasonable efforts to have the registration
statement declared effective within 21 days following the Filing Date (or, in the event that the staff of the Securities and Exchange
Commission reviews and has written comments to such registration statement, within the later of (a) 45 days following the Filing Date
and (b) 15 days following the last comment received from the Staff of the Securities and Exchange Commission). In addition, as soon as
practicable following the receipt of the Stockholder Approval (also, a “Filing Date”) (and in any event no later than
three days thereafter), the Company shall file a registration statement providing for the resale by the Preferred Investors of the Common
Stock issuable upon conversion of the Registrable Shares (as defined in the Purchase Agreements, as applicable) and to use commercially
reasonable efforts to have the registration statement declared effective within 21 days following the Filing Date (or, in the event that
the staff of the Securities and Exchange Commission reviews and has written comments to such registration statement, within the later
of (a) 45 days following the Filing Date and (b) 15 days following the last comment received from the Staff of the Securities and Exchange
Commission). The Company further agreed to take all steps necessary to keep such registration statement effective at all times until
all Registrable Shares have been resold, or there remains no Registrable Shares.
The
Purchase Agreement contains certain representations and warranties, covenants and indemnities customary for similar transactions. The
representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the
Purchase Agreement and may be subject to limitations agreed upon by the contracting parties.
The
Offering was conducted pursuant to a Placement Agency Agreement, dated February 19, 2024 (the “Placement Agency Agreement”),
between the Company and Roth Capital Partners, LLC (the “Placement Agent”). The Placement Agent has no obligation
to purchase any of the securities or to arrange for the purchase or sale of any specific number or dollar amount of securities. The Company
has agreed to pay: (i) the Placement Agent a cash fee equal in total to an aggregate of 7.0% of the gross proceeds raised in the offering
from sales of the Common Stock, Series B-1 Preferred Stock and Warrants, (ii) the Placement Agent a cash fee equal in total to 7.0% of
the gross proceeds raised in the offering from the exercise, if any, of the Preferred Warrants, and (iii) reimbursement for certain expenses,
including counsel to the Placement Agent, up to an aggregate of $125,000.
The
securities issued in the Offering have not been registered under the Securities Act of 1933, as amended (the “Securities Act”),
and until so registered the securities may not be offered or sold absent registration or availability of an applicable exemption from
registration. There is no established public trading market for the Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series B-3
Preferred Stock or Preferred Warrants and the Company does not intend to list such securities on any national securities exchange or
nationally recognized trading system.
The
form of the Preferred Warrant and the Purchase Agreement are filed as Exhibits 4.1 and 10.3, respectively, to this Current Report on
Form 8-K. The foregoing summaries of the terms of the Certificate of Designation, the Series B-1 Preferred Stock, the Series B-2 Preferred
Stock, the Series B-3 Preferred Stock and the Preferred Warrant Shares and the terms of the Purchase Agreement are subject to, and qualified
in their entirety by, the full text of such documents, where applicable, which are incorporated herein by reference.
No
statement in this report or the attached exhibits is an offer to sell or a solicitation of an offer to purchase the Company’s securities,
and no offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
Item
3.02 Unregistered Sales of Equity Securities.
The
information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. The Common Stock, Series B-1 Preferred
Stock and Preferred Warrants are being sold and, upon exercise the securities underlying the Preferred Warrants and the Common Stock
and Series B-2 Preferred Stock issuable upon conversion of the Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series B-3
Preferred Stock will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2)
of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to
accredited investors, and in reliance on similar exemptions under applicable state laws.
Item
3.03 Material Modification to Rights of Security Holders
The
information in response to Item 5.03 below is incorporated by reference in response to this Item 3.03.
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Series
B Preferred Stock
The
information contained above in Item 1.01 is hereby incorporated by reference into this Item 5.03.
Pursuant
to the terms of the Purchase Agreement, on February 20, 2024, the Company filed the Certificate of Designation with the Delaware Secretary
of State designating 6,586 shares of its authorized and unissued preferred stock as Series B-1 Preferred Stock, 6,586 shares as Series
B-2 Preferred Stock and 8,000 shares as Series B-3 Convertible Preferred Stock (all such series of preferred stock referred to herein
collectively as “Series B Preferred Stock”), each with a stated value of $1,000 per share (the “Original
Per Share Price”). The Certificate of Designation sets forth the rights, preferences and limitations of the shares of Series
B Preferred Stock. Terms not otherwise defined in this item shall have the meanings given in the Certificate of Designation.
The
following is a summary of the terms of the Series B Preferred Stock:
Voting
Rights. Subject to certain limitations described in the Certificate of Designation, the Series B Preferred Stock is voting stock.
Holders of the Series B Preferred Stock are entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock basis.
Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders.
Accordingly, holders of Series B Preferred Stock will be entitled to one vote for each whole share of Common Stock into which their Series
B Preferred Stock is then-convertible on all matters submitted to a vote of stockholders.
Unless
and until the Company has obtained the Stockholder Approval, the number of shares of Common Stock that shall be deemed issued upon conversion
of the Series B Preferred Stock (for purposes of calculating the number of aggregate votes that the holders of Series B Preferred Stock
are entitled to on an as-converted basis) will be equal to that number of shares equal to 9.9% of the Company’s outstanding Common
Stock as of the Signing Date (excluding for purposes of the calculation, any securities issued on the Signing Date) (the “Cap”),
which each such holder being able to vote the number of shares of Series B Preferred Stock held by it relative to the total number of
shares of Series B Preferred Stock then outstanding multiplied by the Cap. Notwithstanding the foregoing, the holders of the Series B
Preferred Stock are not entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock-basis with regard to the
approval of the issuance of units upon conversion of the Series B-1 Preferred Stock and the issuance of all Common Stock upon conversion
of the Series B Preferred Stock.
Conversion.
Prior to the Stockholder Approval, the Series B Preferred Stock is not convertible in excess of the Cap. Following the Stockholder
Approval, each share of Series B-1 Preferred Stock will automatically convert into either Common Stock or, to the extent the conversion
would cause a holder to exceed their beneficial ownership limitation, shares of Series B-2 Preferred Stock.
Liquidation.
Prior to the Stockholder Approval, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company,
including a change of control transaction, or Deemed Liquidation Event (any such event, a “Liquidation”) the holders
of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution
to its stockholders, and in the event of a Deemed Liquidation Event, the holders of shares of Series B Preferred Stock then outstanding
shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or the other proceeds
available for distribution to stockholders, before any payment shall be made to the holders of any other shares of capital stock of the
Company by reason of their ownership thereof, an amount per share equal to the greater of (i) three times the Original Per Share Price,
together with any dividends accrued but unpaid thereon (the “Liquidation Preference”) or (ii) such amount per share
as would have been payable had all shares of Series B Preferred Stock been converted into Common Stock (without regard to any limitations
on conversion set forth in the Certificate of Designation or otherwise) immediately prior to such Liquidation (the amount payable pursuant
to this sentence is hereinafter referred to as the “Series B Liquidation Amount”). If upon any such Liquidation, the
assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series B Preferred
Stock the full Liquidation Preference, the holders of shares of Series B Preferred Stock shall share ratably in any distribution of the
assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held
by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. After the payment in full
of all Series B Liquidation Amount, the remaining assets of the Company available for distribution to its stockholders or, in the case
of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Series B Preferred Stock pursuant to the Certificate
of Designation shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each
such holder.
Following
the Stockholder Approval, upon any Liquidation, the assets of the Company available for distribution to its stockholders shall be distributed
among the holders of the shares of Series B Preferred Stock and Common Stock, pro rata based on the number of shares held by each such
holder, treating for this purpose all shares of Series B Preferred Stock as if they had been converted to Common Stock pursuant to the
terms of the Certificate of Designation immediately prior to such Liquidation, without regard to any limitations on conversion set forth
in the Certificate of Designation or otherwise.
Redemption.
Unless prohibited by Delaware law governing distributions to stockholders, in the event the Stockholder Approval is not obtained
within one year following the Issuance Date, shares of Series B-1 Preferred Stock shall be redeemed by the Company at a price equal to
the then Liquidation Preference at any time for up to three years following the Issuance Date commencing not more than 60 days after
receipt by the Company at any time on or after the one year anniversary of the Issuance Date of written notice from the holders of a
majority of the then outstanding shares of Series B-1 Preferred Stock, voting together as a single class (the “Redemption Request”)
requesting redemption of all shares of Series B-1 Preferred Stock (such date, the “Redemption Date”). Upon receipt
of a Redemption Request, the Company shall apply all of its assets to any such redemption, and to no other corporate purpose, except
to the extent prohibited by Delaware law governing distributions to stockholders. On the Redemption Date, the Company shall redeem, on
a pro rata basis in accordance with the number of shares of Series B-1 Preferred Stock owned by each holder, the total number of shares
of Series B-1 Preferred Stock outstanding immediately prior to the Redemption Date; provided, however, that Excluded Shares (as defined
in the Certificate of Designation) shall not be redeemed and shall be excluded from the calculations set forth in this sentence. If,
on the Redemption Date, Delaware law governing distributions to stockholders prevents the Company from redeeming all shares of Series
B-1 Preferred Stock to be redeemed, the Company shall ratably redeem the maximum number of shares that it may redeem consistent with
such law, and shall redeem the remaining shares as soon as it may lawfully do so under such law.
Participation
Right. For a period of one year following closing of the transactions, the purchasers will have the right to participate as an
investor in any securities offering consummated by the Company.
The
foregoing summary of the terms of the Series B Preferred Stock is qualified in its entirety by reference to the text of the Certificate
of Designation, which is filed hereto as Exhibit 3.1 and is incorporated herein by reference.
Item
7.01 Regulation FD Disclosure
On
February 23, 2024, the Company issued a press release announcing the closing of the Offering, a copy of which is attached hereto as
Exhibit 99.2.
The
information in Item 7.01 of this Current Report is being furnished and shall not be deemed “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item
7.01 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended.
Item
8.01 Other Events.
On
February 22, 2024, concurrent with the closing of the Offering, each purchaser delivered a notice of initial conversion requesting that
the Company convert the Series B Preferred Stock they had acquired in the Offering up to the Cap (as defined in the Certificate of Designation)
for each purchaser.
As
a result of this conversion, the Company issued 2,516,785 shares of the Company’s common stock to the purchasers and as of February
22, 2024 the total number of the Company’s outstanding shares of common stock is 5,089,413 and the total number of the Company’s
outstanding shares of Series B-1 Convertible Preferred Stock is 4,806.
Item
9.01 |
Financial
Statements and Exhibits. |
3.1 |
Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock |
4.1 |
Form of Series B-3 Convertible Preferred Stock Warrant |
10.1* |
Form of Securities Purchase Agreement, dated February 19, 2024, by and amount Biofrontera Inc. and the purchasers named therein |
10.2* |
Placement
Agency Agreement, dated February 19, 2024, by and between Biofrontera Inc. and Roth Capital Partners, LLC |
99.1 |
Press release with, dated February 23, 2024 |
104 |
Cover
Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
* |
Certain schedules and similar attachments have been
omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplement copies of any of the omitted schedules
upon request by the SEC. |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
February
23, 2024
(Date) |
|
Biofrontera
Inc.
(Registrant) |
|
|
|
|
By: |
/s/
E. Fred Leffler III |
|
|
E.
Fred Leffler III |
|
|
Chief
Financial Officer |
Exhibit
3.1
BIOFRONTERA,
INC.
Certificate
of Designation of Preferences, Rights and Limitations
of
Series
B Convertible Preferred Stock
Pursuant
To Section 151 of the Delaware General Corporation Law
BIOFRONTERA
INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the
Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accordance with Sections 141(c)
and 151 of the DGCL, the following resolution was duly adopted by a committee of the Board of Directors of the Corporation acting upon
authority delegated by the Board of Directors, which resolution remains in full force and effect on the date hereof:
RESOLVED,
pursuant to authority expressly set forth in the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”),
the issuance of a series of Preferred Stock designated as the Series B Convertible Preferred Stock, par value $0.001 per share, of the
Corporation is hereby authorized and the designation, number of shares, powers, preferences, rights, qualifications, limitations and
restrictions thereof (in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred
Stock of all classes and series) are hereby fixed, and the Certificate of Designation of Preferences, Rights and Limitations of Series
B Convertible Preferred Stock is hereby approved as follows:
SERIES
B CONVERTIBLE PREFERRED STOCK
Section
1. Definitions. For the purposes hereof, the following terms shall have
the following meanings:
“Affiliate”
means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under
common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act of 1933. With
respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment manager as
such Holder will be deemed to be an Affiliate of such Holder.
“Business
Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
“Commission”
means the U.S. Securities and Exchange Commission.
“Common
Stock” means the Corporation’s common stock, par value $0.001 per share, and stock of any other class of securities
into which such securities may hereafter be reclassified into.
“Conversion
Date” means the date on which the Series B Preferred Stock is converted pursuant to Section 6.
“Conversion
Price” for:
(i)
the Series B-1 Preferred Stock shall be $0.7074 per share of Common Stock,
(ii)
for the Series B-2 Preferred Stock shall be $0.7074 per share of Common Stock and
(iii)
for the Series B-3 Preferred Stock shall be $0.7074 per share of Common Stock,
in
each case subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization.
“Conversion
Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B Preferred Stock
in accordance with the terms hereof.
“Cap”
means, (a) with respect to a conversion of the Series B Preferred Stock, the number of shares equal to 9.99% of the Corporation’s
outstanding Common Stock as of the date on which the shares
are issued in a conversion of the Series B Preferred Stock (including any other shares that are issued on the same date upon the conversion
of Series B Preferred Stock by other Holders) and (b) with respect to the number of shares that may be voted by a Holder, the number
of shares equal to a 9.99% beneficial ownership of the Corporation’s outstanding Common Stock as calculated in accordance with
Rule 13d-3 of the Securities and Exchange Act of 1934, as amended.
“Deemed
Liquidation Event” means (a) a merger or consolidation in which (i) the Corporation is a constituent party or (ii) a subsidiary
of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation,
except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation
outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of
capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital
stock of (1) the surviving or resulting corporation; or (2) if the surviving or resulting corporation is a wholly owned subsidiary of
another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation;
or (b) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions,
by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries
taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation
if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries,
except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation.
“DGCL”
shall mean the Delaware General Corporation Law.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Excluded
Shares” has the meaning set forth in Section 9(b).
“Holder”
means any holder of Series B Preferred Stock.
“Issuance
Date” means February 20, 2024.
“Maximum
Permitted Rate” has the meaning set forth in Section 9(d).
“Original
Per Share Price” means $1,000 per share.
“Person”
means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Proposals”
has the meaning set forth in Section 8.
“Redemption
Date” has the meaning set forth in Section 9(a).
“Redemption
Notice” has the meaning set forth in Section 9(b).
“Redemption
Price” has the meaning set forth in Section 9(a).
“Redemption
Request” has the meaning set forth in Section 9(a).
“Requisite
Approval” means the date that the Corporation’s stockholders first approve the Proposals relating to the issuance
of the Conversion Shares.
“Requisite
Holders” means Holders of a majority of the then outstanding shares of Series B Preferred Stock, voting together as a single
class.
“Series
B Preferred Stock” has the meaning set forth in Section 2(a).
“Series
B-1 Preferred Stock” has the meaning set forth in Section 2(a).
“Series
B-2 Preferred Stock” has the meaning set forth in Section 2(a).
“Series
B-3 Preferred Stock” has the meaning set forth in Section 2(a).
“Share
Conversion Number” has the meaning set forth in Section 6(b)(i).
“Signing
Date” means the effective date of that certain Securities Purchase Agreement for the purchase and sale of the Series B
Preferred Stock and Warrants.
Series B Certificate of Designation | Page 2 |
“Trading
Day” means a day on which the Common Stock is traded for any period on a principal securities exchange or if the Common
Stock is not traded on a principal securities exchange, on a day that the Common Stock is traded on another securities market on which
the Common Stock is then being traded.
“Warrant”
means a warrant to purchase shares of Series B-3 Preferred Stock at an exercise price of $1,000 per share of Series B-3 Preferred Stock.
“Voting
Conversion Price” means for the Series B Preferred Stock shall be the lowest of (i) the Nasdaq Official Closing Price of
the Common Stock immediately preceding the Signing Date and (iii) the average Nasdaq Official Closing Price of the Common Stock for the
five trading days immediately preceding the Signing Date.
Section
2. Designation, Amount and Par Value; Assignment; Ranking.
(a)
The distinctive serial designations of the series of Preferred Stock designated by this Certificate of Designation shall be designated
as the Corporation’s Series B-1 Convertible Preferred Stock (the “Series B-1 Preferred Stock”), the Series
B-2 Convertible Preferred Stock (the “Series B-2 Preferred Stock”) and the Series B-3 Convertible Preferred
Stock (the “Series B-3 Preferred Stock” and, together with the Series B-1 Preferred Stock and Series B-2 Preferred
Stock, the “Series B Preferred Stock”). Each share of Series B Preferred Stock shall be identical in all respects
to every other share of Series B Preferred Stock, except as set forth herein. The number of shares of Series B-1 Preferred Stock so designated
shall be 6,586, the number of shares of Series B-2 Preferred Stock so designated shall be 6,586 and the number of shares
of Series B-3 Preferred Stock so designated shall be 8,000. The Series B Preferred Stock shall have a par value of $0.001 per
share.
(b)
The Corporation shall register shares of the Series B Preferred Stock, upon records to be maintained by the Corporation’s transfer
agent for that purpose (the “Series B Preferred Stock Register”), in the name of the Holders thereof from time
to time. The Corporation and its transfer agent may deem and treat the registered Holder of shares of Series B Preferred Stock as the
absolute owner thereof for the purpose of any conversion thereof and for all other purposes. Shares of Series B Preferred Stock may be
issued solely in book-entry form. The Corporation or its transfer agent shall register the transfer of any shares of Series B Preferred
Stock in the Series B Preferred Stock Register, upon surrender of the shares of Series B Preferred Stock evidencing such shares to be
transferred, to the Corporation’s transfer agent. Upon any such registration or transfer, a new or book-entry notation evidencing
the shares of Series B Preferred Stock so transferred shall be issued to the transferee and a new book-entry notation evidencing the
remaining portion of the shares not so transferred, if any, shall be issued to the transferring Holder, in each case, within two Business
Days. The provisions of this Certificate of Designation are intended to be for the benefit of all Holders from time to time and shall
be enforceable by any such Holder.
(c)
Prior to the Requisite Approval, the Series B Preferred Stock will be senior to the Common Stock and all other series or classes of stock
and equity securities of the Corporation with respect to dividend rights and rights on the distribution of assets on any voluntary or
involuntary Liquidation, dissolution or winding up of the affairs of the Corporation.
Section
3. Dividends.
(a)
At all times following the Issuance Date, while shares of Series B Preferred Stock are issued and outstanding, holders of Series B Preferred
Stock shall be entitled to receive, and the Corporation shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-Common-Stock
basis and without regard to any limitations on conversion set forth herein or otherwise) to and in the same form as dividends actually
paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. If such dividends are not declared
and paid in cash, the dividend amounts will be added to the aggregate Liquidation Preference then outstanding of the Series B Preferred
Stock (such dividends will accumulate and will be included (i) in the payments made upon redemption or Liquidation and (ii) for purposes
of conversion and voting, but not to exceed 19.9% of the number of shares of Common Stock outstanding as of the Signing Date without
the Requisite Approval).
Series B Certificate of Designation | Page 3 |
Section
4. Voting Rights.
(a)
Subject to the last sentence of this Section 4(a), Section 4(b) and Section 6(f), the Series B Preferred Stock is voting stock. Holders
of the Series B Preferred Stock are entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock basis as determined
by dividing the Liquidation Preference with respect to such shares of Series B Preferred Stock by the Voting Conversion Price. Holders
of Common Stock are entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders. Accordingly,
holders of Series B Preferred Stock will be entitled to one vote for each whole share of Common Stock into which their Series B Preferred
Stock is then-convertible on all matters submitted to a vote of stockholders. Unless and until the Corporation has obtained the Requisite
Approval, the number of shares of Common Stock that shall be deemed issued upon conversion of the Series B Preferred Stock (for purposes
of calculating the number of aggregate votes the Holders of Series B Preferred Stock are entitled to on an as-if-converted basis) will
be equal to that number of shares equal to the Cap, which each such holder being able to vote the number of shares of Series B Preferred
Stock held by it relative to the total number of shares of Series B Preferred Stock then outstanding multiplied by the Cap. Notwithstanding
the foregoing, the Holders of the Series B Preferred Stock are not entitled to vote together with the Common Stock on an as-if-converted-to-Common-Stock-basis
on the Proposals set forth in Section 8(i) herein.
(b)
In addition to Section 4(a), prior to the Requisite Approval, neither the Corporation nor any of its subsidiaries shall take any of the
following actions without the consent of the Requisite Holders:
(i)
effect any Liquidation;
(ii)
materially change the nature of the Corporation’s business;
(iii)
amend or waive any provisions of their respective organizational documents in a manner that adversely and disproportionately affects
the rights, preferences, privileges or power of the shares of Series B Preferred Stock;
(iv)
issue additional equity securities senior to or pari passu with the Series B Preferred Stock;
(v)
pay any dividends on the Common Stock or any equity securities junior to or pari passu with the Series B Preferred Stock or repurchase
any equity interests (other than repurchases of, or dividends paid (including through payment-in-kind) on, the shares of Series B Preferred
Stock or dividends paid solely in the form of equity securities junior to the Series B Preferred Stock);
(vi)
enter into or be a party to any transaction with any director, officer, or employee of the Corporation or any “associate”
(as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person or entity except for transactions made in the ordinary
course of business and pursuant to reasonable requirements of the Corporation’s business and upon fair and reasonable terms that
are approved by a majority of the Corporation’s Board of Directors;
(vii)
sell, assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted in the ordinary
course of business; or
(viii)
enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Corporation or to the Corporation
of money or assets greater than $1,000,000.
Section
5. Liquidation.
(a)
Prior to the Requisite Approval, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation,
including a change of control transaction, or Deemed Liquidation Event (any such event, a “Liquidation”) the
holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available
for distribution to its stockholders, and in the event of a Deemed Liquidation Event, the holders of shares of Series B Preferred Stock
then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or the
other proceeds available for distribution to stockholders, before any payment shall be made to the holders of any other shares of capital
stock of the Corporation by reason of their ownership thereof, an amount per share equal to the greater of (i) three times (3X) the Original
Per Share Price, together with any dividends declared but unpaid thereon (the “Liquidation Preference”) or
(ii) such amount per share as would have been payable had all shares of Series B Preferred Stock been converted into Common Stock (without
regard to any limitations on conversion set forth herein or otherwise) pursuant to Section 4 immediately prior to such Liquidation (the
amount payable pursuant to this sentence is hereinafter referred to as the “Series B Liquidation Amount”).
If upon any such Liquidation, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay
the holders of shares of Series B Preferred Stock the full Liquidation Preference, the holders of shares of Series B Preferred Stock
shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would
otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares
were paid in full. After the payment in full of all Series B Liquidation Amount, the remaining assets of the Corporation available for
distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares
of Series B Preferred Stock pursuant to the paragraph above shall be distributed among the holders of shares of Common Stock, pro rata
based on the number of shares held by each such holder.
Series B Certificate of Designation | Page 4 |
(b)
Following the Requisite Approval, upon any Liquidation, the assets of the Corporation available for distribution to its stockholders
shall be distributed among the holders of the shares of Series B Preferred Stock and Common Stock, pro rata based on the number of
shares held by each such holder, treating for this purpose all shares of Series B Preferred Stock as if they had been converted to
Common Stock pursuant to the terms of this Certificate of Designation immediately prior to such Liquidation, without regard to any
limitations on conversion set forth herein or otherwise.
Section
6. Conversion.
(a)
Limitations on Conversion. Prior to the receipt of the Requisite Approval, subject to Section 4(a) above, the Series B Preferred
Stock is not convertible by the Holder thereof in excess of the Cap.
(b)
Automatic Conversion. Subject to the limitations set forth in Section 6(f), on the first Trading Day following the announcement
of the Requisite Approval (the “Automatic Conversion Date”), each share of Series B-1 Preferred Stock shall
automatically convert into the number of shares of Common Stock equal to the quotient of (A) the Original Per Share Price divided by
(B) the Conversion Price (the “Share Conversion Number”), provided that, to the extent the Share Conversion
Number would cause such Holder’s beneficial ownership to exceed the Maximum Percentage (as defined below), such Holder shall receive
shares of Series B-2 Preferred Stock in lieu of Common Stock, with respect to the number of shares of Common Stock that would result
in the Share Conversion Number exceeding the Maximum Percentage, calculated by dividing such excess shares by $1,000.
(c)
Conversions at Option of Holder. Subject to Section 6(b) and the limitations set forth in Section 6(f), at the option of the Holder
thereof, each share of Series B-2 Preferred Stock and Series B-3 Preferred Stock shall be convertible into shares of Common Stock at
the applicable Conversion Price, rounded down to the nearest whole share.
(d)
Mechanics of Conversion.
(i) Notice
of Conversion. Holders shall effect conversions by providing the Corporation and its transfer agent with the form of conversion
notice attached hereto as Annex A-1, Annex A-2 or Annex A-3, as applicable (each a “Notice of
Conversion”), duly completed and executed. The Notice of Conversion must specify the number of shares of Series B-2
Preferred Stock or Series B-3 Preferred Stock to be converted, the number of shares of Series B-2 Preferred Stock or Series B-3
Preferred Stock owned prior to the conversion at issue, and the number of shares of Common Stock to be issued in respect of the
conversion at issue. Provided the Corporation’s transfer agent is participating in the Depository Trust Company
(“DTC”) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the
Holder’s election, whether the applicable Conversion Shares shall be credited to the DTC participant account nominated by the
Holder through DTC’s Deposit Withdrawal Agent Commission system (a “DWAC Delivery”). The date on
which such a conversion shall be deemed effective (an “Optional Conversion Date”, and together with the
Automatic Conversion Date, a “Conversion Date”), shall be defined as the Trading Day that the Notice of
Conversion, completed and executed, is sent by facsimile or other electronic transmission to, and received during regular business
hours by, the Corporation and its transfer agent. The calculations set forth in the Notice of Conversion shall control in the
absence of manifest or mathematical error.
Series B Certificate of Designation | Page 5 |
(ii)
Delivery of Electronic Issuance Upon Conversion. Not later than two Trading Days after the applicable Conversion Date (the “Share
Delivery Date”), the Corporation’s transfer agent shall (a) in the case of a DWAC Delivery (if so requested by the
Holder), electronically transfer such Conversion Shares by crediting the DTC participant account nominated by the Holder through DTC’s
DWAC system or (b) if the shares of Series B Preferred stock being converted have been issued in global form eligible for book-entry
settlement with DTC, the Conversion Shares shall be delivered to the Holder through book-entry transfer through the facilities of DTC.
If in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share
Delivery Date, the applicable Holder shall be entitled to elect to rescind such Conversion Notice by written notice to the Corporation
and its transfer agent at any time on or before its electronic receipt of such shares, as applicable, in which event the Corporation’s
transfer agent shall promptly direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing
the shares of Series B Preferred Stock unsuccessfully tendered for conversion to the Corporation.
(iii)
Obligation Absolute. Subject to Holder’s right to rescind a Conversion Notice pursuant to Section 6(d)(ii) above, the Corporation’s
obligation to issue and deliver the Conversion Shares upon conversion of Series B Preferred Stock in accordance with the terms hereof
are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect
to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim,
recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation
or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might
otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Nothing
herein shall limit a Holder’s right to pursue actual damages for the Corporation’s failure to deliver Conversion Shares within
the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief; provided that Holder shall not receive duplicate
damages for the Corporation’s failure to deliver Conversion Shares within the period specified herein. The exercise of any such
rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.
(iv)
Compensation for Buy-In on Failure to Timely Deliver Shares Upon Conversion. If the Corporation fails to effect a DWAC Delivery,
as applicable, by the Share Delivery Date pursuant to Section 6(d)(ii) (other than a failure caused by incorrect or incomplete information
provided by Holder to the Corporation), and if after such Share Delivery Date such Holder is required to or otherwise purchases (in an
open market transaction or otherwise), shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares
which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a “Buy-In”),
then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder)
the amount by which (x) such Holder’s total purchase price (including any brokerage commissions) for the shares of Common Stock
so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive from
the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed
(including any brokerage commissions) and (B) at the option of such Holder, either reissue (if surrendered) the shares of Series B-2
Preferred Stock or Series B-3 Preferred Stock, as applicable, equal to the number of shares of Series B-2 Preferred Stock or Series B-3
Preferred Stock, as applicable, submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have
been issued if the Corporation had timely complied with its delivery requirements under Section 6(d)(ii). For example, if a Holder purchases
shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of
Series B-2 Preferred Stock or Series B-3 Preferred Stock, as applicable with respect to which the actual sale price (including any brokerage
commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the
Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three Trading
Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable
confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder’s right to pursue
any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Corporation’s failure to timely deliver shares of Common Stock upon conversion of the shares
of Series B-2 Preferred Stock or Series B-3 Preferred Stock as required pursuant to the terms hereof; provided, however, that the Holder
shall not be entitled to both (i) require the reissuance of the shares of Series B-2 Preferred Stock or Series B-3 Preferred Stock submitted
for conversion for which such conversion was not timely honored and (ii) receive the number of shares of Common Stock that would have
been issued if the Corporation had timely complied with its delivery requirements under Section 6(d)(ii).
Series B Certificate of Designation | Page 6 |
(v)
Reservation of Shares Issuable Upon Conversion. The Corporation covenants that it will at all times reserve and keep available
out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B Preferred
Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series B Preferred
Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of
Section 7) upon the conversion of all outstanding shares of Series B Preferred Stock. Such reservation shall comply without regard to
the provisions of Section 6(f). The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue,
be duly authorized, validly issued, fully paid, non-assessable and free and clear of all liens and other encumbrances.
(vi)
Fractional Shares. No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the conversion
of the Series B Preferred Stock. All fractional shares shall be rounded down to the nearest whole shares of Common Stock.
(vii)
Transfer Taxes. The issuance of book entry notations for Conversion Shares shall be made without charge to any Holder for any
documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such book entry notation, provided that
the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery
of any such book entry notation upon conversion in a name other than that of the registered Holder(s) of such shares of Series B Preferred
Stock and the Corporation shall not be required to issue or deliver such book entry notation unless or until the Person or Persons requesting
the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation
that such tax has been paid.
(e)
Status as Stockholder. Upon each Conversion Date in which the Series B Preferred Stock converts into Common Stock: (i) the shares
of Series B Preferred Stock being converted shall be deemed converted into shares of Common Stock; and (ii) the Holder’s rights
as a holder of such converted shares of Series B Preferred Stock shall cease and terminate, excepting only the right to receive book
entry notations for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such
Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the holder
shall retain all of its rights and remedies for the Corporation’s failure to convert Series B Preferred Stock.
Series B Certificate of Designation | Page 7 |
(f)
Limitations on Conversion. Except as set forth in this Section 6(f), a Holder shall not have the right to convert any portion
of the Series B Preferred Stock and such Series B Preferred Stock shall not be automatically converted, to the extent that after giving
effect to such conversion, such Holder (together with such Holder’s Affiliates, any other Persons acting as a group together, and
any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s and the other Attribution Parties
for purposes of Section 13(d) of the Exchange Act (such Persons, “Attribution Parties”)) would beneficially
own in excess of 9.99% (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after
giving effect to such conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially
owned by such Person and its Affiliates shall include the number of shares of Common Stock issuable upon conversion of the Series B Preferred
Stock with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be
issuable upon (i) exercise of the remaining, unconverted portion of the Series B Preferred Stock beneficially owned by such Person and
its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation beneficially
owned by such Person and its Affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants)
subject to a limitation on conversion or exercise analogous to the limitation contained herein. For purposes of this Section 6(f), in
determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as
reflected in (1) the Corporation’s most recent Form 10-K, Proxy Statement, Form 10-Q, Current Report on Form 8-K or other public
filing with the Commission, as the case may be, (2) a more recent public announcement by the Corporation or (3) any other notice by the
Corporation or the Corporation’s transfer agent setting forth the number of shares of Common Stock outstanding. For any reason
at any time, upon the written or oral request of a Holder, where such request indicates that it is being made pursuant to this Section
6(f), the Corporation shall within one Trading Day confirm orally and in writing to such Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Corporation, including the Series B Preferred Stock, by a Holder and its Affiliates since the date as
of which such number of outstanding shares of Common Stock was reported. Upon delivery of a written notice to the Corporation, a Holder
may from time to time increase or decrease the Maximum Percentage to any other percentage (not in excess of 19.99% of the issued and
outstanding Common Stock immediately after giving effect to the issuance of the Common Stock issuable upon conversion of the Series B
Preferred Stock if exceeding that limit would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule and, notwithstanding the foregoing, in no event in excess of 49.99%)
as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the 61st day
after such notice is delivered to the Corporation and (ii) any such increase or decrease will apply only to such Holder and other Attribution
Parties and not to any other holder of Series B Preferred Stock, provided, for the avoidance of doubt, that no such decrease shall affect
the validity of any prior conversion of the Series B Preferred Stock by Holder or any Attribution Party. For purposes of clarity, the
shares of Common Stock issuable pursuant to the terms hereof in excess of the Maximum Percentage shall not be deemed to be beneficially
owned by a Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. No prior inability
to convert Series B Preferred Stock pursuant to this Section 6(f) shall have any effect on the applicability of the provisions of this
Section 6(f) with respect to any subsequent determination of whether Series B Preferred Stock may be converted. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 6(f) to the
extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended
beneficial ownership limitation contained in this Section 6(f) or to make changes or supplements necessary or desirable to properly give
effect to such limitation. The limitations set forth in this Section 6(f) shall not apply to any conversions of the Series B Preferred
that occur prior to and expressly in connection with a Deemed Liquidation Event.
Section
7. Certain Adjustments.
(a)
Stock Dividends and Stock Splits. If the Corporation, at any time while any shares of Series B Preferred Stock are outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock with respect to the then
outstanding shares of Common Stock; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; or (iii) combines
(including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares
of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock
outstanding immediately after such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this Section
7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.
(b)
Calculations. All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.
(c)
Notice to the Holders.
(i)
Adjustment to Conversion Price. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation
shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.
Series B Certificate of Designation | Page 8 |
(ii)
Other Notices. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock,
(B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation shall
authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all
of the assets of the Corporation, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash
or property, or (E) the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Corporation, then, in each case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of
conversion of the shares of Series B Preferred Stock, and shall cause to be delivered to each Holder at its last address as it shall
appear upon the stock books of the Corporation, at least ten calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice; and provided further, that in each case, the Corporation will only be required to provide such information
to the Holder if such information shall have be made known to the public prior to or in conjunction with such notice being provided to
the Holder.
Section
8. Requisite Approval. The Corporation shall, as soon as practicable following
the Issuance Date, but not more than 30 days thereafter, file a preliminary proxy statement for a vote of its stockholders to approve
(i) the issuance of all Conversion Shares to the extent required under Nasdaq Listing Rule 5635 and (ii) an increase to its authorized
share capital sufficient to permit the issuance of all Conversion Shares (collectively, the “Proposals”); provided
that the Corporation may, with the consent of the Purchasers, split stockholder approval of the Proposals into more than one
meeting so long as the preliminary proxy statement for each subsequent meeting is filed within 30 days of the immediately preceding meeting
to approve one or more of the Proposals. The Corporation shall, as soon as practicable following notification from the staff of the Commission
that it has completed its review of the preliminary proxy statement or that it will not review the preliminary proxy statement, file
and mail a definitive proxy statement for the vote of its stockholders to approve the Proposals. The Corporation covenants and agrees
that its Board of Directors shall unanimously recommend that the Proposals be approved by the Corporation’s stockholders at all
meetings in which such Proposals are considered and promptly file the necessary amendments to the Corporation’s certificate of
incorporation after the Proposals are approved. If the Corporation’s stockholders do not approve such Proposals at the first meeting
in which they are voted on by stockholders, the Corporation covenants and agrees that it will submit the Proposals for approval of the
Corporation’s stockholders at least semi-annually until such approval is obtained. From and after the time of the Requisite Approval,
the Cap shall no longer be applicable for any purposes hereof.
Section
9. Redemption by the Corporation.
(a)
General. Unless prohibited by (i) Delaware law governing distributions to stockholders or (ii) applicable stock exchange rule
or regulation, one year following the Issuance Date, shares of Series B-1 Preferred Stock shall be redeemed by the Corporation at a price
equal to the then Liquidation Preference (the “Redemption Price”) at any time for up to three years following
the Issuance Date commencing not more than 60 days after receipt by the Corporation at any time on or after the one year anniversary
of the Issuance Date from the Requisite Holders of written notice (the “Redemption Request”) requesting redemption
of all shares of Series B-1 Preferred Stock (such date, the “Redemption Date”). Upon receipt of a Redemption
Request, the Corporation shall apply all of its assets to any such redemption, and to no other corporate purpose, except to the extent
prohibited by Delaware law governing distributions to stockholders. On the Redemption Date, the Corporation shall redeem, on a pro rata
basis in accordance with the number of shares of Series B-1 Preferred Stock owned by each holder, the total number of shares of Series
B-1 Preferred Stock outstanding immediately prior to the Redemption Date; provided, however, that Excluded Shares (as defined below)
shall not be redeemed and shall be excluded from the calculations set forth in this sentence. If on the Redemption Date Delaware law
governing distributions to stockholders prevents the Corporation from redeeming all shares of Series B-1 Preferred Stock to be redeemed,
the Corporation shall ratably redeem the maximum number of shares that it may redeem consistent with such law, and shall redeem the remaining
shares as soon as it may lawfully do so under such law.
Series B Certificate of Designation | Page 9 |
(b)
Redemption Notice. The Corporation shall send written notice of the mandatory redemption (the “Redemption Notice”)
to each holder of record of Series B-1 Preferred Stock not less than 40 days prior to the Redemption Date. The Redemption Notice shall
state:
(i)
the number of shares of Series B-1 Preferred Stock held by the holder that the Corporation shall redeem on the Redemption Date specified
in the Redemption Notice;
(ii)
the Redemption Price;
(iii)
the date upon which the holder’s right to convert such shares terminates (which shall be the date that is one Business Day immediately
preceding the Redemption Date); and
(iv)
for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place designated,
his, her or its certificate or certificates representing the shares of Series B-1 Preferred Stock to be redeemed.
If
the Corporation receives, on or prior to the 20th day after the date of delivery of the Redemption Notice to a holder of Series
B-1 Preferred Stock, written notice from such holder that such holder elects to be excluded from the redemption provided in this Section
9, then the shares of Series B-1 Preferred Stock registered on the books of the Corporation in the name of such holder at the time of
the Corporation’s receipt of such notice shall thereafter be “Excluded Shares.” Excluded Shares shall
not be redeemed or redeemable pursuant to this Section 9, whether on the Redemption Date or thereafter.
(c)
Surrender of Certificates; Payment. On or before the Redemption Date, each holder of shares of Series B-1 Preferred Stock to be
redeemed on the Redemption Date, unless such holder has exercised his, her or its right to convert such shares as provided in Section
6, shall, if a holder of shares in certificated form, surrender the certificate or certificates representing such shares (or, if such
registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably
acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the
alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption
Notice, and thereupon the Redemption Price for such shares shall be payable to the order of the person whose name appears on such certificate
or certificates as the owner thereof. In the event less than all of the shares of Series B-1 Preferred Stock represented by a certificate
are redeemed, a new certificate, instrument, or book entry representing the unredeemed shares of Series B-1 Preferred Stock shall promptly
be issued to such holder.
(d)
Interest. If any shares of Series B-1 Preferred Stock are not redeemed for any reason on the Redemption Date, all such unredeemed
shares shall remain outstanding and entitled to all the rights and preferences provided herein, and the Corporation shall pay interest
on the Redemption Price applicable to such unredeemed shares at an aggregate per annum rate equal to 10% (increased by 1% (i.e, from
10% to 11%) each month following the Redemption Date until the Redemption Price, and any interest thereon, is paid in full), with such
interest to accrue daily in arrears and be compounded annually; provided, however, that in no event shall such interest exceed the maximum
permitted rate of interest under applicable law (the “Maximum Permitted Rate”), provided, however, that the
Corporation shall take all such actions as may be necessary, including without limitation, making any applicable governmental filings,
to cause the Maximum Permitted Rate to be the highest possible rate. In the event any provision hereof would result in the rate of interest
payable hereunder being in excess of the Maximum Permitted Rate, the amount of interest required to be paid hereunder shall automatically
be reduced to eliminate such excess; provided, however, that any subsequent increase in the Maximum Permitted Rate shall be retroactively
effective to the Redemption Date to the extent permitted by law.
Series B Certificate of Designation | Page 10 |
(e)
Rights Subsequent to Redemption. If the Redemption Notice shall have been duly given, and if on the Redemption Date the Redemption
Price (including any accrued and unpaid interest as provided in Section 9(d) above) payable upon redemption of the shares of Series B-1
Preferred Stock to be redeemed on the Redemption Date is paid or tendered for payment or deposited with an independent payment agent
so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Series
B-1 Preferred Stock so called for redemption shall not have been surrendered, dividends with respect to such shares of Series B-1 Preferred
Stock shall cease to accrue after the Redemption Date and all rights with respect to such shares shall forthwith after the Redemption
Date terminate, except only the right of the holders to receive the Redemption Price (plus accrued and unpaid interest as provided in
Section 9(d) above) upon surrender of any such certificate or certificates therefor.
Section
10. Miscellaneous.
(a)
Waiver; Amendment. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation
shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of
this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence
to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any
other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation.
Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the
contrary, any provision contained herein and any right of the Holders of Series B Preferred Stock granted hereunder may be waived or
amended, subject to agreement with the Corporation as required, as to all shares of Series B Preferred Stock (and the Holders thereof)
upon the written consent of the Holders of a majority of the shares of Series B Preferred Stock then outstanding, unless a higher percentage
is required by the DGCL, in which case the written consent of the Holders of not less than such higher percentage shall be required.
Any waiver or amendment effected in accordance with this Section 10(a) shall
be binding on all the Holders of Series B Preferred Stock, and all of such party’s successors and permitted assigns, whether
or not any such party, successor or assignee entered into or approved such waiver or amendment.
(b)
Severability. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate
of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain
applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder
violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the
maximum rate of interest permitted under applicable law.
(c)Next
Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall
be made on the next succeeding Business Day.
(d)
Headings. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation
and shall not be deemed to limit or affect any of the provisions hereof.
(e)
Status of Converted Series B Preferred Stock. If any shares of Series B Preferred Stock shall be converted or redeemed by the
Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated
as Series B Preferred Stock.
********************
Series B Certificate of Designation | Page 11 |
IN
WITNESS WHEREOF, Biofrontera Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible
Preferred Stock to be executed by its duly authorized officer this February 20, 2024.
|
/s/ E. Fred Leffler, III |
|
By: |
E. Fred Leffler, III |
|
Title:
|
Chief Financial Officer |
Series B Certificate of Designation | Page 12 |
ANNEX
A-1
NOTICE
OF CONVERSION
(To
Be Executed by the Registered Holder
in
Order to Convert Shares of Series B-1 Preferred Stock)
The
undersigned Holder hereby irrevocably elects to convert the number of shares of Series B-1 Preferred Stock indicated below, represented
by book-entry notation in the register of the transfer agent, into the number of shares of Common Stock of Biofrontera Inc., a
Delaware corporation (the “Corporation”), equal to the Share Conversion Number, provided that, to the extent
the Share Conversion Number causes such Holder to exceed the Maximum Percentage (as defined in Section 6(f) of the Certificate of Designation),
such Holder shall receive shares of Series B-2 Preferred Stock in lieu of the Share Conversion Number, as of the date written below.
If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable
with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain
Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “Certificate
of Designation”) filed by the Corporation with the Delaware Secretary of State on February 20, 2024.
The
undersigned Holder’s right to convert the shares of Series B-1 Preferred Stock is subject to the Maximum Percentage described in
Section 6(f) of the Certificate of Designation. Therefore, the number of shares of Common Stock beneficially owned by the undersigned
Holder (together with any Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series
B-1 Preferred Stock subject to this Notice of Conversion, but excluding (i) exercise of the remaining, unconverted portion of the Series
B-1 Preferred Stock beneficially owned by such Person and its Attribution Parties and (ii) exercise or conversion of the unexercised
or unconverted portion of any other securities of the Corporation beneficially owned by such Person and its Attribution Parties (including,
without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein, is 9.99%.
Conversion
calculations:
Date
to Effect Conversion: |
|
Number
of shares of Series B-1 Preferred Stock owned prior to Conversion: |
|
Number
of shares of Series B-1 Preferred Stock to be Converted: |
|
Number
of Units to be Issued: |
|
Address
for delivery of physical certificates: |
|
OR |
|
for
DWAC Delivery: |
|
DWAC
Instructions: |
|
Broker
no: |
|
Account
no: |
|
HOLDER: |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
Date: |
|
|
Series B Certificate of Designation | Page 13 |
ANNEX
A-2
NOTICE
OF CONVERSION
(To
Be Executed by the Registered Holder
in Order to Convert Shares of Series B-2 Preferred Stock)
The
undersigned Holder hereby irrevocably elects to convert the number of shares of Series B-2 Preferred Stock indicated below, represented
by book-entry notation in the register of the transfer agent,, into shares of Common Stock of Biofrontera Inc., a Delaware corporation
(the “Corporation”), as of the date written below. If securities are to be issued in the name of a person other
than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined
herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations
of Series B Convertible Preferred Stock (the “Certificate of Designation”) filed by the Corporation with the
Delaware Secretary of State on February 20, 2024.
The
undersigned Holder’s right to convert the shares of Series B-2 Preferred Stock is subject to the Maximum Percentage described in
Section 6(f) of the Certificate of Designation. Therefore, the number of shares of Common Stock beneficially owned by the undersigned
Holder (together with any Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series
B-2 Preferred Stock subject to this Notice of Conversion, but excluding (i) exercise of the remaining, unconverted portion of the Series
B Preferred Stock beneficially owned by such Person and its Attribution Parties and (ii) exercise or conversion of the unexercised or
unconverted portion of any other securities of the Corporation beneficially owned by such Person and its Attribution Parties (including,
without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein, is 9.99%.
Conversion
calculations:
Date
to Effect Conversion: |
|
Number
of shares of Series B-2 Preferred Stock owned prior to Conversion: |
|
Number
of shares of Series B-2 Preferred Stock to be Converted: |
|
Number
of Units to be Issued: |
|
Address
for delivery of physical certificates: |
|
OR |
|
for
DWAC Delivery: |
|
DWAC
Instructions: |
|
Broker
no: |
|
Account
no: |
|
HOLDER: |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
Date: |
|
|
Series B Certificate of Designation | Page 14 |
ANNEX
A-3
NOTICE
OF CONVERSION
(To
Be Executed by the Registered Holder
in Order to Convert Shares of Series B-3 Preferred Stock)
The
undersigned Holder hereby irrevocably elects to convert the number of shares of Series B-3 Preferred Stock indicated below, represented
by book-entry notation in the register of the transfer agent, into shares of Common Stock of Biofrontera Inc., a Delaware corporation
(the “Corporation”), as of the date written below. If securities are to be issued in the name of a person other
than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined
herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations
of Series B Convertible Preferred Stock (the “Certificate of Designation”) filed by the Corporation with the
Delaware Secretary of State on February 20, 2024.
The
undersigned Holder’s right to convert the shares of Series B-3 Preferred Stock is subject to the Maximum Percentage described in
Section 6(f) of the Certificate of Designation. Therefore, the number of shares of Common Stock beneficially owned by the undersigned
Holder (together with any Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series
B-3 Preferred Stock subject to this Notice of Conversion, but excluding (i) exercise of the remaining, unconverted portion of the Series
B Preferred Stock beneficially owned by such Person and its Attribution Parties and (ii) exercise or conversion of the unexercised or
unconverted portion of any other securities of the Corporation beneficially owned by such Person and its Attribution Parties (including,
without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein, is 9.99%.
Conversion
calculations:
Date
to Effect Conversion: |
|
Number
of shares of Series B-3 Preferred Stock owned prior to Conversion: |
|
Number
of shares of Series B-3 Preferred Stock to be Converted: |
|
Number
of Units to be Issued: |
|
Address
for delivery of physical certificates: |
|
OR |
|
for
DWAC Delivery: |
|
DWAC
Instructions: |
|
Broker
no: |
|
Account
no: |
|
HOLDER: |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
Date: |
|
|
Series B Certificate of Designation | Page 15 |
Exhibit
4.1
NEITHER
THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION OR EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THE SECURITIES ISSUABLE
UPON CONVERSION OR EXERCISE OF THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A)
AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY
LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT
TO RULE 144 UNDER THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
BIOFRONTERA
INC.
WARRANT
TO PURCHASE SERIES B-3 CONVERTIBLE PREFERRED STOCK
Warrant
No.: [_] |
Number
of Warrant Shares: [___] |
Date
of Issuance: |
February
22, 2024 (“Issuance Date”) |
|
|
Expiration
Date: |
The
earlier of (i) 5 days following the date of completion of (A) the Company’s public announcement of (I) at least 95%
of the Company’s territory managers, medical science liaisons, and reimbursement employees are using the Company’s customer
relationship management system routinely or on a performance improvement plan and (II) the Company’s revenue for the period
starting on January 1, 2024 and ending no earlier than April 30, 2024 excluding revenue from related parties (including Biofrontera
AG) is at least 5% higher than the Company’s revenue excluding revenue from related parties (including Biofrontera AG) for
the corresponding period of the same length, starting on January 1, 2023, which
announcement shall be made promptly after certification by the Company’s board of directors that such targets have been completed,
and (B) the approval by the Company’s stockholders of the Proposals (as defined below), and (C) the effectiveness of a registration
statement with the U.S. Securities and Exchange Commission covering the resale of the Common Stock (as defined below) underlying
all shares of Series B-3 Preferred Stock (as defined below) and (ii) February 22, 2027 (“Expiration Date”). |
Biofrontera
Inc., a Delaware corporation (the “Company”), certifies that, for good and valuable consideration, the receipt
and sufficiency of which are acknowledged, ______, the registered holder hereof
or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from
the Company, at the Exercise Price (as defined below) then in effect, upon surrender of this Warrant to Purchase Series B-3 Convertible
Preferred Stock (including any Warrants to Purchase Series B-3 Convertible Preferred Stock issued in exchange, transfer or replacement
hereof, the “Warrant”), at any time or times on or after the Exercisability Date, but not after 5:30 p.m.,
New York Time, on the Expiration Date, Warrant Shares (as defined below). Except as otherwise defined herein, capitalized terms in this
Warrant shall have the meanings set forth in Section 15. This Warrant is one of the warrants to purchase the Series B-3 Convertible Preferred
Stock, par value $0.001 per share, of the Company (the “Series B-3 Preferred Stock”) issued pursuant to that
certain Securities Purchase Agreement, dated as of February 19, 2024 by and between the Company and investors named therein (the
“Securities Purchase Agreement”).
1.
EXERCISE OF WARRANT.
(a)
Mechanics of Exercise. Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder on any day on or
after the Exercisability Date, in whole or in part (but not as to fractional shares), by delivery of a written notice (which may be by
facsimile or email), in the form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s
election to exercise this Warrant and payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number
of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”) in cash or wire
transfer of immediately available funds (a “Cash Exercise”). The Holder shall not be required to surrender
this Warrant in order to effect an exercise hereunder; provided, that in the event of an exercise of this Warrant for all Warrant
Shares then issuable hereunder, this Warrant is surrendered to the Company’s transfer agent by the second Trading Day following
the date on which the Company’s transfer agent for the Warrants and Preferred Stock (“Transfer Agent”)
has received the Exercise Notice. Within one Trading Day following the date of exercise as aforesaid, the Holder shall deliver the Aggregate
Exercise Price for the shares specified in the applicable Exercise Notice by wire transfer or cashier’s check drawn on a United
States bank. No ink-original Exercise Notice shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Exercise Notice form be required, except as may be required by the Company’s transfer agent. On or before the first Trading
Day following the date on which the Company or the Transfer Agent has received the Exercise Notice, the Company or the Transfer Agent
shall transmit by email or facsimile an acknowledgment of confirmation of receipt of the Exercise Notice to the Holder and the Transfer
Agent. The Company or the Transfer Agent shall deliver any objection to the Exercise Notice on or before the first Trading Day following
the date on which the Company or the Transfer Agent has received the Exercise Notice. In the event of any discrepancy or dispute, the
records of the Company and the Transfer Agent shall be controlling and determinative in the absence of manifest error. On or before the
earlier of (i) the second Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below)
following the date on which the Holder has delivered to the Company a duly completed and executed Exercise Notice (the “Share
Delivery Date”) and the Aggregate Exercise Price, the Company or its Transfer Agent shall, upon the request of the Holder,
issue and register such aggregate number of shares of Series B-3 Preferred Stock to which the Holder is entitled pursuant to such exercise
in book-entry form in the name of such Holder thereof in accordance with the instructions delivered to the Transfer Agent by the Company.
Upon delivery of the Exercise Notice and the Aggregate Exercise Price, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of
delivery of the book-entry accounts evidencing such Warrant Shares. As used herein, “Standard Settlement Period”
means the standard settlement period, expressed in a number of Trading Days, on the Principal Market with respect to the Common Stock
as in effect on the date of delivery of the Exercise Notice.
If
this Warrant is submitted in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented
by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Transfer
Agent shall as soon as practicable and in no event later than ten Trading Days after any exercise and at its own expense, issue a new
Warrant (in accordance with Section 7(e)) representing the right to purchase the number of Warrant Shares purchasable immediately prior
to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. The Company shall
pay any and all taxes that may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant;
provided, however, that the Company shall not be required to pay any tax which may be payable based on the income of the
Holder or in respect of any transfer involved in the registration of any book-entry accounts for Warrant Shares or Warrants in a name
other than that of the Holder or an affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as
a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.
If
the Company shall fail for any reason or for no reason to register Warrant Shares in the Holder’s account for such number of Warrant
Shares to which the Holder is entitled upon the Holder’s exercise of this Warrant, then the Holder shall be entitled, but not required,
to rescind the applicable previously submitted Exercise Notice and the Company or the Transfer Agent shall return all consideration paid
by Holder for such shares upon such rescission. Notwithstanding anything herein to the contrary, the Company shall not be required to
make any cash payments to the Holder in lieu of issuance of the Warrant Shares.
(b)
Exercise Price. For purposes of this Warrant, “Exercise Price” means $1,000 per share of Series B-3
Preferred Stock, subject to adjustment as provided herein.
(c)
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share that the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price.
Warrant to Purchase Series B-3 Convertible Preferred Stock | Page 2 |
2.
ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be adjusted
from time to time as follows:
(a)
Adjustment upon Subdivision or Combination of Shares of Series B-3 Preferred Stock or Common Stock. If the Company at any time
on or after the Issuance Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its
outstanding shares of Series B-3 Preferred Stock or Common Stock into a greater number of shares, the Exercise Price in effect immediately
prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the
Company at any time on or after the Issuance Date combines (by combination, reverse stock split or otherwise) one or more classes of
its outstanding shares of Series B-3 Preferred Stock or Common Stock into a smaller number of shares, the Exercise Price in effect immediately
prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment
under this Section 2(a) shall become effective at the close of business on the date the subdivision or combination becomes effective.
(b)
Par Value. Notwithstanding anything to the contrary in this Warrant, in no event shall the Exercise Price be reduced below the
par value of the Series B-3 Preferred Stock.
3.
RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company shall declare or make any dividend or other distribution of its assets (or
rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate
rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the
issuance of this Warrant, then, in each such case:
(a)
any Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders of
shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such record date,
to a price determined by multiplying such Exercise Price by a fraction of which (i) the numerator shall be the Weighted Average Price
of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution (as determined
in good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the denominator shall be the
Weighted Average Price of the shares of Common Stock on the Trading Day immediately preceding such record date; and
(b)
the number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock issuable upon conversion
of the Warrant Shares immediately prior to the close of business on the record date fixed for the determination of holders of shares
of Common Stock entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding
paragraph (a).
4.
PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.
(a)
Purchase Rights. In addition to any adjustments pursuant to Section 2 above, if at any time prior to the Expiration Date, the
Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property
pro rata to all of the record holders of any class of shares of Common Stock (the “Purchase Rights”), then
the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of shares of Common Stock issuable upon conversion of the Warrant Shares (without
regard to any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights.
(b)
Fundamental Transactions. If, at any time while this Warrant is outstanding, the Company shall enter into or be party to a Fundamental
Transaction, then the Company (or the successor entity) shall purchase this Warrant and all other outstanding Warrants from the Holders
by paying to the Holders cash in an amount equal to the Black Scholes Value of the remaining unexercised portion of each Warrant on the
effective date of such Fundamental Transaction. For the sake of clarity, such calculation shall assume full exercisability of this Warrant
(e.g. without regard to any limitations on the exercise of this Warrant).
Warrant to Purchase Series B-3 Convertible Preferred Stock | Page 3 |
5.
RESERVATION OF WARRANT SHARES.
(a)
The Company covenants that it will at all times after the Exercisability Date reserve and keep available out of the aggregate of its
authorized but unissued and otherwise unreserved Series B-3 Preferred Stock, solely for the purpose of enabling it to issue Warrant Shares
upon exercise of this Warrant as herein provided, the number of shares of Series B-3 Preferred Stock which are then issuable and deliverable
upon the exercise of this entire Warrant, free from preemptive or any other contingent purchase rights of Persons other than the Holder.
The Company covenants that all shares of Series B-3 Preferred Stock so issuable and deliverable shall be, upon issuance and the payment
of the applicable Exercise Price in accordance with the terms hereof, duly authorized, validly issued and fully paid and nonassessable.
The Company will take all such actions as may be reasonably necessary to ensure that such shares of Series B-3 Preferred Stock may be
issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or
automated quotation system upon which the Series B-3 Preferred Stock may be listed. The Company covenants that it will at all times reserve
and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the
Series B-3 Preferred Stock not less than such aggregate number of shares of the Common Stock as shall be issuable upon the conversion
of all outstanding shares of Series B-3 Preferred Stock. The Company covenants that all shares of Common Stock that shall be so issuable
shall, upon issue, be duly authorized, validly issued, fully paid, non-assessable and free and clear of all liens and other encumbrances.
(b)
As soon as practicable following the Issuance Date, but not more than 30 days thereafter, the Company shall file a preliminary proxy
statement for a vote of its stockholders to approve (i) the issuance of all Common Stock upon conversion of the Series B Preferred Stock
and (ii) the issuance of the Warrant Shares upon exercise of the Warrants (collectively, “Proposals”). The
Company shall, as soon as practicable following notification from the staff of the Securities and Exchange Commission that it has completed
its review of the preliminary proxy statement or that it will not review the preliminary proxy statement, file and mail a definitive
proxy statement for the vote of its stockholders to approve the Proposals. The Company covenants and agrees that its Board of Directors
shall unanimously recommend that the Proposals be approved by the Company’s stockholders at all meetings in which such Proposals
are considered and promptly file the necessary amendments to the Company’s certificate of incorporation after the Proposals are
approved. If the Company’s stockholders do not approve such Proposals at the first meeting in which they are voted on by stockholders,
the Company covenants and agrees that it will submit the Proposals for approval of the Company’s stockholders at least semi-annually
until such approval is obtained.
6.
WARRANT HOLDER NOT DEEMED A SHAREHOLDER. Except as otherwise specifically provided herein, the Holder, solely in such Person’s
capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of
the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s
capacity as the Holder of this Warrant, any of the rights of a shareholder of the Company or any right to vote, give or withhold consent
to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or
otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of
the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained
in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant
or otherwise) or as a shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.
7.
REGISTRATION AND REISSUANCE OF WARRANTS.
(a)
Registration of Warrant. The Company or its Transfer Agent shall register this Warrant, upon the records to be maintained by the
Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time.
The Company and its Transfer Agent may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose
of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. The Company
and its Transfer Agent shall also register any transfer, exchange, reissuance or cancellation of any portion of this Warrant in the Warrant
Register.
(b)
Transfer of Warrant. This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company, except
as may otherwise be required by applicable securities laws. Subject to applicable securities laws, if this Warrant is to be transferred,
the Holder shall surrender this Warrant to the Company or its Transfer Agent, as directed by the Company, together with all applicable
transfer taxes, whereupon the Company will, or will cause its Transfer Agent to, forthwith issue and deliver upon the order of the Holder
a new Warrant (in accordance with Section 7(e)), registered as the Holder may request, representing the right to purchase the number
of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is
being transferred, a new Warrant (in accordance with Section 7(e)) to the Holder representing the right to purchase the number of Warrant
Shares not being transferred. The acceptance of the new Warrant by the transferee thereof shall be deemed the acceptance by such transferee
of all of the rights and obligations in respect of the new Warrant that the Holder has in respect of this Warrant.
Warrant to Purchase Series B-3 Convertible Preferred Stock | Page 4 |
(c)
Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking
by the Holder to the Company in customary form (which shall not include the posting of any bond) and, in the case of mutilation, upon
surrender and cancellation of this Warrant, the Company or its Transfer Agent, as directed by the Company, shall execute and deliver
to the Holder a new Warrant (in accordance with Section 7(e)) representing the right to purchase the Warrant Shares then underlying this
Warrant.
(d)
Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office
of the Company or its Transfer Agent, as directed by the Company, together with all applicable transfer taxes, for a new Warrant or Warrants
(in accordance with Section 7(e)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this
Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder
at the time of such surrender; provided, however, that the Company or its Transfer Agent, as directed by the Company, shall
not be required to issue Warrants for fractional shares of Series B-3 Preferred Stock hereunder.
(e)
Issuance of New Warrants. Whenever the Company or its Transfer Agent, as directed by the Company, is required to issue a new Warrant
pursuant to the terms of this Warrant, such new Warrant shall (i) be of like tenor with this Warrant, (ii) represent, as indicated on
the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant
being issued pursuant to Section 7(b) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of
shares of Series B-3 Preferred Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number
of Warrant Shares then underlying this Warrant), (iii) have an issuance date, as indicated on the face of such new Warrant, which is
the same as the Issuance Date and (iv) have the same rights and conditions as this Warrant.
(f)
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.
8.
NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given
in accordance with the information set forth in the Warrant Register. The Company shall give written notice to the Holder (i) reasonably
promptly following any adjustment of the Exercise Price, setting forth in reasonable detail the calculation of such adjustment and (ii)
at least ten days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution
upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights
to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock or (C)
for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation; provided, that in each
case, the Company will only be required to provide such information to the Holder if such information shall have been made known to the
public prior to or in conjunction with such notice being provided to the Holder.
9.
AMENDMENT AND WAIVER. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder.
10.
LIMITATION OF LIABILITY. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase
price of any Warrant Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of
the Company.
11.
GOVERNING LAW. This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the
construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of Delaware,
without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the State of Delaware.
Warrant to Purchase Series B-3 Convertible Preferred Stock | Page 5 |
12.
CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed
against any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or
affect the interpretation of, this Warrant.
13.
DISPUTE RESOLUTION. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the
Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via email or facsimile within five Trading
Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company
are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within five Trading Days of such
disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two Trading Days thereafter
submit via email or facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected
by the Company and approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent,
outside accountant. The Company shall cause the investment bank or the accountant, as the case may be, to perform the determinations
or calculations and notify the Company and the Holder of the results no later than 20 Trading Days from the time it receives the disputed
determinations or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be,
shall be binding upon all parties absent demonstrable error. The expenses of the investment bank and accountant will be borne by the
Company unless the investment bank or accountant determines that the determination of the Exercise Price or the arithmetic calculation
of the Warrant Shares by the Holder was incorrect by more than 25%, in which case the expenses of the investment bank and accountant
will be borne by the Holder.
14.
REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in
addition to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other
injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to
comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder may cause irreparable
harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event
of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to
seek an injunction restraining any breach. Notwithstanding the foregoing or anything else herein to the contrary, if the Company is for
any reason unable to issue and deliver Warrant Shares upon exercise of this Warrant as required pursuant to the terms hereof, the Company
shall have no obligation to pay to the Holder any cash or other consideration or otherwise “net cash settle” this Warrant.
15.
CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:
(a)
“Black Scholes Value” means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained
from the “OV” function on Bloomberg determined as of the day immediately following the public announcement of the applicable
Fundamental Transaction and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the
remaining term of this Warrant as of such date of request and (ii) an expected volatility equal to the 100 day volatility obtained from
the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public
announcement of the applicable Fundamental Transaction.
(b)
“Bloomberg” means Bloomberg Financial Markets.
(c)
“Common Stock” means (i) the Company’s shares of Common Stock, $0.001 par value per share, and (ii) any
share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common
Stock.
(d)
“Convertible Securities” means any stock or securities (other than Options) directly or indirectly convertible
into or exercisable or exchangeable for shares of Common Stock.
(e)
“Eligible Market” means the NYSE MKT LLC, The New York Stock Exchange, Inc., The Nasdaq Stock Market, or the
OTC Bulletin Board®.
(f)
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
(g)
“Exercisability Date” means the date that all Proposals have been approved by the requisite stockholders of
the Company; provided, however, in the event of a Fundamental Transaction prior to obtaining shareholder approval of the
Proposals, the first Trading Day following the closing of the Fundamental Transaction shall be deemed the Exercisability Date; provided,
further, that treatment of this Warrant in the event of a Fundamental Transaction is addressed in Section 4(b) above.
Warrant to Purchase Series B-3 Convertible Preferred Stock | Page 6 |
(h)
“Fundamental Transaction” means that (A) the Company shall, directly or indirectly, in one or more related
transactions, (i) consolidate or merge with or into (in which the Company is not the surviving corporation) another Person or the stockholders
of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power
of the surviving Person immediately after such merger or consolidation, or (ii) sell, assign, transfer, convey or otherwise dispose of
all or substantially all of the properties or assets of the Company to another Person, or (iii) allow another Person to make a purchase,
tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares of Common Stock (not including any
shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party
to, such purchase, tender or exchange offer), or (iv) consummate a stock purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or
other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement
or other business combination) or (B) any “person” or “group” (as these terms are used for purposes of Sections
13(d) and 14(d) of the Exchange Act) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the Exchange
Act), directly or indirectly, of more than 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock.
(i)
“Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible
Securities.
(j)
“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a
trust, an unincorporated organization, any other entity and a government or any department or agency thereof.
(k)
“Principal Market” means (i) The Nasdaq Capital Market, or (ii) if the Nasdaq Capital Market is not the principal
trading market for the Common Stock, then the principal securities exchange or securities market on which the Common Stock is then traded.
(l)
“Securities Act” means the Securities Act of 1933, as amended.
(m)
“Trading Day” means any day on which the Common Stock is traded on the Principal Market.
(n)
“Warrant Shares” means that number of fully paid and nonassessable shares of Series B-3 Preferred Stock equal
to the quotient of (i) the Holder’s Subscription Amount pursuant to the Securities Purchase Agreement divided by (ii) the Exercise
Price, which Exercise Price is subject to adjustment as provided herein.
(o)
“Weighted Average Price” means, for any security as of any date, the dollar volume-weighted average price for
such security on the Principal Market during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New
York City time, as reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the
dollar volume-weighted average price of such security in the over-the-counter market for such security during the period beginning at
9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg, or, if no dollar volume-weighted
average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest
closing ask price of any of the market makers for such security as reported by OTC Markets Group Inc. (formerly OTC Markets Inc.). If
the Weighted Average Price cannot be calculated for such security on such date on any of the foregoing bases, the Weighted Average Price
of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and
the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 13
with the term “Weighted Average Price” being substituted for the term “Exercise Price.” All such determinations
shall be appropriately adjusted for any share dividend, share split or other similar transaction during such period.
Warrant to Purchase Series B-3 Convertible Preferred Stock | Page 7 |
IN
WITNESS WHEREOF, the Company has caused this Warrant to Purchase Series B-3 Convertible Preferred Stock to be duly executed as of
the Issuance Date set out above.
|
BIOFRONTERA
INC. |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
Warrant to Purchase Series B-3 Convertible Preferred Stock | Page 8 |
EXHIBIT
A
EXERCISE
NOTICE
To
be Executed by the Registered Holder to Exercise This
Warrant
to Purchase Series B-3 Convertible Preferred Stock
BIOFRONTERA
INC.
The
undersigned holder hereby exercises the right to purchase __________ of the shares of Series B-3 Convertible Preferred Stock (“Warrant
Shares”) of Biofrontera Inc., a Delaware corporation (the “Company”), evidenced by the attached Warrant
to Purchase Series B-3 Preferred Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined shall
have the respective meanings set forth in the Warrant.
1.
Exercise Price. The Holder intends that payment of the Exercise Price shall be made as a cash exercise under Section 1(a).
2.
Cash Exercise. The Holder shall pay the sum of $____________ to the Company in accordance with the terms of the Warrant.
3.
Delivery of Warrant Shares. The Company shall deliver to the holder ___________ Warrant Shares in accordance with the terms of
the Warrant.
DATED:
|
|
|
|
|
|
|
(Signature
must conform in all respects |
|
|
|
to
name of the Holder as specified on |
|
|
|
the
face of the Warrant) |
|
|
|
|
|
|
|
|
|
|
|
Registered
Holder |
|
|
|
|
|
|
|
Address: |
Warrant to Purchase Series B-3 Convertible Preferred Stock | Page 9 |
Exhibit
10.1
SECURITIES
PURCHASE AGREEMENT
This
Securities Purchase Agreement (this “Agreement”) is dated as of February 19, 2024, by and among Biofrontera
Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each,
including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
RECITALS
A.
The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation
D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “Commission”)
under the Securities Act.
B.
Each Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in
this Agreement, (i) that aggregate number of shares of Series B-1 Convertible Preferred Stock, par value $0.001 per share, of the Company
(the “Series B-1 Convertible Preferred Stock”), set forth below such Purchaser’s name on the signature
page of this Agreement (which aggregate amount for all Purchasers together shall be 6,586 shares of Series B-1 Convertible Preferred
Stock and shall be collectively referred to herein as the “Shares”) and (ii) that aggregate number of Warrants
to acquire shares of Series B-3 Convertible Preferred Stock, par value $0.001 per share, of the Company (the “Series B-3
Convertible Preferred Stock”), set forth below such Purchaser’s name on the
signature page of this Agreement (which aggregate amount for all Purchasers together shall be 8,000 Warrants), in substantially
the form attached hereto as Exhibit A (the “Warrant”).
C.
Pursuant to the Certificate of Designation of the Series B-1 Convertible Preferred Stock, in substantially the form attached hereto as
Exhibit B (the “Certificate of Designation”), each Share and each share of Series B-3 Convertible Preferred
Stock issuable upon exercise of the Warrants is convertible into shares of common stock, par value $0.001 per share, of the Company (the
“Common Stock”) and/or, if applicable, shares of Series B-2 Convertible Preferred Stock, par value $0.001 per
share, of the Company (the “Series B-2 Convertible Preferred Stock”), in lieu of Common Stock.
D.
Pursuant to the Certificate of Designation, each share of Series B-2 Convertible Preferred Stock issuable upon conversion of the Shares
and each share of Series B-3 Convertible Preferred Stock issuable upon exercise of the Warrants is convertible into shares of Common
Stock. The shares of Common Stock issuable upon conversion of the Shares, the Series B-2 Convertible Preferred Stock and the Series B-3
Convertible Preferred Stock collectively are referred to herein as the “Conversion Shares.”
E.
The Shares, the Warrants, the Series B-2 Convertible Preferred Stock issuable upon conversion of the Shares, the Series B-3 Convertible
Preferred Stock issuable upon exercise of the Warrants and the Conversion Shares collectively are referred to herein as the “Securities.”
NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchasers hereby agree as follows:
ARTICLE
I.
DEFINITIONS
1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
shall have the meanings indicated in this Section 1.1:
“Acquiring
Person” has the meaning set forth in Section 4.6.
“Action”
means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation
pending or, to the Company’s Knowledge, threatened in writing against the Company, any Subsidiary or any of their respective properties
or any officer, director or employee of the Company or any Subsidiary acting in his or her capacity as an officer, director or employee
before or by any federal, state, county, local or foreign court, arbitrator, governmental or administrative agency, regulatory authority,
stock market, stock exchange or trading facility.
“Advance
Indemnification Payment” has the meaning set forth in Section 4.15I(iv).
“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, Controls, is controlled
by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act. With
respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by the same investment manager
as such Purchaser will be deemed to be an Affiliate of such Purchaser.
“Agreement”
has the meaning set forth in the Preamble.
“Appointed
Director” has the meaning set forth in Section 4.17(a).
“Board
of Directors” means the board of directors of the Company.
“Business
Day” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any day on
which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
“Buy-In”
has the meaning set forth in Section 4.1(f).
“Certificate
of Designation” has the meaning set forth in the Recitals.
“Closing”
means the closing of the purchase and sale of the Shares and the Warrants pursuant to this Agreement.
“Closing
Bid Price” means, for any security as of any date, (a) the last reported closing bid price per share of Common Stock
for such security on the Principal Trading Market, as reported by Bloomberg Financial Markets, or, (b) if the Principal Trading Market
begins to operate on an extended hours basis and does not designate the closing bid price then the last bid price of such security prior
to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or (c) if the foregoing do not apply, the last closing
price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial
Markets, or (d) if no closing bid price is reported for such security by Bloomberg Financial Markets, the average of the bid prices of
any market makers for such security as reported in the “pink sheets” by Pink Sheets LLC. If the Closing Bid Price cannot
be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price of such security on such date
shall be the fair market value as mutually determined by the Company and the holder of such security. If the Company and such holder
are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 13 of the Warrants.
All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction
during the applicable calculation period.
“Closing
Date” means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all of the conditions set forth in Sections 2.1, 2.2, 5.1 and 5.2 hereof are satisfied or waived,
as the case may be, or such other date as the parties may agree.
“Commission”
has the meaning set forth in the Recitals.
“Common
Stock” has the meaning set forth in the Recitals, and also includes any other class of securities into which the Common
Stock may hereafter be reclassified or changed into.
“Common
Stock Equivalents” means any securities of the Company or any Subsidiary which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock or other securities
that entitle the holder to receive, directly or indirectly, Common Stock.
“Company”
has the meaning set forth in the Preamble.
“Company
Counsel” means McGuireWoods LLP, with offices located at 1251 Avenue of the Americas, 20th Floor, New York,
NY 10020.
“Company
Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated under
the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).
“Company
Deliverables” has the meaning set forth in Section 2.2(a).
“Company
Intellectual Property” has the meaning set forth in Section 3.1(p).
Securities Purchase Agreement | Page 2 |
“Company’s
Knowledge” means with respect to any statement made to the Company’s Knowledge, that the statement is based upon
the actual knowledge of the executive officers of the Company having responsibility for the matter or matters that are the subject of
the statement.
“Company
Party” has the meaning set forth in Section 4.15(c)(ii).
“Control”
(including the terms “controlling,” “controlled by” or “under common control with”) means the possession,
direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership
of voting securities, by contract or otherwise.
“Conversion
Shares” has the meaning set forth in the Recitals.
“Cutback
Shares” has the meaning set forth in Section 4.15(b)
“Disclosure
Materials” has the meaning set forth in Section 3.1(h).
“Disclosure
Schedules” has the meaning set forth in Section 3.1.
“DTC”
has the meaning set forth in Section 4.1(c).
“Effective
Date” has the meaning set forth in Section 4.15(a)(vii).
“Effectiveness
Deadline” has the meaning set forth in Section 4.15(a)(ii).
“Environmental
Laws” has the meaning set forth in Section 3.1(dd).
“Evaluation
Date” has the meaning set forth in Section 3.1(t).
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated
thereunder.
“Exempt
Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the
Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of
Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to
the Company and (b) shares of Common Stock upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other
securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement,
provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to
decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations)
or to extend the term of such securities.
“FDA”
has the meaning set forth in Section 3.1(nn).
“FDCA”
has the meaning set forth in Section 3.1(nn).
“Filing
Date” has the meaning set forth in Section 4.15(a)(i).
“GAAP”
means U.S. generally accepted accounting principles, as applied by the Company.
“Hazardous
Materials” has the meaning set forth in Section 3.1(dd).
“Irrevocable
Transfer Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in the form
of Exhibit D, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent.
“Intellectual
Property Rights” means any and all of the following statutory and/or common law rights in any jurisdiction throughout the
world: (i) patents, patent applications and patent disclosures; (ii) Internet domain names, trademarks, service marks, trade dress, trade
names, logos and corporate names, and registrations and applications for registration thereof together with all translations, transliterations,
adaptations, derivations and combinations thereof and including all of the goodwill associated therewith; (iii) copyrights and copyrightable
works (registered or unregistered); (iv) trade secrets and other confidential information (including ideas, formulas, recipes, compositions,
inventions, discoveries or invention disclosures and improvements (whether patentable or unpatentable and whether or not reduced to practice)),
know-how, manufacturing and production processes and techniques, research and development information, drawings, specifications, designs,
plans, proposals, non-public data and databases, financial and marketing plans and customer and supplier lists and information; (v) all
rights in software; (vi) registrations and applications for any of the foregoing; and (vii) other proprietary, intellectual property
and/or industrial rights.
Securities Purchase Agreement | Page 3 |
“Late
Registration Payments” has the meaning set forth in Section 4.15(g).
“Legend
Removal Date” has the meaning set forth in Section 4.1(c).
“Losses”
has the meaning set forth in Section 4.15(c)(i).
“Lien”
means any lien, charge, claim, encumbrance, security interest, right of first refusal, preemptive right or other restrictions of any
kind.
“Material
Adverse Effect” means a material adverse effect on the results of operations, assets, prospects, business or financial
condition of the Company and the Subsidiaries, taken as a whole, except that any of the following, either alone or in combination, shall
not be deemed a Material Adverse Effect: (i) effects caused by changes or circumstances affecting general market conditions in the U.S.
economy or which are generally applicable to the industry in which the Company operates, provided that such effects are not borne
disproportionately by the Company, (ii) effects resulting from or relating to the announcement or disclosure of the sale of the Securities
or other transactions contemplated by this Agreement, or (iii) effects caused by any event, occurrence or condition resulting from or
relating to the taking of any action in accordance with this Agreement.
“Material
Contract” means any contract of the Company that has been filed or was required to have been filed as an exhibit to the
SEC Reports pursuant to Item 601(b)(2), Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.
“Material
Permits” has the meaning set forth in Section 3.1(n).
“New
York Courts” means the state and federal courts sitting in the City of New York, Borough of Manhattan.
“Outside
Date” means the fifth Business Day following the date of this Agreement.
“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint
venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed
herein.
“Pharmaceutical
Products” has the meaning set forth in Section 3.1(nn).
“Placement
Agent” means Roth Capital Partners, LLC.
“B-1
Preferred Shares Purchase Price” means $1,000 per Share.
“Preferred
Share Subscription Amount” means, with respect to each Purchaser, the aggregate amount
to be paid for the Shares purchased hereunder as indicated on such Purchaser’s signature page to this Agreement next to the heading
“Aggregate B-1 Preferred Share Purchase Price (Preferred Share Subscription Amount)” in United States dollars and in immediately
available funds.
“Press
Release” has the meaning set forth in Section 4.5.
“Principal
Trading Market” means the Trading Market on which the Common Stock is primarily listed on and quoted for trading, which,
as of the date of this Agreement and the Closing Date, shall be The Nasdaq Capital Market.
“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such
as a deposition), whether commenced or threatened.
“Proposals”
has the meaning set forth in Section 4.16.
“Purchaser”
or “Purchasers” has the meaning set forth in the Recitals.
“Purchaser
Deliverables” has the meaning set forth in Section 2.2(b).
“Purchaser
Party” has the meaning set forth in Section 4.9.
Securities Purchase Agreement | Page 4 |
“Registrable
Shares” means (a) all Common Stock issuable upon the conversion of the shares of Series B-1 Convertible Preferred Stock
purchased pursuant to this Agreement and Conversion Shares issuable upon conversion of the Series B-1 Convertible Preferred Stock, without
taking into account any limitations upon conversion set forth in the Certificate of Designation (such shares and Conversion Shares, the
“Series B-1 Registrable Shares”) and (b) all Common Stock issuable upon the conversion of the shares of Series B-2
Convertible Preferred Stock issuable upon conversion of Series B-1 Convertible Stock or Series B-3 Convertible Stock and Series B-3 Convertible
Preferred Stock issuable upon exercise of Warrants purchased pursuant to this Agreement, without taking into account any limitations
upon conversion set forth in the Certificate of Designation (such shares and Conversion Shares, the “Series B-3 Registrable
Shares”); provided, however, that a security shall cease to be a Registrable Share upon the earliest to occur
of the following: (i) a Resale Registration Statement registering such security under the Securities Act has been declared or becomes
effective and such security has been sold or otherwise transferred by the holder thereof pursuant to and in a manner contemplated by
such effective Resale Registration Statement, (ii) such security is sold pursuant to Rule 144 under circumstances in which any legend
borne by such security relating to restrictions on transferability thereof, under the Securities Act or otherwise, is removed by the
Company, (iii) such security is eligible to be sold pursuant to Rule 144 without any limitation as to volume of sales and without the
holder complying with any method of sale requirements or notice requirements under Rule 144, or (iv) such security shall cease to be
outstanding following its issuance. “Regulation D” has the meaning set forth in the Recitals.
“Required
Approvals” has the meaning set forth in Section 3.1(e).
“Required
Effective Date” has the meaning set forth in Section 4.15(g).
“Resale
Registration Statement” means a registration statement or registration statements of the Company filed under the Securities
Act pursuant to Section 4.15 hereof, and shall include any preliminary prospectus, final prospectus, exhibit or amendment included
in or relating to such registration statements.
“Restriction
Termination Date” has the meaning set forth in Section 4.15(b).
“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.
“Sanctioned
Country” means, at any time, a country, region or territory which is itself the subject or target of any Sanctions (at
the time of this Agreement, the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic, the Crimea
Region of Ukraine, Cuba, Iran, North Korea and Syria).
“Sanctioned
Person” means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons, (b) any Person operating,
organized or resident in a Sanctioned Country, (c) any Person owned or controlled by any such Person or Persons described in the foregoing
clauses (a) or (b), or (d) any Person otherwise the subject or target of any Sanctions.
“Sanctions”
means all economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government,
including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of
State or (b) the United Nations Security Council, the European Union, any European Union member state, His Majesty’s Treasury of
the United Kingdom or other relevant sanctions authority.
“SEC
Reports” has the meaning set forth in Section 3.1(h).
“SEC
Restrictions” has the meaning set forth in Section 4.15(b).
“Secretary’s
Certificate” has the meaning set forth in Section 2.2(a)(vi).
“Securities
Act” has the meaning set forth in the Recitals.
“Series
B-1 Convertible Preferred Stock” has the meaning set forth in the Recitals.
“Series
B-2 Convertible Preferred Stock” has the meaning set forth in the Recitals.
“Series
B-3 Convertible Preferred Stock” has the meaning set forth in the Recitals.
“Shares”
has the meaning set forth in the Recitals.
“Short
Sales” include, without limitation, (i) all “short sales” as defined in Rule 200 promulgated under Regulation
SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts,
options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act)
and similar arrangements (including on a total return basis), and (ii) sales and other transactions through non-U.S. broker dealers or
foreign regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).
Securities Purchase Agreement | Page 5 |
“Staff”
means the staff of the Commission.
“Stock
Certificates” has the meaning set forth in Section 2.2(a)(ii).
“Stockholder
Approval” has the meaning set forth in Section 3.1(e).
“Subscription
Amount” means, with respect to each Purchaser, the Preferred Share Suscription Amount plus the Warrant Subscription Amount.
“Subsidiary”
means any subsidiary of the Company as set forth on Schedule 3.1(a), and shall, where applicable, include any subsidiary of the
Company formed or acquired after the date hereof.
“Support
Agreement” means that certain support agreement, dated the date hereof, by and among the Company and Biofrontera AG, in
substantially the form attached hereto as Exhibit H.
“Tax”
or “Taxes” means all federal, state, local, non-U.S. and other taxes, charges, fees, duties, levies, imposts,
customs or other assessments, including all net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits,
profit share, license, lease, service, service use, value added, withholding, payroll, employment, excise, estimated, severance, stamp,
occupation, premium, real property, personal property, payroll, escheat, unclaimed property, windfall profits, environmental, capital
stock, social security (or similar), unemployment, disability, registration, alternative or add-on minimum, estimated, or other taxes,
fees, assessments, customs, duties, levies, imposts or charges of any kind whatsoever, whether disputed or not, together with any interest,
penalties, additions to tax, fines or other additional amounts imposed thereon or related thereto.
“Tax
Returns” means any return, statement, schedule, declaration, claim for refund, report, document or form filed or required
to be filed with respect to Taxes, including any amendment, attachment and supplement thereof.
“Trading
Affiliate” has the meaning set forth in Section 3.2(g).
“Trading
Day” means (i) a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market (other than
the OTC Bulletin Board), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board), a day on
which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock
is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by OTC Markets
Group Inc. (formerly OTC Markets Inc.) (or any similar organization or agency succeeding to its functions of reporting prices); provided,
that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean
a Business Day.
“Trading
Market” means whichever of the NYSE American, the Nasdaq Capital Market, the Nasdaq
Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the Pink Open Market, OTCQB or the OTCQX (or any successors
to any of the foregoing) on which the Common Stock is listed or quoted for trading on the date in question.
“Transaction
Documents” means this Agreement, the schedules and exhibits attached hereto, the Certificate of Designation, the Warrants,
the Irrevocable Transfer Agent Instructions, the Support Agreement and any other documents or agreements explicitly contemplated hereunder.
“Transfer
Agent” means Computershare Trust Company, N.A., the current transfer agent of the Company, or any successor transfer agent
for the Company.
“Warrant
Purchase Price” means $176.703 per Warrant.
“Warrant
Subscription Amount” means, with respect to each Purchaser, the aggregate amount to be
paid for the Warrants purchased hereunder as indicated on such Purchaser’s signature page to this Agreement next to the heading
“Aggregate Warrant Purchase Price (Warrant Subscription Amount)” in United States dollars and in immediately available funds.
“Warrants”
has the meaning set forth in the Recitals to this Agreement.
ARTICLE
II.
PURCHASE
AND SALE
2.1
Closing.
(a)
Amount. Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to each
Purchaser, and each Purchaser shall, severally and not jointly, purchase from the Company, such number of shares of Series B-1 Convertible
Preferred Stock equal to the quotient resulting from dividing (i) the Preferred Share Subscription Amount for such Purchaser by
(ii) the B-1 Preferred Share Purchase Price, which shall be equal to the number of Shares such Purchaser is purchasing as is set forth on such Purchaser’s
signature page to this Agreement next to the heading “Number of Shares to be Acquired.” In addition, at the Closing, the
Company shall issue to each Purchaser a Warrant in the amounts set forth in Section 2.1(c) hereof.
Securities Purchase Agreement | Page 6 |
(b)
Closing. The Closing of the purchase and sale of the Shares and Warrants shall take place at the offices of Faegre
Drinker Biddle & Reath LLP, 2200 Wells Fargo Center, 90 South Seventh Street, Minneapolis, MN 55402-3901, on the Closing Date
or at such other locations or remotely by facsimile transmission or other electronic means as the parties may mutually agree.
(c)
Form of Payment. Except as may otherwise be agreed to among the Company and one or more of the Purchasers, on the Closing Date,
each Purchaser shall wire its Subscription Amount, in United States dollars and in immediately available funds, to an account established
by the Company. On the Closing Date, (i) the Company shall irrevocably instruct the Transfer Agent to deliver to each Purchaser book-entry
statements, free and clear of all restrictive and other legends (except as expressly provided in Section 4.1(b) hereof), evidencing
the number of Shares such Purchaser is purchasing as is set forth on such Purchaser’s signature page to this Agreement next to
the heading “Number of Shares to be Acquired,” (ii) the Company shall deliver to each Purchaser one or more Warrants, free
and clear of all restrictive and other legends (except as expressly provided in Section 4.1(b) hereof), evidencing the number
of Warrants such Purchaser is purchasing equal to the quotient resulting from dividing (A) the Warrant Subscription Amount for such
Purchaser by (B) the Warrant Purchase Price, as is set forth on such Purchaser’s signature page to this Agreement next to the
heading “Number of Warrants to Purchase B-3 Preferred Shares to be Acquired”, in each case within two Trading Days of the Closing.
2.2
Closing Deliveries. (a) On or prior to the Closing, the Company shall issue, deliver or cause to be delivered to each Purchaser
the following (the “Company Deliverables”):
(i)
this Agreement, duly executed by the Company;
(ii)
facsimile or other electronic copies of one or more book-entry statements from the Transfer Agent, free and clear of all restrictive
and other legends (except as provided in Section 4.1(b) hereof), evidencing the Shares subscribed for by such Purchaser hereunder,
registered in the name of such Purchaser as set forth on the Book Entry Questionnaire included as Exhibit C-2 hereto (the “Book-Entry
Statements”);
(iii)
facsimile or other electronic copies of one or more Warrants, executed by the Company and registered in the name of such Purchaser as
set forth on the Book Entry Questionnaire included as Exhibit C-2 hereto, with the original Warrants delivered within two Trading
Days of the Closing;
(iv)
a legal opinion of Company Counsel, dated as of the Closing Date, executed by such counsel and addressed to the Purchasers and the Placement
Agent, in a form reasonably acceptable to such parties;
(v)
the Certificate of Designation shall have been filed with the Secretary of State of Delaware, which Certificate of Designation shall
continue to be in full force and effect as of the Closing Date;
(vi)
duly executed Irrevocable Transfer Agent Instructions acknowledged in writing by the Transfer Agent instructing the Transfer Agent to
deliver, on an expedited basis, the book-entry statements evidencing a number of Shares equal to such Purchaser’s Preferred
Share Subscription Amount divided by the B-1 Preferred Share Purchase Price, registered in the name of such Purchaser;
(vii)
a certificate of the Secretary of the Company (the “Secretary’s Certificate”), dated as of the Closing
Date, (a) certifying the resolutions adopted by the Board of Directors of the Company or a duly authorized committee thereof approving
the transactions contemplated by this Agreement and the other Transaction Documents, the filing of the Certificate of Designation and
the issuance of the Securities, (b) certifying the current versions of the certificate of incorporation, as amended, the Certificate
of Designation and by-laws of the Company and (c) certifying as to the signatures and authority of persons signing the Transaction Documents
and related documents on behalf of the Company, in the form attached hereto as Exhibit E;
(viii)
the Compliance Certificate referred to in Section 5.1(i);
Securities Purchase Agreement | Page 7 |
(ix)
a certificate evidencing the formation and good standing of the Company issued by the Secretary of State (or comparable office) of the
State of Delaware, as of a date within three Business Days of the Closing Date;
(x)
a certificate evidencing the Company’s qualification as a foreign corporation and good standing issued by the Secretary of State
(or comparable office) of each jurisdiction in which the Company is qualified to do business as a foreign corporation, as of a date within
three Business Days of the Closing Date;
(xi)
a certified copy of the certificate of incorporation and Certificate of Designation, each as certified by the Secretary of State (or
comparable office) of the State of Delaware, as of a date within two Business Days of the Closing Date; and
(xii)
the Support Agreement duly executed by the Company and all parties thereto.
(b)
On or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the Company the following (the “Purchaser
Deliverables”):
(i)
this Agreement, duly executed by such Purchaser;
(ii)
its Subscription Amount, in United States dollars and in immediately available funds, in the amount set forth as the “Purchase
Price” indicated below such Purchaser’s name on the applicable signature page hereto under the heading “Aggregate Purchase
Price (Subscription Amount)” by wire transfer to the Company;
(iii)
a fully completed and duly executed Selling Stockholder Questionnaire in the form attached as Annex A attached hereto; and
(iv)
a fully completed and duly executed Accredited Investor Questionnaire, satisfactory to the Company, and Book Entry Questionnaire in the
forms attached hereto as Exhibits C-1 and C-2, respectively.
ARTICLE
III.
REPRESENTATIONS
AND WARRANTIES
3.1
Representations and Warranties of the Company. Except (i) as set forth in the schedules delivered herewith (the “Disclosure
Schedules”), which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation made herein
to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, or (ii) disclosed in the SEC Reports,
the Company hereby represents and warrants as of the date hereof and the Closing Date (except for the representations and warranties
that speak as of a specific date, which shall be made as of such date), to each of the Purchasers:
(a)
Subsidiaries. The Company has no direct or indirect Subsidiaries other than those listed in the SEC Reports. Except as disclosed
in Schedule 3.1(a) hereto, the Company owns, directly or indirectly, all of the capital stock or comparable equity interests of
each Subsidiary free and clear of any and all Liens, and all the issued and outstanding shares of capital stock or comparable equity
interest of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe
for or purchase securities.
(b)
Organization and Qualification. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the
requisite corporate power and authority to own or lease and use its properties and assets and to carry on its business as currently conducted.
Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate of incorporation,
bylaws or other organizational or charter documents. The Company and each of its Subsidiaries is duly qualified to conduct business and
is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be,
would not have or reasonably be expected to result in a Material Adverse Effect, and no Proceeding has been instituted, is pending, or,
to the Company’s Knowledge, has been threatened in writing in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.
Securities Purchase Agreement | Page 8 |
I Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and to consummate the
transactions contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations
hereunder and thereunder. The Company’s execution and delivery of each of the Transaction Documents to which it is a party and
the consummation by it of the transactions contemplated hereby and thereby (including, but not limited to, the sale and delivery of
the Shares and the Warrants and the reservation for issuance and the subsequent issuance of shares of Series B-2 Convertible
Preferred Stock upon conversion of the Shares and Series B-3 Convertible Preferred Stock upon exercise of the Warrants, and the
Conversion Shares) have been duly authorized by all necessary corporate action on the part of the Company, and no further corporate
action is required by the Company, its Board of Directors or its stockholders in connection therewith other than in connection with
the Required Approvals. Each of the Transaction Documents to which it is a party has been (or upon delivery will have been) duly
executed by the Company and is, or when delivered in accordance with the terms hereof, will constitute the legal, valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, except (i) as such enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.
(d)
No Conflicts. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the
consummation by the Company of the transactions contemplated hereby or thereby (including, without limitation, the issuance of the Shares
and Warrants and the reservation for issuance and issuance of shares of Series B-2 Convertible Preferred Stock upon conversion of the
Shares and Series B-3 Convertible Preferred Stock upon exercise of the Warrants, and the Conversion Shares) do not and will not (i) conflict
with or violate any provisions of the Company’s or any Subsidiary’s certificate of incorporation, bylaws or otherwise result
in a violation of the organizational documents of the Company, (ii) conflict with, or constitute a default (or an event that with notice
or lapse of time or both would result in a default) under, result in the creation of any Lien upon any of the properties or assets of
the Company or any Subsidiary or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice,
lapse of time or both) of, any Material Contract, or (iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
the Company or a Subsidiary is subject (including federal and state securities laws and regulations and the rules and regulations, assuming
the correctness of the representations and warranties made by the Purchasers herein, of any self-regulatory organization to which the
Company or its securities are subject, including all applicable Trading Markets), or by which any property or asset of the Company or
a Subsidiary is bound or affected, except in the case of clauses (ii) and (iii) such as would not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect.
(e)
Filings, Consents and Approvals. Neither the Company nor any of its Subsidiaries is required to obtain any consent, waiver, authorization
or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents (including
the issuance of the Securities), other than (i) the filing with the Commission of one or more Resale Registration Statements in accordance
with the requirements hereof, (ii) filings required by applicable state securities laws, (iii) the filing of a Notice of Sale of Securities
on Form D with the Commission under Regulation D of the Securities Act, (iv) the filing of any requisite notices and/or application(s)
to the Principal Trading Market for the issuance and sale of the Securities and the listing of the Common Stock for trading or quotation,
as the case may be, thereon in the time and manner required thereby, (v) the filings required in accordance with Section 4.5 of
this Agreement, (vi) approval of the Proposals by the stockholders of the Company (the “Stockholder Approval”)
and (vii) those that have been made or obtained prior to the date of this Agreement (collectively, the “Required Approvals”).
Securities Purchase Agreement | Page 9 |
(f)
Issuance of the Securities. The Shares have been duly authorized and, when issued and paid for in accordance with the terms of
the Transaction Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of all Liens, other than
restrictions on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject
to preemptive or similar rights. The Warrants have been duly authorized and, when issued and paid for in accordance with the terms of
the Transaction Documents, will be duly and validly issued, free and clear of all Liens, other than restrictions on transfer provided
for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights of
stockholders. The Series B-3 Convertible Preferred Stock issuable upon exercise of the Warrants have been duly authorized and, when issued
in accordance with the terms of the Warrants, Transaction Documents and the Certificate of Designation will be duly and validly issued,
fully paid and nonassessable, free and clear of all Liens, other than restrictions on transfer provided for in the Transaction Documents
or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights of stockholders. The Conversion Shares
issuable upon conversion of the Shares, the Series B-2 Convertible Preferred Stock and the Series B-3 Convertible Preferred Stock have
been duly authorized and, when issued in accordance with the terms of the Transaction Documents, will be duly and validly issued, fully
paid and nonassessable and free and clear of all Liens, other than restrictions on transfer provided for in the Transaction Documents
or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights. Assuming the accuracy of the representations
and warranties of the Purchasers in this Agreement, the Securities will be issued in compliance with all applicable federal and state
securities laws. As of the Closing Date, the Company shall have reserved from its duly authorized capital stock (i) the maximum number
of Conversion Shares issuable upon conversion of the Shares and (ii) the maximum number of Conversion Shares issuable upon conversion
of the shares of Series B-2 Convertible Preferred Stock and the Series B-3 Convertible Preferred Stock (without taking into account limitations
set forth in the Certificate of Designation). The Company shall, so long as any of the Shares, the Warrants the Series B-2 Convertible
Preferred Stock and the Series B-3 Convertible Preferred Stock are outstanding, take all action necessary to reserve and keep available
out of its authorized and unissued capital stock, solely for the purpose of effecting the conversion of the Shares, the exercise of the
Warrants and the conversion of the Series B-2 Convertible Preferred Stock and the Series B-3 Convertible Preferred Stock, the maximum
number of shares of Common Stock issuable upon the exercise or conversion thereof (without taking into account any limitations set forth
in the Certificate of Designation).
(g)
Capitalization. The number of shares and type of all authorized, issued and outstanding capital stock, options and other securities
of the Company (whether or not presently convertible into or exercisable or exchangeable for shares of capital stock of the Company)
is set forth in Schedule 3.1(g) hereto. The Company has not issued any capital stock since the date of its most recently filed SEC Report
other than to reflect stock option and warrant exercises that do not, individually or in the aggregate, have a material effect on the
issued and outstanding capital stock, options and other securities. No Person has any right of first refusal, preemptive right, right
of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents that have not been
effectively waived as of the Closing Date. Except as set forth on Schedule 3.1(g) or a result of the purchase and sale of the
Shares and Warrants, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person
any right to subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which
the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance
and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than
the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset
price under any of such securities. All of the outstanding shares of capital stock of the Company are validly issued, fully paid and
nonassessable, have been issued in compliance with all applicable federal and state securities laws, and none of such outstanding shares
was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities other than the Stockholder
Approval. Except as disclosed in the SEC Reports and the Support Agreement, there are no stockholders agreements, voting agreements or
other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the Company’s
Knowledge, between or among any of the Company’s stockholders.
Securities Purchase Agreement | Page 10 |
(h)
SEC Reports; Disclosure Materials. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date
hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including
the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”,
and the SEC Reports, together with the Disclosure Schedules, being collectively referred to as the “Disclosure Materials”)
on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension, except where the failure to file on a timely basis would not have or reasonably be expected to result in a Material
Adverse Effect (including, or this purpose only, any failure to qualify to register the Common Stock for resale on Form S-3 or which
would prevent any Purchaser from using Rule 144 to resell any Securities). As of their respective filing dates, or to the extent corrected
by a subsequent restatement, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange
Act and the rules and regulations of the Commission promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule
144(i) under the Securities Act. Each of the Material Contracts to which the Company or any Subsidiary is a party or to which the property
or assets of the Company or any of its Subsidiaries are subject has been filed as an exhibit to the SEC Reports.
(i)
Financial Statements. The financial statements of the Company included in the SEC Reports comply in all material respects with
applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing
(or to the extent corrected by a subsequent restatement). Such financial statements have been prepared in accordance with GAAP applied
on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto
and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated subsidiaries taken as a whole as of and for the dates thereof and the results
of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial year-end
audit adjustments.
(j)
Material Changes. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically
disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there have been no events, occurrences or developments that
have had or would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect, (ii) the Company
has not incurred any material liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the
ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial
statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered materially its method
of accounting or the manner in which it keeps its accounting books and records, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock (other than in connection with repurchases of unvested stock issued to employees of the Company), and (v)
the Company has not issued any equity securities to any officer, director or Affiliate, except Common Stock issued in the ordinary course
as dividends on outstanding preferred stock or issued pursuant to existing Company stock option or stock purchase plans or executive
and director compensation arrangements disclosed in the SEC Reports. Except for the issuance of the Shares and Warrants and the transactions
contemplated by the Transaction Documents, no event, liability or development has occurred or exists with respect to the Company or its
Subsidiaries or their respective business, properties, operations or financial condition, that would be required to be disclosed by the
Company under applicable securities laws at the time this representation is made that has not been publicly disclosed at least one Trading
Day prior to the date that this representation is made.
(k)
Litigation. There is no Action which (i) adversely affects or challenges the legality, validity or enforceability of any of the
Transaction Documents or the Securities or (ii) except as specifically disclosed in the SEC Reports, would, if there were an unfavorable
decision, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company
nor any Subsidiary, nor to the Company’s Knowledge any director or officer thereof, is or has been the subject of any Action involving
a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been,
and to the Company’s Knowledge there is not pending or contemplated, any investigation by the Commission involving the Company
or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the
effectiveness of any registration statement filed by the Company or any of its Subsidiaries under the Exchange Act or the Securities
Act.
Securities Purchase Agreement | Page 11 |
(l)
Employment Matters. No material labor dispute exists or, to the Company’s Knowledge, is imminent with respect to any of
the employees of the Company which would have or reasonably be expected to result in a Material Adverse Effect. None of the Company’s
or any Subsidiary’s employees is a member of a union that relates to such employee’s relationship with the Company, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and each Subsidiary believes
that its relationship with its employees is good. No executive officer of the Company (as defined in Rule 501(f) of the Securities Act)
has notified the Company or any such Subsidiary that such officer intends to leave the Company or any such Subsidiary or otherwise terminate
such officer’s employment with the Company or any such Subsidiary. To the Company’s Knowledge, no executive officer, to the
Company’s Knowledge, is, or is now expected to be, in violation of any term of any material term of any employment contract, confidentiality,
disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of a third party, and to the Company’s Knowledge, the continued employment of each such executive officer does not subject
the Company or any Subsidiary to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in
compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms
and conditions of employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect.
(m)
Compliance. Neither the Company nor any of its Subsidiaries (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of its Subsidiaries
under), nor has the Company or any of its Subsidiaries received written notice of a claim that it is in default under or that it is in
violation of, any Material Contract (whether or not such default or violation has been waived), (ii) is in violation of any order of
any court, arbitrator or governmental body having jurisdiction over the Company or its properties or assets, or (iii) is in violation
of, or in receipt of written notice that it is in violation of, any statute, rule or regulation of any governmental authority applicable
to the Company, except in each case as would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect.
(n)
Regulatory Permits. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct its respective business as currently conducted
and as described in the SEC Reports, except where the failure to possess such permits, individually or in the aggregate, has not and
would not have or reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither
the Company nor any of its Subsidiaries has received any notice of Proceedings relating to the revocation or modification of any such
Material Permits.
(o)
Title to Assets. The Company and its Subsidiaries have good and marketable title in fee simple to all real property owned by them.
Other than as disclosed in the SEC Reports, the Company and its Subsidiaries have good and marketable title to all tangible personal
property owned by them that is material to the business of the Company and its Subsidiaries, taken as whole, in each case free and clear
of all Liens except such as do not materially affect the value of such property and do not interfere with the use made and proposed to
be made of such property by the Company and any of its Subsidiaries. Any real property and facilities held under lease by the Company
and any of its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material
and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries.
(p)
Intellectual Property.
(i)
Schedule 3.1(p) contains a complete and accurate description and list of all (A) patented or registered Intellectual Property
Rights (or applications therefor) owned by the Company or any of its Subsidiaries or filed in the name of the Company or any of its Subsidiaries,
and (B) unregistered Intellectual Property Rights that are material to the conduct of the Company’s business or the business of
any of its Subsidiaries, each as presently conducted and as presently proposed to be conducted, including any such Intellectual Property
Rights embodied or used in any product proposed to be developed, produced or marketed by the Company. Except as set forth on Schedule
3.1(p), the Company or one of its Subsidiaries (A) owns and possesses all right, title and interest in and to all Intellectual Property
Rights set forth, or required to be set forth, on Schedule 3.1(p), and (B) owns and possesses all right, title and interest in
all other Intellectual Property Rights used in or necessary for the operation of their respective businesses as presently conducted and
as presently proposed to be conducted (the Intellectual Property Rights referred to collectively in (A) and (B), the “Company
Intellectual Property Rights”), each, free and clear of all Liens, other than as disclosed in the SEC Reports. No loss
or expiration of any Company Intellectual Property Right is threatened, pending or, to the Company’s knowledge, reasonably foreseeable,
except for patents expiring at the end of their statutory term. The Company and each of its Subsidiaries have taken all actions reasonable
under the circumstances to maintain and protect the Company Intellectual Property Rights. Each of the patented or registered Intellectual
Property Rights (or applications therefor) set forth on Schedule 3.1(p) is subsisting, in full force and effect, and valid and
enforceable. All renewal and maintenance fees in respect of each item of patented or registered Intellectual Property Rights (or applications
therefor) set forth on Schedule 3.1(p) have been duly paid and none of the registrations or applications are subject to any challenge,
opposition, nullity proceeding or interference or, to the Company’s knowledge, threats to commence the same.
Securities Purchase Agreement | Page 12 |
(ii)
There have been no claims made or threatened against the Company or any of its Subsidiaries with respect to the validity, infringement,
use, ownership or enforceability of any of the Company Intellectual Property Rights and, to the Company’s knowledge, there is no
basis for any such claim. Neither the Company or any of its Subsidiaries has received any notices of, and has no knowledge of any facts
that indicate a likelihood of, the Company or any of its Subsidiaries infringing, misappropriating, or conflicting with any Intellectual
Property Rights of any other Person (including any demand or request that the Company or any of its Subsidiaries license any rights from
a third party or any unsolicited offer to license a patent). The conduct of the Company’s and its Subsidiaries’ businesses
has not infringed, misappropriated, violated or conflicted with, and the continued conduct of the Company’s and its Subsidiaries’
businesses as presently conducted and as presently proposed to be conducted will not infringe, misappropriate, violate or conflict with,
any Intellectual Property Rights of any other Persons. To the Company’s knowledge, the Company Intellectual Property Rights have
not been infringed, misappropriated, violated or conflicted by other Persons.
(iii)
The Company and each of its Subsidiaries have taken steps reasonable under the circumstances to maintain and protect the confidentiality
of their trade secrets and material confidential information. Each employee, officer, consultant, or outside contractor that has had
access to the confidential or proprietary information of the Company or any of its Subsidiaries has executed a confidentiality or similar
agreement for the protection, confidentiality and non-disclosure of such confidential and proprietary information, and neither the Company
nor any of its Subsidiaries has received notice that, nor is aware of any facts that, indicate a likelihood that, any Person is in violation
or breach of any such agreements.
(q)
Insurance. The Company and each of the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as the Company believes to be prudent and customary in the businesses and locations in which the
Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage and clinical trial
liability coverage. Neither the Company nor any of its Subsidiaries has received any notice of cancellation of any such insurance, nor,
to the Company’s Knowledge, will it or any Subsidiary be unable to renew their respective existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant
increase in cost.
(r)
Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company
and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company
or any Subsidiary (other than for services as employees, officers and directors), that would be required to be disclosed pursuant to
Item 404 of Regulation S-K promulgated under the Securities Act that has not otherwise been appropriately disclosed in accordance with
the Exchange Act.
(s)
Internal Accounting Controls. The Company maintains a system of internal accounting controls designed to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability,
(iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization,
and (iv) the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals
and appropriate action is taken with respect to any differences.
(t)
Sarbanes-Oxley; Disclosure Controls. The Company is in compliance in all material respects with all of the provisions of the Sarbanes-Oxley
Act of 2002 which are applicable to it as of the Closing Date. The Company has established disclosure controls and procedures (as such
term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) for the Company and designed such disclosure controls and procedures
to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The Company’s
certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period
covered by the Company’s most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”).
The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about
the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation
Date, there have been no changes in the Company’s internal control over financial reporting (as such term is defined in the Exchange
Act) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial
reporting.
Securities Purchase Agreement | Page 13 |
(u)
Certain Fees. Except for the fees and expenses of the Placement Agent payable by the Company, no person or entity will have, as
a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or a Purchaser
for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of
the Company with respect to the offer and sale of the Shares and Warrants. The Purchasers shall have no obligation with respect to any
fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this paragraph (u) that may
be due in connection with the transactions contemplated by the Transaction Documents. The Company shall indemnify, pay, and hold each
Purchaser harmless against, any liability, loss or expense (including, without limitation, attorneys’ fees and out-of-pocket expenses)
arising in connection with any such right, interest or claim.
(v)
Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2
of this Agreement and the accuracy of the information disclosed in the Accredited Investor Questionnaires provided by the Purchasers,
no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers under
the Transaction Documents. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading
Market.
(w)
Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration
under the Investment Company Act of 1940, as amended.
(x)
Registration Rights. Other than each of the Purchasers pursuant to Section 4.15 hereof or as set forth in Schedule 3.1(x)
hereto, no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the
Company other than those securities which are currently registered on an effective registration statement on file with the Commission.
(y)
Listing and Maintenance Requirements. The Company’s Common Stock is registered pursuant to Section 12(b) or 12(g) of the
Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act nor
has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth in
the SEC Reports, the Company has not, in the twelve months preceding the date hereof, received written notice from any Trading Market
on which the Common Stock is listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements
of such Trading Market. The Company is in compliance with all listing and maintenance requirements of the Principal Trading Market on
the date hereof.
(z)
Application of Takeover Protections; Rights Agreements. The Company and the Board of Directors have taken all necessary action,
if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the Company’s charter documents or the laws of its state
of incorporation that is or could reasonably be expected to become applicable to any of the Purchasers as a result of the Purchasers
and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including, without limitation,
the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.
(aa)
Disclosure. The Company confirms that it has not provided, and to the Company’s Knowledge, none of its officers or directors
nor any other Person acting on its or their behalf has provided, any Purchaser or its respective agents or counsel with any information
that it believes constitutes material, non-public information except insofar as the existence, provisions and terms of the Transaction
Documents and the proposed transactions hereunder may constitute such information, all of which will be disclosed by the Company in the
Press Release as contemplated by Section 4.5 hereof. The Company understands and confirms that the Purchasers will rely on the
foregoing representations in effecting transactions in securities of the Company.
Securities Purchase Agreement | Page 14 |
(bb)
No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section
3.2, none of the Company, its Subsidiaries nor, to the Company’s Knowledge, any of its Affiliates or any Person acting on its
behalf has, directly or indirectly, at any time within the past six months, made any offers or sales of any Company security or solicited
any offers to buy any security under circumstances that would (i) eliminate the availability of the exemption from registration under
Regulation D under the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or
(ii) cause the offering of the Securities pursuant to the Transaction Documents to be integrated with prior offerings by the Company
for purposes of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and
regulations of any Trading Market on which any of the securities of the Company are listed or designated.
(cc)
Tax Matters. Except for matters that would not, individually or in the aggregate, have or
reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United
States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction
to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or
determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for
the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are
no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
or of any Subsidiary know of no basis for any such claim.
(dd)
Environmental Matters. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws
relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface
or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.
(ee)
No General Solicitation. Neither the Company nor, to the Company’s Knowledge, any person acting on behalf of the Company
has offered or sold any of the Securities by any form of general solicitation or general advertising.
(ff)
Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge
of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly,
used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties
or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by
any person acting on its behalf of which the Company is aware) which is in violation of law or (iv) taken any action that would reasonably
be expected to subject the Company to any damage or penalty in any criminal or governmental litigation or proceeding under any provision
of Foreign Corrupt Practices Act of 1977.
(gg)
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company (or any Subsidiary)
and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in SEC Reports and is not so
disclosed and would have or reasonably be expected to result in a Material Adverse Effect.
(hh)
Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
hereby and thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or
in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by
any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to each
Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on
the independent evaluation of the transactions contemplated hereby by the Company and its representatives.
Securities Purchase Agreement | Page 15 |
(ii)
Regulation M Compliance. The Company has not, and to its knowledge no one acting on its
behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the
price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid
any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for
soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid
to the Company’s placement agent in connection with the placement of the Securities.
(jj)
PFIC. No Subsidiary of the Company is or intends to become a “passive foreign investment company” within the meaning
of Section 1297 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) or a “controlled foreign
corporation” within the meaning of Section 957 of the Code.
(kk)
Real Property Holding Corporation. The Company is not now and has never been a “United States real property holding corporation”
as defined in the Code and any applicable regulations promulgated thereunder.
(ll)
Sanctions. Neither the Company nor any Subsidiary nor, to the Company’s Knowledge, any director, officer, agent, employee,
Affiliate or Person acting on behalf of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department; and the Company will not directly or indirectly use the proceeds of
the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or
other Person or entity, for the purpose of financing or facilitating any activities, business or transaction with any Sanctioned Person
or in any Sanctioned Country or in any manner that would result in the violation of any Sanctions applicable to any party hereto.
(mm)
No Bad Actors. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification
Event”) is applicable to the Company or, to the Company’s Knowledge, any Company Covered Person, except for a Disqualification
Event as to which Rule 506(d)(2)(ii–iv) or (d)(3) is applicable.
(nn)
FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration
(“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”)
that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such
product, a “Pharmaceutical Product”), such Pharmaceutical Product is, to the knowledge of the Company, being
manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements
under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or
application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling,
advertising, record keeping and filing of reports, except where the failure to Ie in compliance would not have a Material Adverse
Effect. There is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration,
or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries,
and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any
other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution
of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii)
withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales
promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company
or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes
to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation
of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would
have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material
respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that
the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed
by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed
to be developed by the Company.
Securities Purchase Agreement | Page 16 |
(oo)
Healthcare Laws. The Company and its Subsidiaries are, and during the last three years, has been, in compliance with all Healthcare
Laws, except where failure to comply would not be expected, individually or in the aggregate, to result in a Material Adverse Effect.
For purposes of this Agreement, “Healthcare Laws” means: (i) the FDCA and the Public Health Service Act (42
U.S.C. Section 201 et seq.); (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without
limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the
criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286, 287, 1347 and 1349, the civil monetary penalties
law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section
1320-7h), and applicable laws governing government funded or sponsored healthcare programs; (iii) the Health Insurance Portability and
Accountability Act (“HIPAA”), as amended by the Health Information Technology for Economic and Clinical Health
Act (42 U.S.C. Section 17921 et seq.); (iv) all other similar local, state, federal, national, supranational and foreign laws; and (v)
the regulations promulgated pursuant to such laws set forth in subparts (i) through (iv). Except as would not be expected, individually
or in the aggregate, to result in a Material Adverse Effect. During the last three (3) years, the Company has not received written notice
of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator
or governmental authority alleging that any product, operation, or activity is in violation of any Healthcare Laws nor, to the Company’s
Knowledge, is any such written claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened.
Except as would not be expected, individually or in the aggregate, to result in a Material Adverse Effect, during the last three (3)
years, the Company has filed, maintained or submitted all written reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments (“Submissions”) as required by any Healthcare Laws, and all such Submissions
were accurate on the date filed (or were corrected or supplemented by a subsequent submission). The Company is not a party to any corporate
integrity agreements, deferred or non-prosecution agreements, monitoring agreements, consent decrees, settlement orders, or similar written
agreements with or imposed by any Governmental Entity. During the last three years, neither the Company nor any of its respective employees,
officers, directors, or, to the Company’s Knowledge, agents has been excluded, suspended or debarred from participation in any
U.S. federal health care program or human clinical research.
(pp)
Preclinical Data, Clinical Trials and Regulatory Compliance. The preclinical tests and clinical trials, and other studies (collectively,
“studies”) that are described in, or the results of which are referred to in, the SEC Reports were and, if
still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved
for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate
and complete in all material respects and fairly presents the data derived from such studies, and to the Company’s Knowledge no
other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the
SEC Reports; the Company and its Subsidiaries have made all such filings and obtained all such approvals as may be required by the FDA
or the U.S. Department of Health and Human Services or any committee thereof or from any other United States or foreign government or
drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory
Agencies”); neither the Company nor any of its Subsidiaries has received any notice of, or correspondence from, any Regulatory
Agency requiring the termination, suspension or modification of any clinical trials or preclinical tests that are described or referred
to in the SEC Reports; and the Company and its Subsidiaries have each operated and currently are in compliance in all material respects
with all applicable rules, regulations and policies of the Regulatory Agencies.
(qq)
No Additional Agreements. The Company does not have any agreement or understanding with any Purchaser with respect to the transactions
contemplated by the Transaction Documents other than as specified in the Transaction Documents.
(rr)
Use of Form S-3. The Company meets the registration and transaction requirements for use of Form S-3 for the registration of the
Common Stock for resale by the Purchasers.
Securities Purchase Agreement | Page 17 |
3.2
Representations and Warranties of the Purchasers. Each Purchaser hereby, for itself and for no other Purchaser, represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows:
(a)
Organization; Authority. Such Purchaser is an entity validly existing and in good standing under the laws of the jurisdiction
of its organization with the requisite corporate or partnership power and authority to enter into and to consummate the transactions
contemplated by the applicable Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution
and delivery of this Agreement by such Purchaser and performance by such Purchaser of the transactions contemplated by this Agreement
have been duly authorized by all necessary corporate or, if such Purchaser is not a corporation, such partnership, limited liability
company or other applicable like action, on the part of such Purchaser. Each Transaction document to which it is a party has been duly
executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally
binding obligation of such Purchaser, enforceable against it in accordance with its terms, except as such enforceability may be limited
by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the
enforcement of, creditors’ rights and remedies or by other equitable principles of general application.
(b)
No Conflicts. The execution, delivery and performance by such Purchaser of this Agreement and the consummation by such Purchaser
of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Purchaser,
(ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or
give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which
such Purchaser is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal
and state securities laws) applicable to such Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults,
rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the
ability of such Purchaser to perform its obligations hereunder.
(c)
Investment Intent. Such Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Shares and Warrants, and will acquire the shares
of Series B-2 Convertible Preferred Stock (upon conversion of the Shares), the Series B-3 Convertible Preferred Stock (upon exercise
of the Warrants) and the Conversion Shares (upon conversion of the Shares, the Series B-2 Convertible Preferred Stock and the Series
B-3 Convertible Preferred Stock) as principal for its own account and not with a view to, or for distributing or reselling such Securities
or any part thereof in violation of the Securities Act or any applicable state securities laws, provided, however, that by making
the representations herein, such Purchaser does not agree to hold any of the Securities for any minimum period of time and reserves the
right, subject to the provisions of this Agreement, at all times to sell or otherwise dispose of all or any part of such Securities pursuant
to an effective registration statement under the Securities Act or under an exemption from such registration and in compliance with applicable
federal and state securities laws. Such Purchaser does not presently have any agreement, plan or understanding, directly or indirectly,
with any Person to distribute or effect any distribution of any of the Securities (or any securities which are derivatives thereof) to
or through any person or entity; such Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged
in a business that would require it to be so registered as a broker-dealer.
(d)
Purchaser Status. At the time such Purchaser was offered the Shares and Warrants, it was, and at the date hereof it is, an “accredited
investor” as defined in Rule 501(a) under the Securities Act.
(e)
General Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or
presented at any seminar or any other general advertisement.
(f)
Access to Information. Such Purchaser acknowledges that it has been afforded (i) the opportunity to ask such questions as it has
deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering
of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and the Subsidiaries
and their respective financial condition, results of operations, business, properties, management and prospects sufficient to enable
it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire
without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Neither
such inquiries nor any other investigation conducted by or on behalf of such Purchaser or its representatives or counsel shall modify,
amend or affect such Purchaser’s right to rely on the truth, accuracy and completeness of the Disclosure Materials and the Company’s
representations and warranties contained in the Transaction Documents. Such Purchaser has sought such accounting, legal and tax advice
as it has considered necessary to make an informed decision with respect to its acquisition of the Securities.
Securities Purchase Agreement | Page 18 |
(g)
Certain Trading Activities. Other than with respect to the transactions contemplated herein, since the time that such Purchaser
was first contacted by the Company or any other Person regarding the transactions contemplated hereby, neither the Purchaser nor any
Affiliate of such Purchaser which (x) had knowledge of the transactions contemplated hereby, (y) has or shares discretion relating to
such Purchaser’s investments or trading or information concerning such Purchaser’s investments, including in respect of the
Securities, and (z) is subject to such Purchaser’s review or input concerning such Affiliate’s investments or trading (collectively,
“Trading Affiliates”) has directly or indirectly, nor has any Person acting on behalf of or pursuant to any
understanding with such Purchaser or Trading Affiliate, effected or agreed to effect any purchases or sales of the securities of the
Company (including, without limitation, any Short Sales involving the Company’s securities). Notwithstanding the foregoing, in
the case of a Purchaser and/or Trading Affiliate that is, individually or collectively, a multi-managed investment bank or vehicle whereby
separate portfolio managers manage separate portions of such Purchaser’s or Trading Affiliate’s assets and the portfolio
managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s
or Trading Affiliate’s assets, the representation set forth above shall apply only with respect to the portion of assets managed
by the portfolio manager that have knowledge about the financing transaction contemplated by this Agreement. Other than to other Persons
party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein
shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or
securing of, available shares to borrow in order to effect short sales or similar transactions in the future.
(h)
Brokers and Finders. Except for the fees and expenses of the Placement Agent payable by the Company, no Person will have, as a
result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or any Purchaser
for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of
the Purchaser.
(i)
Independent Investment Decision. Such Purchaser has independently evaluated the merits of its decision to purchase Securities
pursuant to the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Purchaser’s
business and/or legal counsel or of the Placement Agent in making such decision. Such Purchaser understands that nothing in this Agreement
or any other materials presented by or on behalf of the Company, including without limitation by the Placement Agent, to the Purchaser
in connection with the purchase of the Securities constitutes legal, tax or investment advice. Such Purchaser has consulted such legal,
tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the
Securities. Such Purchaser confirms that none of such Persons has made any representations or warranties to such Purchaser in connection
with the transactions contemplated by the Transaction Documents.
(j)
Reliance on Exemptions. Such Purchaser understands that the Securities being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the
truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgements and
understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such
Purchaser to acquire the Securities.
(k)
Beneficial Ownership. The purchase by such Purchaser of the Shares and Warrants issuable to it at the Closing will not result
in such Purchaser (individually or together with any other Person with whom such Purchaser has identified, or will have identified, itself
as part of a “group” in a public filing made with the Commission involving the Company’s securities) acquiring, or
obtaining the right to acquire, in excess of 9.99% of the outstanding shares of Common Stock or the voting power of the Company on a
post transaction basis that assumes that such Closing shall have occurred. Such Purchaser does not presently intend to, alone or together
with others, make a public filing with the Commission to disclose that it has (or that it together with such other Persons have) acquired,
or obtained the right to acquire, as a result of such Closing (when added to any other securities of the Company that it or they then
own or have the right to acquire), in excess of 9.99% of the outstanding shares of Common Stock or the voting power of the Company on
a post transaction basis that assumes that each Closing shall have occurred. Notwithstanding the foregoing, in the case of a Purchaser
and/or Trading Affiliate that is, individually or collectively, a multi-managed investment bank or vehicle whereby separate portfolio
managers manage separate portions of such Purchaser’s or Trading Affiliate’s assets and the portfolio managers have no direct
knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s or Trading Affiliate’s
assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio manager that
has knowledge about the financing transaction contemplated by this Agreement.
Securities Purchase Agreement | Page 19 |
(l)
Residency. Such Purchaser’s residence (if an individual) or offices in which its investment decision with respect to the
Securities was made (if an entity) are located at the address immediately below such Purchaser’s name on its signature page hereto.
(m)
Acknowledgements Regarding Placement Agent by each Purchaser. Such Purchaser acknowledges and agrees that (a) the Placement Agent
is acting solely as the Company’s placement agent in connection with the transactions contemplated by this Agreement and is not
acting as an underwriter or in any other capacity and is not and will not be construed as a fiduciary for such Purchaser, the Company
or any other person or entity in connection with the transactions contemplated by this Agreement, (b) the Placement Agent has not made
and will not make any representation or warranty, whether express or implied, of any kind or character and has not provided any advice
or recommendation in connection with the transactions contemplated by this Agreement, (c) the Placement Agent will have no responsibility
with respect to (i) any representations, warranties or agreements made by any person or entity under or in connection with the transactions
contemplated by this Agreement or any of the documents furnished pursuant thereto or in connection therewith, or the execution, legality,
validity or enforceability (with respect to any person) or any thereof, or (ii) the business, affairs, financial condition, operations,
properties or prospects of, or any other matter concerning the Company or the transactions contemplated by this Agreement, and (d) the
Placement Agent shall have no liability or obligation (including without limitation, for or with respect to any losses, claims, damages,
obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by you, the Company or any other person
or entity), whether in contract, tort or otherwise, to such Purchaser, or to any person claiming through such Purchaser, in respect of
the transactions contemplated by this Agreement.
The
Company and each of the Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction
Documents.
ARTICLE
IV.
OTHER
AGREEMENTS OF THE PARTIES
4.1
Transfer Restrictions.
(a)
Compliance with Laws. Notwithstanding any other provision of this Article IV, each Purchaser covenants that the Securities
may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities
Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities
Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer of the Securities other
than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant to Rule 144 (provided that the Purchaser
provides the Company with reasonable assurances (in the form of seller and, if applicable, broker representation letters) that the securities
may be sold pursuant to such rule) or (iv) in connection with a bona fide pledge as contemplated in Section 4.1(b), the Company
may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of such transferred Securities under the Securities Act. As a condition of a transfer other than pursuant
to (i) through (iv) above, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights
of a Purchaser under this Agreement with respect to such transferred Securities.
(b)
Legends. Certificates, including, if applicable, book entry statements with the Transfer Agent, evidencing the Securities shall
bear any legend as required by the “blue sky” laws of any state and a restrictive legend in substantially the following form,
until such time as they are not required under Section 4.1(c):
NEITHER
THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION OR EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THE SECURITIES
ISSUABLE UPON CONVERSION OR EXERCISE OF THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE
OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY
LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT
TO RULE 144 UNDER THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
Securities Purchase Agreement | Page 20 |
The
Company acknowledges and agrees that a Purchaser may from time to time pledge, and/or grant a security interest in, some or all of the
legended Securities in connection with applicable securities laws, pursuant to a bona fide margin agreement in compliance with a bona
fide margin loan. Such a pledge would not be subject to approval or consent of the Company and no legal opinion of legal counsel to the
pledgee, secured party or pledgor shall be required in connection with the pledge, but such legal opinion shall be required in connection
with a subsequent transfer or foreclosure following default by the Purchaser transferee of the pledge. No notice shall be required of
such pledge, but Purchaser’s transferee shall promptly notify the Company of any such subsequent transfer or foreclosure. Each
Purchaser acknowledges that the Company shall not be responsible for any pledges relating to, or the grant of any security interest in,
any of the Securities or for any agreement, understanding or arrangement between any Purchaser and its pledgee or secured party. At the
appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party
of Securities may reasonably request in connection with a pledge or transfer of the Securities, including the preparation and filing
of any required prospectus supplement under Rule 424(b)(3) of the Securities Act or other applicable provision of the Securities Act
to appropriately amend the list of Selling Stockholders thereunder. Each Purchaser acknowledges and agrees that, except as otherwise
provided in Section 4.1(c), any Securities subject to a pledge or security interest as contemplated by this Section 4.1(b)
shall continue to bear the legend set forth in this Section 4.1(b) and be subject to the restrictions on transfer set forth
in Section 4.1(a).
(c)
Removal of Legends. The legend set forth in Section 4.1(b) above shall be removed and the Company shall cause its Transfer
Agent to issue book entry statements without such legend or any other legend to the holder of the applicable Securities upon which it
is stamped or issue to such holder by electronic delivery at the applicable balance account at the Depository Trust Company (“DTC”),
if (i) such Securities are registered for sale or transfer pursuant to the effective registration statement registering the Securities
for resale (during such time that such registration statement is effective and not withdrawn or suspended, and only as permitted by such
registration statement) or sold or transferred pursuant to Rule 144 (if the transferor is not an Affiliate of the Company), or (ii) such
Securities are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public
information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions. Following the earlier of
(A) one year from the Closing Date or (B) Rule 144 becoming available for the resale of Securities, without the requirement for the Company
to be in compliance with the current public information required under Rule 144 as to such securities and without volume or manner-of-sale
restrictions, upon request of a Purchaser, the Company shall cause Company Counsel to issue to the Transfer Agent the legal opinion referred
to in the Irrevocable Transfer Agent Instructions. Any fees (with respect to the Transfer Agent, Company Counsel or otherwise) associated
with the issuance of such opinion or the removal of such legend shall be borne by the Company. Following such time as a legend is no
longer required for certain Securities, the Company will no later than two Trading Days following the delivery by a Purchaser to the
Company (with notice to the Company) of a legended book entry statement representing Conversion Shares (endorsed or with stock powers
attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer) (such second Trading Day,
the “Legend Removal Date”), deliver or cause to be delivered via DTC to such Purchaser such Securities that
are free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer
Agent that enlarge the restrictions on transfer set forth in this Section 4.1(c). Electronic certificates for Conversion Shares
subject to legend removal hereunder may be transmitted by the Transfer Agent to the Purchasers by crediting the account of the Purchaser’s
prime broker with DTC as directed by such Purchaser.
Securities Purchase Agreement | Page 21 |
(d)
Irrevocable Transfer Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent, and any subsequent
transfer agent, in the form of Exhibit D attached hereto (the “Irrevocable Transfer Agent Instructions”).
The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section
4.1(d) (or instructions that are consistent therewith) will be given by the Company to its transfer agent in connection with this
Agreement, and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent
provided in this Agreement and the other Transaction Documents and applicable law. The Company acknowledges that a breach by it of its
obligations under this Section 4.1(d) will cause irreparable harm to a Purchaser. Accordingly, the Company acknowledges that the
remedy at law for a breach of its obligations under this Section 4.1(d) will be inadequate and agrees, in the event of a breach
or threatened breach by the Company of the provisions of this Section 4.1(d), that a Purchaser shall be entitled, in addition
to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer,
without the necessity of showing economic loss and without any bond or other security being required.
(e)
Acknowledgement. Each Purchaser hereunder acknowledges its primary responsibilities under the Securities Act and accordingly will
not sell or otherwise transfer the Securities or any interest therein without complying with the requirements of the Securities Act.
While the Resale Registration Statement remains effective, each Purchaser hereunder may sell the Conversion Shares in accordance with
the plan of distribution contained in the Resale Registration Statement and if it does so it will comply therewith and with the related
prospectus delivery requirements unless an exemption therefrom is available. Each Purchaser, severally and not jointly with the other
Purchasers, agrees that if it is notified by the Company in writing at any time that the Resale Registration Statement registering the
resale of the Conversion Shares is not effective or that the prospectus included in such Resale Registration Statement no longer complies
with the requirements of Section 10 of the Securities Act, the Purchaser will refrain from selling such Conversion Shares until such
time as the Purchaser is notified by the Company that such Resale Registration Statement is effective or such prospectus is compliant
with Section 10 of the Securities Act, unless such Purchaser is able to, and does, sell such Conversion Shares pursuant to an available
exemption from the registration requirements of Section 5 of the Securities Act. Both the Company and its Transfer Agent, and their respective
directors, officers, employees and agents, may rely on this Section 4.1(e) and each Purchaser hereunder will indemnify and hold
harmless each of such persons from any breaches or violations of this Section 4.1(e).
(f)
Buy-In. If the Company shall fail for any reason or for no reason to issue via DTC to a Purchaser Securities that are free from
all restrictive and other legends within two Trading Days of receipt of all documents necessary for the removal of the legend set forth
above, then, in addition to all other remedies available to such Purchaser, if on or after the Trading Day immediately following such
two Trading Day period, such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction
of a sale by the holder of shares of Common Stock that such Purchaser anticipated receiving from the Company without any restrictive
legend (a “Buy-In”), then the Company shall, within two trading Days after such Purchaser’s request and
in such Purchaser’s sole discretion, (a) pay in cash to such Purchaser the amount by which (x) such Purchaser’s total purchase
price (including any brokerage commissions). for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate
number of shares of Common Stock that such Purchaser was entitled to receive from the conversion at issue multiplied by (2) the actual
sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)
at the option of such Purchaser, either reissue (if surrendered) the shares of Series B-2 Convertible Preferred Stock or Series B-3 Convertible
Preferred Stock, as applicable, equal to the number of shares of Series B-2 Convertible Preferred Stock or Series B-3 Convertible Preferred
Stock, as applicable, submitted for conversion or deliver to such Purchaser the number of shares of Common Stock that would have been
issued if the Company had timely complied with its delivery requirements under this Section 4.1. The Purchaser shall provide the Company
written notice, within two Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Purchaser in respect
of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Company. Nothing herein shall limit
a Purchaser’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common
Stock upon conversion of the shares of Series B-2 Convertible Preferred Stock or Series B-3 Convertible Preferred Stock as required pursuant
to the terms hereof; provided, however, that the Purchaser shall not be entitled to both (i) require the reissuance of the shares of
Series B-2 Convertible Preferred Stock or Series B-3 Convertible Preferred Stock submitted for conversion for which such conversion was
not timely honored and (ii) receive the number of shares of Common Stock that would have been issued if the Company had timely complied
with its delivery requirements under this Section 4.1.
Securities Purchase Agreement | Page 22 |
4.2
Reservation of Stock. The Company shall take all action necessary to at all times have authorized, subject to approval of the
Additional Proposal by the Company’s stockholders, if applicable, and reserved for the purpose of issuance from and after the Closing
Date, for so long as any of the Shares, the Warrants, the Series B-2 Convertible Preferred Stock and the Series B-3 Convertible Preferred
Stock are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued capital stock, solely
for the purpose of effecting the conversion of the Shares, the exercise of the Warrants and the conversion of the Series B-2 Convertible
Preferred Stock and the Series B-3 Convertible Preferred Stock, the maximum number of shares of Common Stock issuable upon the exercise
or conversion thereof (without taking into account any limitations set forth in the Certificate of Designation).
4.3
Furnishing of Information. In order to enable the Purchasers to sell the Securities under Rule 144, for a period of 12 months
from the Closing, the Company shall use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and
file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange
Act. During such 12 month period, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish
to the Purchasers and make publicly available in accordance with Rule 144(c) such information as is required for the Purchasers to sell
the Securities under Rule 144.
4.4
Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the
Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would require the registration under
the Securities Act of the sale of the Securities to the Purchasers, or that will be integrated with the offer or sale of the Securities
for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval prior to the closing
of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.
4.5
Securities Laws Disclosure; Publicity. By 9:00 A.M., New York City time, on the Trading Day immediately following the date hereof,
the Company shall issue a press release (the “Press Release”) reasonably acceptable to the Purchasers disclosing
all material terms of the transactions contemplated hereby. On or before 9:00 A.M., New York City time, on the second Trading Day immediately
following the execution of this Agreement, the Company will file a Current Report on Form 8-K with the Commission describing the terms
of the Transaction Documents (and including as exhibits to such Current Report on Form 8-K the material Transaction Documents (including,
without limitation, this Agreement, the Certificate of Designation, the forms of Warrants and the Support Agreement)) and the contemplated
change to the Company’s dividend policy as described in Section 5.1(k) below. Notwithstanding the foregoing, the Company
shall not publicly disclose the name of any Purchaser or an Affiliate of any Purchaser, or include the name of any Purchaser or an Affiliate
of any Purchaser in any press release or filing with the Commission (other than the Resale Registration Statement) or any regulatory
agency or Trading Market, without the prior written consent of such Purchaser, such consent not to be unreasonably withheld, except (i)
as required by federal securities law in connection with (A) any registration statement contemplated by Section 4.15 hereto and
(B) the filing of final Transaction Documents (including signature pages thereto) with the Commission and (ii) to the extent such disclosure
is required by law, request of the Staff or Trading Market regulations, in which case the Company shall provide the Purchasers with prior
written notice of such disclosure permitted under this subclause (ii). From and after the issuance of the Press Release, no Purchaser
shall be in possession of any material, non-public information received from the Company, any Subsidiary or any of their respective officers,
directors, employees or agents, that is not disclosed in the Press Release unless a Purchaser shall have executed a written agreement
regarding the confidentiality and use of such information. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that until such time as the transactions contemplated by this Agreement are required to be publicly disclosed by the Company as described
in this Section 4.5, such Purchaser will maintain the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction).
4.6
Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted
by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, in either case solely
by virtue of receiving Securities under the Transaction Documents or under any other written agreement between the Company and the Purchasers;
provided, however, that no such Purchaser owns any equity in the Company prior to its purchase of the Securities hereunder.
Securities Purchase Agreement | Page 23 |
4.7
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, including this Agreement, or as expressly required by any applicable securities law, the Company covenants and agrees that
neither it, nor any other Person acting on its behalf, will provide any Purchaser or its agents or counsel with any information regarding
the Company that the Company believes constitutes material non-public information without the express written consent of such Purchaser.
The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company.
4.8
Use of Proceeds. The Company shall use the net proceeds from the sale of the Shares and Warrants hereunder for working capital
and general corporate purposes and shall not use such proceeds for: (a) the satisfaction of any portion of the Company’s debt (other
than (i) debt outstanding as of the date hereof, as disclosed in the SEC Reports, and (ii) payment of trade payables in the ordinary
course of the Company’s business and prior practices), (b) the redemption of any Common Stock or Common Stock Equivalents or (c)
the settlement of any outstanding litigation.
4.9
Indemnification of Purchasers. Subject to the provisions of this Section 4.9 (and in addition to the indemnification provisions
set forth in Section 4.15), the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members,
partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other
Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title)
of such controlling persons (each, a “Purchaser Party”) harmless from any and all losses, liabilities, obligations,
claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable
attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a)
any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction
Documents or (b) any action instituted against a Purchaser in any capacity, or any of them or their respective Affiliates, by any stockholder
of the Company who is not an Affiliate of such Purchaser, with respect to any of the transactions contemplated by the Transaction Documents
(unless such action is based upon a breach of such Purchaser’s representations, warranties or covenants under the Transaction Documents
or any agreements or understandings such Purchaser may have with any such stockholder or any violations by the Purchaser of state or
federal securities laws or any conduct by such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance).
Promptly after receipt by any Person (the “Indemnified Person”) of notice of any demand, claim or circumstances
which would or might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which indemnity
may be sought pursuant to this Section 4.9, such Indemnified Person shall promptly notify the Company in writing and the Company
shall assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Person, and shall assume
the payment of all fees and expenses; provided, however, that the failure of any Indemnified Person so to notify the Company
shall not relieve the Company of its obligations hereunder except to the extent that the Company is actually and materially prejudiced
by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees
and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall
have mutually agreed to the retention of such counsel; (ii) the Company shall have failed promptly to assume the defense of such proceeding
and to employ counsel reasonably satisfactory to such Indemnified Person in such proceeding; or (iii) in the reasonable judgment of counsel
to such Indemnified Person, representation of both parties by the same counsel would be inappropriate due to actual or potential differing
interests between them. The Company shall not be liable for any settlement of any proceeding effected without its written consent, which
consent shall not be unreasonably withheld, delayed or conditioned. Without the prior written consent of the Indemnified Person, which
consent shall not be unreasonably withheld, delayed or conditioned, the Company shall not effect any settlement of any pending or threatened
proceeding in respect of which any Indemnified Person is or could have been a party and indemnity could have been sought hereunder by
such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Person from all liability arising
out of such proceeding.
4.10
Principal Trading Market Listing. In the time and manner required by the Principal Trading Market, the Company shall prepare and
file with such Principal Trading Market an additional shares listing application covering all of the Common Stock and shall use its commercially
reasonable efforts to take all steps necessary to cause all of the Common Stock to be approved for listing on the Principal Trading Market
as promptly as possible thereafter. The Company shall use commercially reasonable efforts to maintain the Company’s listing on
the Principal Trading Market through the second anniversary of the Closing Date.
Securities Purchase Agreement | Page 24 |
4.11
Form D; Blue Sky. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and
to provide a copy thereof, promptly upon the written request of any Purchaser. The Company, on or before the Closing Date, shall take
such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities for
sale to the Purchasers under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an
exemption from such qualification) and shall provide evidence of such actions promptly upon the written request of any Purchaser.
4.12
Delivery of Shares and Warrants After Closing. The Company shall deliver, or cause to be delivered, the respective Shares and
Warrants purchased by each Purchaser to such Purchaser within two Trading Days of the Closing Date.
4.13
Short Sales and Confidentiality After The Date Hereof. Such Purchaser shall not, and shall cause its Trading Affiliates not to,
engage, directly or indirectly, in any transactions in the Company’s securities (including, without limitation, any Short Sales
involving the Company’s securities) during the period from the date hereof until the earlier of such time as (i) the transactions
contemplated by this Agreement are first publicly announced as required by and described in Section 4.5 or (ii) this Agreement
is terminated in full pursuant to Section 6.18. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company as described in Section
4.5, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included
in the Transaction Documents and Disclosure Schedules. Notwithstanding the foregoing, no Purchaser makes any representation, warranty
or covenant hereby that it will not engage in Short Sales in the securities of the Company after the time that the transactions contemplated
by this Agreement are first publicly announced as described in Section 4.5; provided, however, each Purchaser agrees, severally
and not jointly with any Purchasers, that they will not enter into any Net Short Sales (as hereinafter defined) from the period commencing
on the Closing Date and ending on the earliest of (x) the Effective Date of the initial Registration Statement, (y) the twenty-four (24)
month anniversary of the Closing Date or (z) the date that such Purchaser no longer holds any Securities. For purposes of this Section
4.13, a “Net Short Sale” by any Purchaser shall mean a sale of Common Stock by such Purchaser that is marked
as a short sale and that is made at a time when there is no equivalent offsetting long position in Common Stock held by such Purchaser.
For purposes of determining whether there is an equivalent offsetting position in Common Stock held by the Purchaser, Conversion Shares
that have not yet been issued pursuant to the conversion of the Shares, Series B-2 Convertible Preferred Stock or Series B-3 Convertible
Preferred Stock shall be deemed to be held long by the Purchaser, and the amount of shares of Common Stock held in a long position shall
be all unconverted Conversion Shares (ignoring any exercise limitations included therein) issuable to such Purchaser on such date, plus
any shares of Common Stock or Common Stock Equivalents otherwise then held by such Purchaser. Notwithstanding the foregoing, in the event
that a Purchaser is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of such Purchaser’s assets, the representation set forth above shall apply only with respect to the portion of assets
managed by the portfolio manager that have knowledge about the financing transaction contemplated by this Agreement. Moreover, notwithstanding
the foregoing, in the event that a Purchaser has sold Securities pursuant to Rule 144 prior to the Effective Date of the Resale Registration
Statement and the Company has failed to deliver via DTC Securities that are free of all restrictive and other legends prior to the settlement
date for such sale (assuming that such electronic certificates meet the requirements set forth in Section 4.1(c) for the removal
of legends), the provisions of this Section 4.13 shall not prohibit the Purchaser from entering into Net Short Sales for the purpose
of delivering shares of Common Stock in settlement of such sale.
4.14
Subsequent Equity Sales. Except for an Exempt Issuance, from the date hereof until 30 days after the later of the Effective Date
and receipt of the Stockholder Approval, neither the Company nor any Subsidiary shall issue shares of Common Stock or Common Stock Equivalents;
provided, however, the 30 day period set forth in this Section 4.14 shall be extended for the number of Trading Days during
such period in which (i) trading in the Common Stock is suspended by any Trading Market, or (ii) following the Effective Date, the Resale
Registration Statement is not effective or the prospectus included in the Resale Registration Statement may not be used by the Purchasers
for the resale of the Common Stock.
Securities Purchase Agreement | Page 25 |
4.15
Registration Rights.
(a)
Registration Procedures and Expenses. The Company shall:
(i)
(A) within 15 days of the Closing Date, file a Resale Registration Statement with the Commission to register all of the Series B-1 Registrable
Shares on Form S-3 under the Securities Act (providing for shelf registration of such Registrable Shares under Commission Rule 415),
and (B) as soon as practicable following receipt of the Stockholder Approval , but, in any event, not later than three days thereafter,
file a Resale Registration Statement with the Commission to register all of the Series B-3 Registrable Shares on Form S-3 under the Securities
Act (providing for shelf registration of such Registrable Shares under Commission Rule 415) (each such date, a “Filing Date”).
In the event that Form S-3 is not available for the registration of any of the Registrable Shares, the Company shall register the resale
of the Registrable Shares on such other form as is available to the Company;
(ii)
use its commercially reasonable efforts to cause each such Resale Registration Statements required by Section 4.15(a)(i) to be
declared effective within 21 days following the applicable Filing Date (or, in the event the Staff reviews and has written comments to
any such Resale Registration Statement, within the later of (a) 45 days following the applicable Filing Date and (b) 15 days following
the last comment received from the Staff with respect to such Resale Registration Statement) (the earlier of the foregoing or the applicable
date set forth in Section 4.15(vi), the “Effectiveness Deadline” with respect to such Resale Registration
Statement), such efforts to include, without limiting the generality of the foregoing, preparing and filing with the Commission any financial
statements or other information that is required to be filed prior to the effectiveness of such Resale Registration Statement; provided that no Resale Registration Statement will be required to be declared effective prior to the Company having
filed its Annual Report on Form 10-K for the year ended December 31, 2023;
(iii)
prepare and file with the Commission such amendments and supplements to any Resale Registration Statements and the prospectus used in
connection therewith as may be necessary to keep such Resale Registration Statements continuously effective and free from any material
misstatement or omission to state a material fact therein until termination of such obligation as provided in Section 4.15(e)
below, subject to the Company’s right to suspend pursuant to Section 4.15(d);
(iv)
furnish to the Purchasers such number of copies of prospectuses in conformity with the requirements of the Securities Act and such other
documents as the Purchasers may reasonably request, in order to facilitate the public sale or other disposition of all or any of the
Registrable Shares by the Purchasers;
(v)
file such documents as may be required of the Company for normal securities law clearance for the resale of the Registrable Shares in
such states of the United States as may be reasonably requested by the Purchasers and use its commercially reasonable efforts to maintain
such blue sky qualifications during the period the Company is required to maintain effectiveness of the Resale Registration Statements;
provided, however, that the Company shall not be required in connection with this Section 4.15(a)(v) to qualify
as a foreign corporation or execute a general consent to service of process in any jurisdiction in which it is not now so qualified or
has not so consented;
(vi)
upon notification by the Commission that a Resale Registration Statement will not be reviewed or is not subject to further review by
the Commission, within one Trading Days following the date of such notification, request acceleration of such Resale Registration Statement
(with the requested effectiveness date to be not more than two Trading Days later);
(vii)
upon notification by the Commission that that a Resale Registration Statement has been declared effective (the date of such notification,
the “Effective Date”) by the Commission, file the final prospectus under Rule 424 within the applicable time
period prescribed by Rule 424;
(viii)
advise the Purchasers promptly, and in any event within 24 hours of (A) the effectiveness of a Resale Registration Statement or any post-effective
amendments thereto, (B) any request by the Commission for amendments to the Resale Registration Statement or amendments to the prospectus
or for additional information relating thereto, (C) the issuance by the Commission of any stop order suspending the effectiveness of
a Resale Registration Statement under the Securities Act or of the suspension by any state securities commission of the qualification
of the Registrable Shares for offering or sale in any jurisdiction, or the initiation of any proceeding for any of the preceding purposes
and (D) the existence of any fact and the happening of any event that makes any statement of a material fact made in a Resale Registration
Statement, the prospectus and amendment or supplement thereto, or any document incorporated by reference therein, untrue, or that requires
the making of any additions to or changes in a Resale Registration Statement or the prospectus in order to make the statements therein
not misleading;
Securities Purchase Agreement | Page 26 |
(ix)
cause all Registrable Shares to be listed on each securities exchange on which equity securities by the Company are then listed, if any;
and
(x)
bear all expenses in connection with the procedures in paragraphs (i) through (ix) of this Section 4.15(a) and the registration
of the Registrable Shares on such Resale Registration Statement and the satisfaction of the blue sky laws of such states.
(b)
Rule 415 Cutback. If at any time the Staff takes the position that the offering of some or all of the Registrable Shares in a
Resale Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the
Securities Act or requires any Purchaser to be named as an “underwriter,” the Company shall use its commercially reasonable
efforts to persuade the Commission that the offering contemplated by such Resale Registration Statement is a valid secondary offering
and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that none of the Purchasers is an “underwriter.”
The Purchasers shall have the right to review and oversee any registration or matters pursuant to this Section 4.15, including
any participation in meetings or discussions with the Commission regarding the Commission’s position and to comment on any written
submission made to the Commission with respect thereto. In the event that, despite the Company’s commercially reasonable efforts
and compliance with the terms of this Section 4.15, the Staff refuses to alter its position, the Company shall (A) remove from
the Resale Registration Statement such portion of the Registrable Shares (the “Cut Back Shares”) and/or (B)
agree to such restrictions and limitations on the registration and resale of the Registrable Shares as the Commission may require to
assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions”);
provided, however, that the Company shall not agree to name any Purchaser as an “underwriter” in such Resale
Registration Statement without the prior written consent of such Purchaser. Any cutback imposed on the Purchasers pursuant to this Section
4.15 shall be allocated among the Purchasers on a pro rata basis and shall be applied first to any of the Registrable Securities
of such Purchaser as such Purchaser shall designate, unless the SEC Restrictions otherwise require or provide or the Purchasers otherwise
agree. No damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect the registration of such Cut
Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination Date” of such
Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this Section
4.15 shall again be applicable to such Cut Back Shares; provided, however, that (x) the filing deadline for the Resale
Registration Statement including such Cut Back Shares shall be 10 Trading Days after such Restriction Termination Date, and (y) the Effectiveness
Deadline with respect to such Cut Back Shares shall be the 60th day immediately after the Restriction Termination Date or the 90th day
if the Staff reviews such Resale Registration Statement (but in any event no later than three Trading Days from the Staff indicating
it has no further comments on such Resale Registration Statement).
(c)
Indemnification.
(i)
The Company agrees to indemnify and hold harmless each Purchaser Party, to the fullest extent permitted by applicable law, from and against
any losses, claims, damages or liabilities (collectively, “Losses”), joint or several, to which they may become
subject (under the Securities Act or otherwise) insofar as such Losses (or actions or proceedings in respect thereof) arise out of, or
are based upon, any material breach of this Agreement by the Company or any untrue or alleged untrue statement of a material fact contained
in a Resale Registration Statement or any omission or alleged omission to state a material fact required to be stated in the prospectus
contained therein or necessary to make the statements in the prospectus contained therein, in light of the circumstances under which
they were made, not misleading or arise out of any failure by the Company to fulfill any undertaking included in the Resale Registration
Statement and the Company will, as incurred, reimburse the Purchaser Parties for any legal or other expenses reasonably incurred in investigating,
defending or preparing to defend any such action, proceeding or claim; provided, however, that the Company shall not be
liable in any such case to the extent that such Loss arises out of, or is based upon: (A) an untrue statement or omission made in such
Resale Registration Statement in reliance upon and in conformity with written information furnished to the Company by or on behalf of
such Purchaser specifically for inclusion in the Resale Registration Statement or (B) any breach of this Agreement by such Purchaser;
provided further, however, that the Company shall not be liable to any Purchaser Party (or any partner, member, officer,
director or controlling Person of the Purchasers) to the extent that any such Loss is caused by an untrue statement or omission made
in any preliminary prospectus if either (1) (a) such Purchaser failed to send or deliver a copy of the final prospectus with or prior
to, or such Purchaser failed to confirm that a final prospectus was deemed to be delivered prior to (in accordance with Rule 172 of the
Securities Act), the delivery of written confirmation of the sale by such Purchaser to the Person asserting the claim from which such
Loss resulted and (b) the final prospectus corrected such untrue statement or omission, (2) (x) such untrue statement or omission is
corrected in an amendment or supplement to the prospectus and (y) having previously been furnished by or on behalf of the Company with
copies of the prospectus as so amended or supplemented or notified by the Company that such amended or supplemented prospectus has been
filed with the Commission, in accordance with Rule 172 of the Securities Act, such Purchaser thereafter fails to deliver such prospectus
as so amended or supplemented, with or prior to or a Purchaser fails to confirm that the prospectus as so amended or supplemented was
deemed to be delivered prior to (in accordance with Rule 172 of the Securities Act), the delivery of written confirmation of the sale
by such Purchaser to the Person asserting the claim from which such Loss resulted or (3) such Purchaser sold Registrable Shares in violation
of such Purchasers’ covenants contained in Article IV of this Agreement.
Securities Purchase Agreement | Page 27 |
(ii)
Each Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company and its officers, directors, affiliates,
agents and representatives and each Person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act (each a “Company Party” and collectively the “Company Parties”),
from and against any Losses to which the Company Parties may become subject (under the Securities Act or otherwise), insofar as such
Losses (or actions or proceedings in respect thereof) arise out of, or are based upon, any material breach of this Agreement by such
Purchaser or untrue statement of a material fact contained in a Resale Registration Statement (or any omission to state therein a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading in each case, on the effective date thereof), if, and only to the extent, such untrue statement or omission was made in
reliance upon and in conformity with written information furnished by or on behalf of such Purchaser specifically for inclusion in the
Resale Registration Statement, and each Purchaser, severally and not jointly, will reimburse each Company Party for any legal or other
expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim; provided,
however, that in no event shall any indemnity under this Section 4.15(c)(ii) be greater in amount than the dollar amount
of the proceeds (net of all expenses paid by such Purchaser in connection with any claim relating to this Section 4.15 and the
amount of any damages such Purchaser has otherwise been required to pay by reason of such untrue statement or omission) received by such
Purchaser upon its sale of the Registrable Shares included in the Resale Registration Statement giving rise to such indemnification obligation.
(iii)
Promptly after receipt by any indemnified Person of a notice of a claim or the beginning of any action in respect of which indemnity
is to be sought against an indemnifying Person pursuant to this Section 4.15(c), such indemnified Person shall notify the indemnifying
Person in writing of such claim or of the commencement of such action, and, subject to the provisions hereinafter stated, in case any
such action shall be brought against an indemnified Person and such indemnifying Person shall have been notified thereof, such indemnifying
Person shall be entitled to participate therein, and, to the extent that it shall wish, to assume the defense thereof, with counsel reasonably
satisfactory to such indemnified Person. After notice from the indemnifying Person to such indemnified Person of its election to assume
the defense thereof, such indemnifying Person shall not be liable to such indemnified Person for any legal expenses subsequently incurred
by such indemnified Person in connection with the defense thereof; provided, however, that if there exists or shall exist
a conflict of interest that would make it inappropriate in the reasonable judgment of the indemnified Person for the same counsel to
represent both the indemnified Person and such indemnifying Person or any affiliate or associate thereof, the indemnified Person shall
be entitled to retain its own counsel at the expense of such indemnifying Person; provided, further, that no indemnifying
Person shall be responsible for the fees and expense of more than one separate counsel for all indemnified parties. The indemnifying
party shall not settle an action without the consent of the indemnified party, which consent shall not be unreasonably withheld.
Securities Purchase Agreement | Page 28 |
(iv)
If after proper notice of a claim or the commencement of any action against the indemnified party, the indemnifying party does not choose
to participate, then the indemnified party shall assume the defense thereof and upon written notice by the indemnified party requesting
advance payment of a stated amount for its reasonable defense costs and expenses, the indemnifying party shall advance payment for such
reasonable defense costs and expenses (the “Advance Indemnification Payment”) to the indemnified party. In
the event that the indemnified party’s actual defense costs and expenses exceed the amount of the Advance Indemnification Payment,
then upon written request by the indemnified party, the indemnifying party shall reimburse the indemnified party for such difference;
in the event that the Advance Indemnification Payment exceeds the indemnified party’s actual costs and expenses, the indemnified
party shall promptly remit payment of such difference to the indemnifying party.
(v)
If the indemnification provided for in this Section 4.15(c) is held by a court of competent jurisdiction to be unavailable to
an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of
indemnifying such indemnified party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or payable
by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative
fault of the indemnifying party on the one hand and of the indemnified party on the other, as well as any other relevant equitable considerations;
provided, that in no event shall any contribution by an indemnifying party hereunder be greater in amount than the dollar amount
of the proceeds received by such indemnifying party upon the sale of such Registrable Shares. No person guilty of fraudulent misrepresentation
within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any person not guilty of such fraudulent
misrepresentation.
(d)
Prospectus Suspension. Each Purchaser acknowledges that there may be times when the Company must suspend the use of the prospectus
forming a part of a Resale Registration Statement until such time as an amendment to such Resale Registration Statement has been filed
by the Company and declared effective by the Commission, or until such time as the Company has filed an appropriate report with the Commission
pursuant to the Exchange Act. Each Purchaser hereby covenants that it will not sell any Registrable Shares pursuant to said prospectus
during the period commencing at the time at which the Company gives the Purchasers notice of the suspension of the use of said prospectus
and ending at the time the Company gives the Purchasers notice that the Purchasers may thereafter effect sales pursuant to said prospectus;
provided, that such suspension periods shall in no event exceed 30 consecutive days or a total of 60 days in any 12-month period
and that, in the good faith judgment of the Company’s Board of Directors, the Company would, in the absence of such delay or suspension
hereunder, be required under state or federal securities laws to disclose any corporate development, a potentially significant transaction
or event involving the Company, or any negotiations, discussions, or proposals directly relating thereto, in either case the disclosure
of which would reasonably be expected to have a Material Adverse Effect upon the Company or its stockholders.
(e)
Termination of Obligations. The obligations of the Company pursuant to Section 4.15(a) hereof shall cease and terminate,
with respect to any Registrable Shares, upon the earlier to occur of (i) such time such Registrable Shares have been resold, or (ii)
such time as such shares no longer remain Registrable Shares.
(f)
Reporting Requirements. With a view to making available the benefits of certain rules and regulations of the Commission that may
at any time permit the sale of the Registrable Shares to the public without registration or pursuant to a registration statement on Form
S-3, the Company agrees to:
(i)
make and keep public information available, as those terms are understood and defined in Rule 144; and
(ii)
so long as a Purchaser owns Registrable Shares, to furnish to such Purchaser upon request (A) a written statement by the Company as to
whether it is in compliance with the reporting requirements of Rule 144 and the Exchange Act, or whether it is qualified as a registrant
whose securities may be resold pursuant to Commission Form S-3 and (B) such other information as may be reasonably requested to permit
the Purchaser to sell such securities pursuant to Rule 144.
Securities Purchase Agreement | Page 29 |
(g)
If a Resale Registration Statement has not been declared effective by the Commission on or before the earlier of the applicable Effectiveness
Deadline or the date set forth in Section 4.15(a)(vi) (the “Required Effective Date”), the Company shall,
on the business day immediately following the Required Effective Date and each 30th day thereafter, make a payment to the
Purchasers as partial liquidated damages for such delay (together, the “Late Registration Payments”) equal
to 1% of the Purchase Price then owned by the Purchasers until the Resale Registration Statement is declared effective by the Commission.
Late Registration Payments will be prorated on a daily basis during each 30-day period and will be paid to the Purchasers by wire transfer
or check within five business days after the earlier of (i) the end of each 30-day period following the Required Effective Date or (ii)
the effective date of the Resale Registration Statement. If the Company fails to pay any liquidated damages pursuant to this section
in full within seven days after the date payable, the Company will pay interest thereon at a rate of 12% per annum (or such lesser maximum
amount that is permitted to be paid by applicable law) to the Purchasers, accruing daily from the date such liquidated damages are due
until such amounts, plus all such interest thereon, are paid in full; provided that no Late
Registration Payments shall accrue for a Resale Registration Statement that is declared effective on the same day as the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023, so long as such Form 10-K is filed with the Commission in a timely manner,
even if the date that such Resale Registration is declared effective is later than the Required Effective Date.
4.16
Stockholder Approval. The Company shall, as soon as practicable following the Closing, but not more than 30 days thereafter, file
a preliminary proxy statement for a vote of its stockholders to approve one or more of the following proposals (if the preliminary proxy
statement does not contain all of the proposals listed below, the Company shall file a preliminary proxy statement for a vote of its
stockholders to approve any of proposals not included in a previous preliminary proxy statement, within 30 days of the annual or special
meeting in which any of such proposals were voted upon by the stockholders):
(i)
the issuance of all Conversion Shares upon conversion of the Shares, shares of Series B-2 Convertible Preferred Stock and the Series
B-3 Convertible Preferred Stock, if required by Nasdaq Rule 5635 (or any successor thereto),
(ii)
the issuance of the Series B-3 Convertible Preferred Stock upon exercise of the Warrants, if required by Nasdaq Rule 5635 (or any successor thereto),
(iii)
an increase to its authorized share capital (together, the “Initial Proposals”), and
(iv)
if any Purchaser following the closing of the transactions contemplated by this Agreement would, other than due to any blockers or caps
contained in the Certificate of Designation or Warrant, hold a number of shares equal to 19.9% of the Company’s outstanding Common
Stock on an as-if-converted to Common Stock basis as of the date of this Agreement (excluding for purposes of the calculation, any securities
issued pursuant to this Agreement), the approval required by Nasdaq Rule 5635(b) (or any successor thereto) to permit full conversion
of the Shares and issuance of the Conversion Shares in full upon conversion of the Shares, shares of Series B-2 Convertible Preferred
Stock and the Series B-3 Convertible Preferred Stock (the “Additional Proposal” and together with the Initial
Proposals, the “Proposals”).
The
Company shall, as soon as practicable following notification from the Staff that it has completed its review of a preliminary proxy statement
filed in accordance with this Section 4.16 or that it will not review such preliminary proxy statement, file and mail a definitive proxy
statement for the vote of its stockholders to approve the applicable Proposals. The Company covenants and agrees that its Board of Directors
shall unanimously recommend that the applicable Proposals be approved by the Company’s stockholders at all meetings in which such
Proposals are considered and promptly file the necessary amendments to the Company’s certificate of incorporation after the Proposals
are approved. If the Company’s stockholders do not approve any of the Initial Proposals at the first meeting in which such proposal
is voted on by stockholders, the Company covenants and agrees that it will submit any such Initial Proposals for approval of the Company’s
stockholders at least semi-annually until such approval is obtained.
4.17
Director Designation Rights.
(a)
The Company agrees to appoint up to two independent directors in consultation with, and subject to the approval of, Rosalind Advisors,
Inc. (the “Appointed Directors”) to the Company’s Board of Directors effective as soon as practicable
following the receipt of Stockholder Approval by taking all necessary action by the Company or its Board of Directors to effect such
appointment. The Appointed Directors will be classified, so long as the Company has a classified Board of Directors, in a manner consistent
with the Company’s organizational documents and in consultation with Rosalind Advisors, Inc. Upon the conclusion of the Appointed
Directors’ term(s) on the Company’s Board of Directors, the Company agrees to include the Appointed Directors as nominees
in the Company’s slate of nominees for election as directors of the Company at the Company’s annual meeting of stockholders
for the applicable year(s), and to use its commercially best efforts to cause the election of the Appointed Directors. For the avoidance
of doubt, the Company shall use substantially the same level of effort and provide substantially the same level of support as is used
and/or provided for the other director nominees of the Company with respect to the applicable meeting of stockholders. Furthermore, for
the avoidance of doubt, failure of the stockholders of the Company to elect the Appointed Directors for one or more additional terms
shall not be deemed a breach of the Company’s obligations hereunder. In such case, and in the event any designated Appointed Director
or serving Appointed Director is not approved or ceases to serve as a director, Rosalind Advisors, Inc. may designate on each such
occasion a substitute Appointed Director and the same Company obligations set forth above with respect to the initial Appointed Directors
shall apply.
Securities Purchase Agreement | Page 30 |
(b)
In connection with the appointment of the Appointed Directors to the Company’s Board of Directors (i) the Appointed Directors must
provide to the Company (A) all information reasonably requested by the Company that is required to be or customarily disclosed for directors,
candidates for directors, and their affiliates and representatives in a proxy statement or other filings under applicable law or regulation
or stock exchange rules or listing standards, in each case, relating to his or her nomination or election as a director of the Company
and (B) information reasonably requested by the Company in connection with assessing eligibility, independence and other criteria applicable
to directors or satisfying compliance and legal or regulatory obligations, in each case, relating to his or her nomination or election
as a director of the Company, including, any customary background checks, interviews, questionnaires or other investigations as may be
conducted by or on behalf of the Company, and (ii) the Appointed Directors must agree to comply with all of the Company’s policies
and procedures to the same extent as each other director of the Company, including, but not limited to, any corporate governance guidelines,
code of conduct and securities trading policy, in each case as may be adopted and/or amended from time to time.
4.18
Participation Right.
(a)
Until the first anniversary of the Closing Date, neither the Company nor any of its Subsidiaries shall, directly or indirectly, effect
any securities offering unless the Company shall have first complied with this Section 4.18. The Company acknowledges and agrees that
the right set forth in this Section 4.18 is a right granted by the Company, separately, to each Purchaser.
(b)
At least two Trading Days prior to such securities offering, the Company shall deliver to each Purchaser a written notice of the Company’s
intention to effect a subsequent securities offering which notice shall describe in reasonable detail the proposed terms of such securities
offering, the amount of proceeds intended to be raised thereunder and the Person or Persons through or with whom such securities offering
is proposed to be effected and shall include a term sheet and transaction documents relating thereto as an attachment.
(c)
Any Purchaser desiring to participate in such securities offering must provide written notice to the Company by 6:30 am (New York City
time) on the Trading Day following the date on which the notice described in Section 4.18(b) is delivered to such Purchaser that such
Purchaser is willing to participate in the securities offering (which notice shall serve as irrevocable instructions to participate in
such securities offering), the amount of such Purchaser’s participation, and representing and warranting that such Purchaser has
such funds ready, willing, and available for investment on the terms set forth in the notice described in Section 4.18(b) above and,
in the event the Company receives such notice from the Purchaser, the Company shall allow the Purchaser to participate in the securities
offering on the terms set forth in the Purchaser’s notice if the securities offering is consummated. If the Company receives no
such notice from a Purchaser as of such time specified in this Section 4.18(c), such Purchaser shall be deemed to have notified the Company
that it does not elect to participate in such securities offering. If more than one Purchaser wish to participate in such securities
offering and their respective participation requests exceed the total amount of the securities offering, the Purchasers shall participate
on a pro rata basis based on the number of shares of Common Stock held by such Purchasers treating all convertible and exercisable securities
such as the Warrants on an as if fully exercised and converted to Common Stock basis.
ARTICLE
V.
CONDITIONS
PRECEDENT TO CLOSING
5.1
Conditions Precedent to the Obligations of the Purchasers to Purchase Securities. The obligation of each Purchaser to acquire
Shares and Warrants at the Closing is subject to the fulfillment to such Purchaser’s satisfaction, on or prior to the Closing Date,
of each of the following conditions, any of which may be waived by such Purchaser (as to itself only):
(a)
Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct in
all material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations
and warranties shall be true and correct in all respects) as of the date when made and as of the Closing Date, as though made on and
as of such date, except for such representations and warranties that speak as of a specific date.
Securities Purchase Agreement | Page 31 |
(b)
Performance. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing.
(c)
No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.
(d)
Consents. The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers
necessary for consummation of the purchase and sale of the Securities (including all Required Approvals), all of which shall be and remain
so long as necessary in full force and effect.
(e)
Adverse Changes. Since the date of execution of this Agreement, no event or series of events shall have occurred that has had
or would reasonably be expected to have a Material Adverse Effect.
(f)
Listing. The Nasdaq Capital Market shall have approved the listing of additional shares application for the Common Stock.
(g)
No Suspensions of Trading in Common Stock. The Common Stock shall not have been suspended, as of the Closing Date, by the Commission
or the Principal Trading Market from trading on the Principal Trading Market nor shall suspension by the Commission or the Principal
Trading Market have been threatened, as of the Closing Date, either (i) in writing by the Commission or the Principal Trading Market
or (ii) by falling below the minimum listing maintenance requirements of the Principal Trading Market.
(h)
Company Deliverables. The Company shall have delivered the Company Deliverables in accordance with Section 2.2(a).
(i)
Compliance Certificate. The Company shall have delivered to each Purchaser a certificate, dated as of the Closing Date and signed
by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions
specified in Sections 5.1(a) and (b) in the form attached hereto as Exhibit F.
(j)
Due Diligence. The Company shall have provided the Purchasers with all documents and materials reasonably requested by the Purchasers
in connection with their due diligence review.
(k)
Dividend Policy. The Company shall modify its dividend policy to state that, subject to compliance with any restrictive covenants
in any of the Company’s existing debt facilities, the Company shall consider in good faith the issuance of dividends or share buybacks,
from time to time, from the Company’s annual net cash flow.
(l)
Termination. This Agreement shall not have been terminated as to such Purchaser in accordance with Section 6.18 herein.
5.2
Conditions Precedent to the Obligations of the Company to sell Securities. The Company’s obligation to sell and issue the
Shares and Warrants at the Closing to the Purchasers is subject to the fulfillment to the satisfaction of the Company on or prior to
the Closing Date of the following conditions, any of which may be waived by the Company:
(a)
Representations and Warranties. The representations and warranties made by the Purchasers in Section 3.2 hereof shall be
true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in
which case such representations and warranties shall be true and correct in all respects) as of the date when made, and as of the Closing
Date as though made on and as of such date, except for representations and warranties that speak as of a specific date.
(b)
Performance. Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the
Closing Date.
(c)
No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.
Securities Purchase Agreement | Page 32 |
(d)
Consents. The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers
necessary for consummation of the purchase and sale of the Securities, all of which shall be and remain so long as necessary in full
force and effect.
(e)
Purchasers Deliverables. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 2.2(b).
(f)
Listing. The Company or its counsel shall have submitted a Listing of Additional Shares notification form with the Nasdaq Stock
Market LLC covering the Conversion Shares and Common Stock.
(g)
Termination. This Agreement shall not have been terminated as to such Purchaser in accordance with Section 6.18 herein.
ARTICLE
VI.
MISCELLANEOUS
6.1
Fees and Expenses. The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection
with the sale and issuance of the Securities to the Purchasers and all expenses in connection with obtaining Stockholder Approval and
the registration of the Common Stock. Each party shall otherwise pay its own expenses in connection with the transactions contemplated
by the Transaction Documents.
6.2
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, discussions and representations,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.
At or after the Closing, and without further consideration, the Company and the Purchasers will execute and deliver to the other such
further documents as may be reasonably requested in order to give practical effect to the intention of the parties under the Transaction
Documents.
6.3
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile (provided the sender receives a machine-generated confirmation of successful transmission) at the facsimile number specified
in this Section 6.3 prior to 5:00 P.M., New York City time, on a Trading Day, (b) the next Trading Day after the date of transmission,
if such notice or communication is delivered via facsimile at the facsimile number specified in this Section 6.3 on a day that
is not a Trading Day or later than 5:00 P.M., New York City time, on any Trading Day, (c) the Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual receipt by the party
to whom such notice is required to be given. The address for such notices and communications shall be as follows:
If
to the Company: |
Biofrontera
Inc.
120
Presidential Way, Suite 330
Woburn,
Massachusetts 01801
Attention:
Fred Leffler
Email:
f.leffler@bfinc.com |
|
|
With
a copy to:
(which
shall not constitute notice) |
McGuireWoods
LLP
1251
Avenue of the Americas, 20th Floor
New
York, New York 10020
Attention:
Stephen Older and Andrew Terjesen
Email:
solder@mcguirewoods.com
aterjesen@mcquirewoods.com |
|
|
If
to a Purchaser: |
To
the address set forth under such Purchaser’s name on the signature page hereof: |
|
|
Or
such other address as may be designated in writing hereafter, in the same manner, by such Person. |
Securities Purchase Agreement | Page 33 |
6.4
Amendments; Waivers; No Additional Consideration. No provision of this Agreement may be waived, modified, supplemented or amended
except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers of at least a majority in interest
of the Securities, if prior to the Closing Date, to be purchased by the Purchasers hereunder, or, if after the Closing Date, still held
by Purchasers or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No waiver of any default
with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or
a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission
of either party to exercise any right hereunder in any manner impair the exercise of any such right. No consideration shall be offered
or paid to any Purchaser to amend or consent to a waiver or modification of any provision of any Transaction Document unless the same
consideration is also offered to all Purchasers who then hold Securities.
6.5
Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the
parties to express their mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be
construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provisions of this Agreement or any of the Transaction Documents.
6.6
Successors and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties and their
successors and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without
the prior written consent of each Purchaser. Any Purchaser may assign its rights hereunder in whole or in part to any Person to whom
such Purchaser assigns or transfers any Securities in compliance with the Transaction Documents and applicable law, provided such transferee
shall agree in writing to be bound, with respect to the transferred Securities, by the terms and conditions of this Agreement that apply
to the “Purchasers.”
6.7
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except (i) each Purchaser
Party is an intended third party beneficiary of Section 4.9 and the Placement Agent shall be the third party beneficiary of the representations
and warranties of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2.
6.8
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles
of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective Affiliates,
employees or agents) shall be commenced exclusively in the Delaware Court of Chancery. Each party hereto hereby irrevocably submits to
the exclusive jurisdiction of the Delaware Court of Chancery for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to
the jurisdiction of any such Delaware Court, or that such Proceeding has been commenced in an improper or inconvenient forum. Each party
hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a
copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH
PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY
LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
6.9
Survival. Subject to applicable statute of limitations, the representations, warranties, agreements and covenants contained herein
shall survive the Closing and the delivery of the Securities.
6.10
Execution. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile,
electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
Securities Purchase Agreement | Page 34 |
6.11
Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such
substitute provision in this Agreement.
6.12
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) the Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part
without prejudice to its future actions and rights.
6.13
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company and the Transfer
Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact
and an agreement to indemnify and hold harmless the Company and the Transfer Agent for any losses in connection therewith or, if required
by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for a new certificate or instrument
under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Securities.
If a replacement certificate or instrument evidencing any Securities is requested due to a mutilation thereof, the Company may require
delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement.
6.14
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing
sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with any action
for a temporary restraining order) the defense that a remedy at law would be adequate.
6.15
Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.
6.16
Adjustments in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares
of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and prior to the Closing, each
reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account
for such event.
Securities Purchase Agreement | Page 35 |
6.17
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
of the obligations of any other Purchaser under any Transaction Document. The decision of each Purchaser to purchase Securities pursuant
to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently of any information,
materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition
(financial or otherwise) or prospects of the Company or any Subsidiary which may have been made or given by any other Purchaser or by
any agent or employee of any other Purchaser, and no Purchaser and any of its agents or employees shall have any liability to any other
Purchaser (or any other Person) relating to or arising from any such information, materials, statement or opinions. Nothing contained
herein or in any Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any
way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder
and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the Securities or enforcing
its rights under the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including
without limitation the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary
for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by
its own separate legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so
by any Purchaser.
6.18
Termination. This Agreement may be terminated and the sale and purchase of the Shares and Warrants abandoned at any time prior
to the Closing by either the Company or any Purchaser (with respect to itself only) upon written notice to the other, if the Closing
has not been consummated on or prior to 5:00 P.M., New York City time, on the Outside Date; provided, however, that the right
to terminate this Agreement under this Section 6.18 shall not be available to any Person whose failure to comply with its obligations
under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such time. Nothing in this
Section 6.18 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions
of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other
party of its obligations under this Agreement or the other Transaction Documents. In the event of a termination pursuant to this Section
6.18, the Company shall promptly notify all non-terminating Purchasers. Upon a termination in accordance with this Section 6.18,
the Company and the terminating Purchaser(s) shall not have any further obligation or liability (including arising from such termination)
to the other, and no Purchaser will have any liability to any other Purchaser under the Transaction Documents as a result therefrom.
6.19
Waiver of Conflicts. Each party to this Agreement acknowledges that Company Counsel, counsel for the Company and Faegre Drinker
Biddle & Reath LLP, counsel for the Placement Agent, may have in the past performed, and may continue to or in the future perform,
legal services for the Purchasers in matters that are similar, but not substantially related, to the transactions described in this Agreement,
including the representation of the Purchasers in financings and other matters. Accordingly, each party to this Agreement hereby acknowledges
that (a) they have had an opportunity to ask for information relevant to this disclosure, (b) Company Counsel represents only the Company
with respect to the Agreement and the transactions contemplated hereby and (c) Faegre Drinker Biddle & Reath LLP represents only
the Placement Agent with respect to the Agreement and the transactions contemplated hereby. Each Purchaser gives its informed consent
to Company Counsel and Faegre Drinker Biddle & Reath LLP’s representation of the Purchasers in matters not substantially related
to this Agreement, and the Purchasers give their informed consent to Company Counsel and Faegre Drinker Biddle & Reath LLP’s
representation of the Company and the Placement Agent, respectively, in connection with this Agreement and the transactions contemplated
hereby.
[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]
Securities Purchase Agreement | Page 36 |
IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.
|
BIOFRONTERA,
INC. |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
Securities Purchase Agreement | Page 37 |
|
NAME
OF PURCHASER: ____________________________ |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
Aggregate
Purchase Price (Subscription Amount): $_____________ |
|
|
|
Aggregate B-1 Preferred Shares Purchase Price (Preferred Share Subscription Amount): $_____________ |
|
|
|
Number
of B-1 Preferred Shares to be Acquired: _______________ |
|
|
|
Aggregate
Warrant
Purchase Price (Warrant Subscription Amount):
______________ |
|
Number of Warrants to Purchase B-3 Preferred Shares to be Acquired |
|
Tax
ID No.: ______________________ |
|
|
|
Address
for Notice: |
|
____________________________ |
|
|
|
____________________________ |
|
|
|
____________________________ |
|
|
|
Telephone
No.:________________________ |
|
|
|
Facsimile
No.:__________________________ |
|
|
|
E-mail
Address:__________________________ |
|
|
|
Attention:__________________________ |
Delivery
Instructions:
(if
different than above)
c/o
_______________________________ |
|
|
|
Street:
_____________________________ |
|
|
|
City/State/Zip:
_______________________ |
|
|
|
Attention:
__________________________ |
|
|
|
Telephone
No.: ___________________________ |
|
Securities Purchase Agreement | Page 38 |
EXHIBITS:
A: |
Form
of Warrant |
B: |
Certificate
of Designation |
C-1: |
Accredited
Investor Questionnaire |
C-2: |
Book
Entry Questionnaire |
D: |
Form
of Irrevocable Transfer Agent Instructions |
E: |
Form
of Secretary’s Certificate |
F: |
Form
of Officer’s Certificate |
G: |
Wire
Instructions |
H: |
Form
of Support Agreement |
SCHEDULES:
3.1(a) |
Subsidiaries |
3.1(g) |
Capitalization |
3.1(x) |
Registration Rights |
ANNEXES:
Annex
A: Selling Securityholder Notice and Questionnaire
Securities Purchase Agreement | Page 39 |
Exhibit
10.2
PLACEMENT
AGENCY AGREEMENT
February
19, 2024
Roth
Capital Partners, LLC
57
W 57th Street, 16th Floor
New
York, NY 10019
Ladies
and Gentlemen:
Introduction.
Subject to the terms and conditions herein (this “Agreement”), Biofrontera
Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of 6,586.373
shares (the “Shares”) of the Company’s Series B-1 Convertible Preferred Stock, $0.001 par value per share
(the “Series B-1 Preferred Stock”), and warrants to purchase up to an aggregate of 8,000 shares of Series B-3
Convertible Preferred Stock, $0.001 par value per share (the “Series B-3 Preferred Stock”) (the “Warrants”,
and the shares of Series B-3 Preferred Stock issuable upon exercise thereof, the “Warrant Shares”, and, together with
the Shares, the “Securities”) directly to various investors (each, an “Investor” and, collectively,
the “Investors”) through Roth Capital Partners, LLC, as placement agent (the “Placement Agent”).
The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including,
without limitation, a securities purchase agreement (the “Purchase Agreement”) and the Warrants, shall be collectively
referred to herein as the “Transaction Documents.” The purchase price to the Investors for each Share shall be
$1,000 and the purchase price for each Warrant shall be $176.703. The Placement Agent may retain other brokers or dealers
to act as sub-agents or selected-dealers on its behalf in connection with the Offering.
The
Company hereby confirms its agreement with the Placement Agent as follows:
Section
1. Agreement to Act as Placement Agent.
(a)
On the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and conditions
of this Agreement, the Placement Agent shall be the exclusive placement agent in connection with the offering and sale by the Company
of the Securities pursuant to the Purchase Agreement, with the terms of such offering (the “Offering”) to be subject
to market conditions and negotiations between the Company, the Placement Agent and the prospective Investors. The Placement Agent will
act on a reasonable best efforts basis and the Company agrees and acknowledges that there is no guarantee of the successful placement
of the Securities, or any portion thereof, in the prospective Offering. Under no circumstances will the Placement Agent or any of its
“Affiliates” (as defined below) be obligated to underwrite or purchase any of the Securities for its own account or otherwise
provide any financing. The Placement Agent shall act solely as the Company’s agent and not as principal. The Placement Agent shall
market the Securities only to “accredited investors” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9),
(a)(12), or (a)(13) under the Securities Act of 1933, as amended (the “Securities Act”). The Placement Agent shall
have no authority to bind the Company with respect to any prospective offer to purchase the Securities and the Company shall have the
sole right to accept offers to purchase the Securities and may reject any such offer, in whole or in part. Subject to the terms and conditions
hereof, payment of the purchase price for, and delivery of, the Securities shall be made at one or more closings (each a “Closing”
and the date on which each Closing occurs, a “Closing Date”). The Closing shall occur via “Delivery Versus Payment”,
i.e., on the Closing Date, the Company shall issue the Shares directly to the account designated by the Placement Agent and, upon receipt
of such Shares, the Placement Agent shall electronically deliver such Shares to the applicable Investor and payment shall be made by
the Placement Agent (or its clearing firm) by wire transfer to the Company. As compensation for services rendered, on each Closing Date,
the Company shall pay to the Placement Agent the fees and expenses set forth below:
(i)
A cash fee equal to 7.0% of the gross proceeds received by the Company from the sale of the Securities at the closing of the Offering
(the “Closing”).
(ii)
A cash fee equal to 7.0% of the gross proceeds received by the Company upon exercise of the Warrants.
(iii)
The Company also agrees to reimburse Placement Agent’s expenses (with supporting invoices/receipts), including, but not limited
to, the expenses of Placement Agent’s legal counsel, up to $125,000.
(b)
The term of the Placement Agent’s exclusive engagement will be as set forth in Section 1 of the Engagement Agreement (as defined
below) and end no earlier than March 31, 2024. Notwithstanding anything to the contrary contained herein, the provisions concerning confidentiality,
indemnification and contribution contained herein and the Company’s obligations contained in the indemnification provisions will
survive any expiration or termination of this Agreement, and the Company’s obligation to pay fees actually earned and payable and
to reimburse expenses actually incurred and reimbursable pursuant to Section 1 hereof and which are permitted to be reimbursed under
the applicable FINRA Rules, will survive any expiration or termination of this Agreement. Nothing in this Agreement shall be construed
to limit the ability of the Placement Agent or its Affiliates to pursue, investigate, analyze, invest in, or engage in investment banking,
financial advisory or any other business relationship with Persons (as defined below) other than the Company. As used herein (i) “Persons”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind and (ii) “Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.
Section
2. Representations, Warranties and Covenants of the Company. The Company hereby represents, warrants and covenants to the Placement
Agent as of the date hereof, and as of each Closing Date, unless such representation, warranty or agreement specifies a different date
or time, as follows:
(a)
Private Placement. Assuming the accuracy of the representations of the Investors in the Purchase Agreement, on the closing date(s)
and solely as this Section relates to the issue and sale of the Warrant Shares on the date(s) of exercise of the Warrants, the offer,
issue and sale of the Securities (assuming no change in applicable law prior to the date the Warrant Shares are issued), are and will
be exempt from the registration and prospectus delivery requirements of the Securities Act and have been or will be registered or qualified
(or are or will be exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable
state securities laws. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or
indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would require
registration under the Securities Act of the issuance of the Securities to the Investors in the Offering. The Shares, and upon the exercise
of the Warrants pursuant to their terms, and the Warrant Shares will be quoted on the Nasdaq Stock Market. Other than the Company’s
SEC Reports (as defined below), the Company has not distributed and will not distribute prior to any closing any offering material in
connection with the offering and sale of the Securities, unless such offering materials are provided to the Placement Agent prior to
or simultaneously with such delivery to the offerees of the Securities. The Company agrees that no Transaction Documents or materials
presented or distributed to the Potential Investors, including the Company’s SEC Reports, shall contain an untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading.
(b)
Assurances. Except for this Agreement and the Transaction Documents, as well as a Form 8-K related thereto which shall be timely
filed by the Company, there are no documents required to be filed with the Securities and Exchange Commission (the “Commission”)
in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or the
Exchange Act or (y) will not be filed within the requisite time period.
(c)
Offering Materials. Neither the Company nor any of its directors and officers has distributed and none of them will distribute,
prior to each Closing Date, any offering material in connection with the offering and sale of the Securities other than the Transaction
Documents.
(d)
Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth in the Company’s SEC Reports (as
defined below). The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free
and clear of any lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction (each,
a “Lien” and collectively, the “Liens”), and all of the issued and outstanding shares of capital
stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe
for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction
Documents shall be disregarded, and if the Company only has one Subsidiary all references to Subsidiaries shall be deemed to refer to
such Subsidiary.
(e)
Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in: (i) a material adverse effect on the results of operations, assets, business, prospects
or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (ii) a material adverse effect on the
Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i)
or (ii) , a “Material Adverse Effect”) and no action, claim, suit, investigation or proceeding (including, without
limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened (each, a “Proceeding”)
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.
(f)
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company’s stockholders in connection herewith or therewith
other than in connection with the Required Approvals (as hereinafter defined). This Agreement and each other Transaction Document to
which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the
terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.
(g)
No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.
(h)
Reliance. The Company has not relied upon the Placement Agent or legal counsel for the Placement Agent for any legal, tax or accounting
advice in connection with the offering and sale of the Securities.
(i)
Forward-Looking Statements. No forward-looking statements (within the meaning of Section 27A of the Securities Act and Section
21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) contained in the Company’s SEC
Reports has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.
(j)
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filing
for a Form D with the Commission, which shall be timely filed by the Company, (ii) such filings as are required to be made under applicable
state securities laws and (iii) the listing of additional shares notification to the Trading Market (as defined below) for the Securities
(collectively, the “Required Approvals”). “Trading Market” means any of the following markets or
exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market,
the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the Pink Open Market, OTCQB or the OTCQX (or
any successors to any of the foregoing).
(k)
Issuance of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer provided for in the Transaction Documents. The Warrant Shares and Conversion Shares (as defined in
the Purchase Agreement), when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction
Documents.
(l)
Transaction Document Representations. Each of the representations and warranties (together with any related disclosure schedules
thereto) and covenants made by the Company to the Investors in the Purchase Agreement is hereby incorporated herein by reference into
this Agreement (as though fully restated herein) and is, as of the date of the Purchase Agreement and as of the Closing Date, hereby
made to, and in favor of, the Placement Agent.
(m)
SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein
as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any
such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material
respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer
subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at
the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments.
(n)
Litigation. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an “Action”). None of the Actions set forth in the SEC Reports (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable
decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor to the knowledge
of the Company, any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability
under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company,
there is not pending or threatened, any investigation by the Commission of the Company or any current or former director or officer of
the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company or any Subsidiary under the Exchange Act or the Securities Act.
(o)
Certain Fees. Except for the fees payable by the Placement Agent in connection with the transactions contemplated by the Transaction
Documents, no brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiary to any broker,
financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. The Investors shall have no obligation with respect to any fees or with respect to any claims made by or
on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated
by the Transaction Documents.
(p)
Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and
the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as disclosed in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Common Stock is currently eligible for electronic transfer through
the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository
Trust Company (or such other established clearing corporation) in connection with such electronic transfer.
(q)
Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become applicable to the Investors as a result of the Investors and the Company fulfilling
their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company’s
issuance of the Securities and the Investors’ ownership of the Securities.
(r)
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Investors or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms
that the Investors will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure
furnished by or on behalf of the Company to the Investors regarding the Company and its Subsidiaries, their respective businesses and
the transactions contemplated hereby is true and correct and does not contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made,
not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as
a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading.
(s)
Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s assets exceeds
the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. The SEC Reports sets forth as of the date hereof all outstanding secured
and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes
of this Agreement, “Indebtedness” means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other
than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations
in respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s consolidated balance
sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions
in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to
be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.
(t)
Accountants. To the knowledge and belief of the Company, Marcum LLP (the “Accountants”) is a registered public
accounting firm as required by the Exchange Act.
(u)
No Disagreements with Accountants and Lawyers. There are no disagreements of any kind presently existing, or reasonably anticipated
by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company
is current with respect to any fees owed to its accountants and lawyers which could affect the Company’s ability to perform any
of its obligations under any of the Transaction Documents.
(v)
Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any
of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement agent in connection
with the placement of the Securities.
(w)
U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended.
(x)
Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the
“Federal Reserve”). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.
(y)
Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in
all material respects with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money
Laundering Laws”), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any
Subsidiary, threatened.
Section
3. Delivery and Payment. Each Closing shall occur at the offices of Faegre Drinker Biddle & Reath LLP, 200 Wells Fargo Center
90 S. Seventh Street, Minneapolis, Minnesota 55402 (“Placement Agent Counsel”) (or at such other place as shall be
agreed upon by the Placement Agent and the Company). Subject to the terms and conditions hereof, at each Closing payment of the purchase
price for the Securities sold on such Closing Date shall be made by Federal Funds wire transfer, against delivery of such Securities,
and such Securities shall be registered in such name or names and shall be in such denominations, as the Placement Agent may request
at least one business day before the Closing Date.
Deliveries
of the documents with respect to the purchase of the Securities, if any, shall be made at the offices of Placement Agent Counsel. All
actions taken at a Closing shall be deemed to have occurred simultaneously.
Section
4. Covenants and Agreements of the Company. The Company further covenants and agrees with the Placement Agent as follows:
(a)
Registration Statement Matters. The Company will advise the Placement Agent immediately prior to filing of any registration statement
(the “Registration Statement”) or any prospectus (a “Prospectus”) related to the Registrable Securities
(as defined in the Purchase Agreement) and promptly after it receives notice thereof of the time when any amendment to the Registration
Statement has been filed or becomes effective or any supplement to a Prospectus has been filed and will furnish the Placement Agent with
copies thereof. The Company will file promptly all reports and any definitive proxy or information statements required to be filed by
the Company with the Commission pursuant to Section 13(a), 14 or 15(d) of the Exchange Act subsequent to the date of any Prospectus and
for so long as the delivery of a prospectus is required in connection with the Offering. The Company will advise the Placement Agent,
promptly after it receives notice thereof (i) of any request by the Commission to amend the Registration Statement or to amend or supplement
any Prospectus or for additional information, and (ii) of the issuance by the Commission of any stop order suspending the effectiveness
of the Registration Statement or any post-effective amendment thereto or any order directed at any Company SEC Report, or any amendment
or supplement thereto or any order preventing or suspending the use of any Prospectus or any amendment or supplement thereto or any post-effective
amendment to the Registration Statement, of the suspension of the qualification of the Securities for offering or sale in any jurisdiction,
of the institution or threatened institution of any proceeding for any such purpose, or of any request by the Commission for the amending
or supplementing of the Registration Statement or a Prospectus or for additional information. The Company shall use its best efforts
to prevent the issuance of any such stop order or prevention or suspension of such use. If the Commission shall enter any such stop order
or order or notice of prevention or suspension at any time, the Company will use its best efforts to obtain the lifting of such order
at the earliest possible moment, or will file a new registration statement and use its best efforts to have such new registration statement
declared effective as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b),
430A, 430B and 430C, as applicable, under the Securities Act, including with respect to the timely filing of documents thereunder, and
will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) are received in a timely manner
by the Commission.
(b)
Blue Sky Compliance. The Company will cooperate with the Placement Agent and the Investors in endeavoring to qualify the Securities
for sale under the securities laws of such jurisdictions (United States and foreign) as the Placement Agent and the Investors may reasonably
request and will make such applications, file such documents, and furnish such information as may be reasonably required for that purpose,
provided the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in
any jurisdiction where it is not now so qualified or required to file such a consent, and provided further that the Company shall not
be required to produce any new disclosure document. The Company will, from time to time, prepare and file such statements, reports and
other documents as are or may be required to continue such qualifications in effect for so long a period as the Placement Agent may reasonably
request for distribution of the Securities. The Company will advise the Placement Agent promptly of the suspension of the qualification
or registration of (or any such exemption relating to) the Securities for offering, sale or trading in any jurisdiction or any initiation
or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration
or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment.
(c)
Copies of any Amendments and Prospectuses. The Company will furnish the Placement Agent, without charge, during the period beginning
on the date hereof and ending on the later of the last Closing Date of the Offering, as many copies of any Prospectus or prospectus supplement
and any amendments and supplements thereto, as the Placement Agent may reasonably request.
(d)
Transfer Agent. The Company will maintain, at its expense, a registrar and transfer agent for the Shares and Warrant Shares, as
well as the Common Stock.
(e)
Additional Documents. The Company will enter into any subscription, purchase or other customary agreements as the Placement
Agent or the Investors deem necessary or appropriate to consummate the Offering, all of which will be in form and substance reasonably
acceptable to the Placement Agent and the Investors. The Company agrees that the Placement Agent may rely upon, and each is a third party
beneficiary of, the representations and warranties, and applicable covenants, set forth in any such purchase, subscription or other agreement
with Investors in the Offering.
(f)
Reservation of Common Stock. As of the Closing Date, the Company has reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Series B-1 Preferred Stock, Series B-2 Preferred
Stock, Series B-3 Preferred Stock and Common Stock, to the extent the Series B-1 Preferred Stock, the Series B-2 Preferred Stock and
Series B-3 Preferred Stock may be converted into Common Stock as of the Closing Date, for the purpose of enabling the Company to issue
the Shares and the Warrant Shares pursuant to any exercise of the Warrants. Promptly following any increase in the number of shares of
Common Stock that the Series B-1 Preferred Stock, the Series B-2 Preferred Stock and Series B-3 Preferred Stock may be converted into,
the Company will reserve and keep available at all time, free of preemptive rights, a sufficient number of shares of Common Stock to
cover such increase.
(g)
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be otherwise be disclosed by the Company, the Company covenants and agrees that neither it, nor any other Person
acting on its behalf will provide any Investor or its agents or counsel with any information that constitutes, or the Company reasonably
believes constitutes, material non-public information, unless prior thereto such Investor shall have consented in writing to the receipt
of such information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms
that each Investor shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that
the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material,
non-public information to a Investor without such Investor’s consent, the Company hereby covenants and agrees that such Investor
shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Investor shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Company understands and confirms that each Investor shall be relying on the foregoing covenant in
effecting transactions in securities of the Company.
(h)
Use of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder as set forth in the Purchase
Agreement.
(i)
Listing of Common Stock. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock
on the Trading Market on which it is currently listed. The Company will take all reasonable action necessary to continue the listing
and trading of its Common Stock on a Trading Market and will comply in all respects with the Company’s reporting, filing and other
obligations under the bylaws or rules of the Trading Market. The Company agrees to take all reasonable action to maintain the eligibility
of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including,
without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection
with such electronic transfer.
(j)
Subsequent Equity Sales.
(i)
From the date hereof until 90 days after the Closing Date (the “Restricted Period”), unless otherwise consented to
by the Placement Agent, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance
or proposed issuance of any shares of Common Stock or Common Stock Equivalents (as defined below) or (ii) file any registration statement
or amendment or supplement thereto, other than as required by the Purchase Agreement or filing a registration statement on Form S-8 in
connection with any employee benefit plan or a post-effective amendment to its registration statement in connection with the publicly
traded warrants (File No. 333-257722), provided the sole purpose of such post-effective amendment is to update the registration statement
to permit forward incorporation by reference.
(ii)
From the date hereof until 180 days after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement
to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units
thereof) involving a Variable Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company
(i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to
receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based
upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of
such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date
after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit or an “at-the-market offering”, whereby the Company may issue securities
at a future determined price. Any Investor shall be entitled to obtain injunctive relief against the Company to preclude any such issuance,
which remedy shall be in addition to any right to collect damages.
(iii)
Notwithstanding the foregoing, this Section 4(n) shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction
shall be an Exempt Issuance.
(iv)
The term “Exempt Issuance” means: (i) the issuance of shares of Common Stock or securities convertible into or exercisable
for shares of Common Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants
or options (including net exercise) or the issuance of shares of Common Stock underlying restricted stock units (“RSUs”)
or performance stock units (“PSUs”) (including net settlement), in each case outstanding on the date of this Agreement
and described in the SEC Reports; (ii) grants of stock options, stock awards, restricted stock, RSUs, PSUs, or any other equity awards
and the issuance of shares of Common Stock or securities convertible into or exercisable or exchangeable for shares of Common Stock (whether
upon the exercise of stock options or otherwise) to the Company’s employees, officers, directors, advisors, or consultants pursuant
to the terms of an equity compensation plan in effect as of the Closing Date and described in the SEC Reports; provided that, in each
case, such recipients who are directors or executive officers have delivered a lock-up agreement to the Placement Agent substantially
in the form of Exhibit A hereto (the Lock-Up Agreement”); and (iii) the issuance of shares of Common Stock or securities
convertible into or exercisable for shares of Common Stock in connection with the Company entering into an agreement providing for the
acquisition by the Company of the securities, business, or other assets of another person or entity or pursuant to an employee benefit
plan assumed by the Company in connection with such acquisition, whether entered into during or prior to the Restricted Period; provided
that the total number of shares of Common Stock issued pursuant to this clause (iii) shall not exceed 10% of the total number of shares
of the Company’s Common Stock issued and outstanding immediately following the completion of the transactions contemplated by this
Agreement (determined on a fully diluted basis and as adjusted for stock splits, stock dividends and other similar events after the date
hereof); provided, further, that the recipients of any shares of Common Stock or securities convertible into or exercisable for shares
of Common Stock issued pursuant to this clause (iii) during the Restricted Period shall enter into an agreement substantially in the
form of Exhibit A hereto with respect to the remaining portion of the Restricted Period on or prior to the date of such issuance.
(v)
“Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder
thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.
(k)
Furnishing of Information. Until the earliest of the time that (i) no Investor owns Securities or (ii) the Warrants have expired,
the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the
reporting requirements of the Exchange Act.
(l)
Lock-Up Agreements. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except
to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If
any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek
specific performance of the terms of such Lock-Up Agreement.
(m)
Warrant and Conversion Shares. If all or any portion of a Warrant is exercised or the Shares are converted at a time when there
is an effective registration statement to cover the issuance or resale of the Warrant Shares if the Warrant is exercised via cashless
exercise or the Conversion Shares, the Warrant Shares and Conversion Shares issued pursuant to any such exercise shall be issued free
of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering
the sale or resale of the Warrant Shares or Conversion Shares) is not effective or is not otherwise available for the sale or resale
of the Warrant Shares and/or Conversion Shares, the Company shall immediately notify the holders of the Warrants and/or Shares in writing
that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement
is effective again and available for the sale or resale of the Warrant Shares and/or Conversion Shares (it being understood and agreed
that the foregoing shall not limit the ability of the Company to issue, or any Investor to sell, any of the Warrant Shares and/or Conversion
Shares in compliance with applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement
(including the Registration Statement) registering the issuance or resale of the Warrant Shares and/or Conversion Shares effective during
the term of the Warrants and/or while the Shares are outstanding.
(n)
No Manipulation of Price. The Company will not take, directly or indirectly, any action designed to cause or result in,
or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities
of the Company.
(o)
Acknowledgment. The Company acknowledges that any advice given by the Placement Agent to the Company is solely for the benefit
and use of the Board of Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without the Placement
Agent’s prior written consent.
(p)
Securities Law Disclosure; Publicity. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company
shall have publicly disclosed all material, non-public information delivered to any of the Investors by the Company or any of its Subsidiaries,
or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent,
in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press
release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written
or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees, Affiliates or
agents, including, without limitation, the Placement Agent, on the one hand, and any of the Investor or any of their Affiliates on the
other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Investor shall rely
on the foregoing covenant in effecting transactions in securities of the Company. Notwithstanding the foregoing, the Company shall not
publicly disclose the name of any Investor, or include the name of any Investor in any filing with the Commission or any regulatory agency
or Trading Market, without the prior written consent of such Investor, except (a) as required by federal securities law in connection
with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading
Market regulations, in which case the Company shall provide the Investors with prior notice of such disclosure permitted under this clause
(b) and reasonably cooperate with such Investors regarding such disclosure. “Disclosure Time” means, (i) if this Agreement
is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any
Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as
to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New
York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to
an earlier time by the Placement Agent.
(q)
Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Investor is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Investor could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under
the Transaction Documents.
(r)
Announcement of Offering. The Company acknowledges and agrees that the Placement Agent and its counsel may, subsequent to the
Closing, make public its involvement with the Offering.
(s)
Reliance on Others. The Company confirms that it will rely on its own counsel and accountants for legal and accounting advice.
(t)
Research Matters. By entering into this Agreement, the Placement Agent does not
provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby
acknowledges and agrees that the Placement Agent’s selection as a placement agent for the Offering was in no way conditioned, explicitly
or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e),
the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating
or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt
of business or compensation.
Section
5. Conditions of the Obligations of the Placement Agent. The obligations of the Placement Agent hereunder shall be subject to the
accuracy of the representations and warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date
hereof and as of each Closing Date as though then made, to the timely performance by each of the Company of its covenants and other obligations
hereunder on and as of such dates, and to each of the following additional conditions:
(a)
Intentionally Omitted.
(b)
No Stop Order. No order having the effect of ceasing or suspending the distribution of the Securities or any other securities
of the Company shall have been issued by any securities commission, securities regulatory authority or stock exchange and no proceedings
for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company, contemplated by any securities commission,
securities regulatory authority or stock exchange; all requests for additional information on the part of the Commission shall have been
complied with.
(c)
Corporate Proceedings. All corporate proceedings and other legal matters in connection with this Agreement and the Purchase Agreement,
and the sale and delivery of the Securities, shall have been completed or resolved in a manner reasonably satisfactory to the Placement
Agent’s counsel, and such counsel shall have been furnished with such papers and information as it may reasonably have requested
to enable such counsel to pass upon the matters referred to in this Section 5.
(d)
No Material Adverse Change. Subsequent to the execution and delivery of this Agreement and prior to each Closing Date, in the
Placement Agent’s sole judgment after consultation with the Company, there shall not have occurred any Material Adverse Effect
or any material adverse change or development involving a prospective material adverse change in the condition or the business activities,
financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Purchase Agreement (“Material
Adverse Change”).
(e)
Opinion of Counsel for the Company. The Placement Agent shall have received on each Closing Date the favorable opinion of McGuireWoods
LLP, counsel to the Company, dated as of such Closing Date, including, without limitation, a negative assurance letter addressed to the
Placement Agent and in form and substance satisfactory to the Placement Agent.
(f)
Officers’ Certificate. The Placement Agent shall have received on each Closing Date a certificate of the Company, dated
as of such Closing Date, signed by the Chief Executive Officer and Chief Financial Officer of the Company, to the effect that, and the
Placement Agent shall be satisfied that, the signers of such certificate have reviewed the Purchase Agreement, and this Agreement and
to the further effect that:
(i)
The representations and warranties of the Company in this Agreement and the Purchase Agreement are true and correct, as if made on and
as of such Closing Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed
or satisfied at or prior to such Closing Date;
(ii)
No order having the effect of ceasing or suspending the distribution of the Securities or any other securities of the Company has been
issued by any securities commission, securities regulatory authority or stock exchange in the United States and no proceedings for that
purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission, securities
regulatory authority or stock exchange in the United States;
(iii)
At the time of sale, and at all times subsequent thereto up to the delivery of such certificate, the Company’s SEC Reports, when
such documents were filed with the Commission, contained all material information required to be included therein by the Securities Act
and the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and in all material respects
conformed to the requirements of the Securities Act and the Exchange Act and the applicable rules and regulations of the Commission thereunder,
as the case may be, and the Company’s SEC Reports, did not and do not include any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading; and
(iv)
Subsequent to filing of the Company’s last Quarterly Report on Form 10-Q, there has not been: (a) any Material Adverse Change;
(b) any transaction that is material to the Company and the Subsidiaries taken as a whole, except transactions entered into in the ordinary
course of business; (c) any obligation, direct or contingent, that is material to the Company and the Subsidiaries taken as a whole,
incurred by the Company or any Subsidiary, except obligations incurred in the ordinary course of business; (d) any material change in
the capital stock (except changes thereto resulting from the exercise of outstanding stock options or warrants) or outstanding indebtedness
of the Company or any Subsidiary; (e) any dividend or distribution of any kind declared, paid or made on the capital stock of the Company;
or (f) any loss or damage (whether or not insured) to the property of the Company or any Subsidiary which has been sustained or will
have been sustained which has a Material Adverse Effect.
(g)
Stock Exchange Listing. The Common Stock shall be registered under the Exchange Act and shall be listed on the Trading Market,
and the Company shall not have taken any action designed to terminate, or likely to have the effect of terminating, the registration
of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market, nor shall
the Company have received any information suggesting that the Commission or the Trading Market is contemplating terminating such registration
or listing except as disclosed in the Company’s SEC Reports.
(h)
Lock-Up Agreements. On the Closing Date, the Placement Agent shall have received the executed lock-up agreement, in the form attached
hereto as Exhibit A, from each of the directors and officers of the Company.
(i)
CFO Certificate. On the date hereof and on each Closing Date, the Company shall have furnished to the Placement Agent, a certificate,
dated as of such date, signed on behalf of the Company by its chief financial officer, regarding certain financial information included
in any Company SEC Report or in certain materials related to the Offering, in form and substance reasonably satisfactory to the Placement
Agent.
(j)
Additional Documents. On or before each Closing Date, the Placement Agent and counsel for the Placement Agent shall have received
such information and documents as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of
the Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction
of any of the conditions or agreements, herein contained.
If
any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Placement Agent by notice to the Company at any time on or prior to a Closing Date, which termination shall be without liability
on the part of any party to any other party, except that Section 6 (Payment of Expenses), Section 7 (Indemnification and Contribution)
and Section 8 (Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive such termination.
Section
6. Payment of Expenses. In addition to the expenses set forth in 1(a)(ii), the Company agrees to pay all costs, fees and expenses
incurred by the Company in connection with the performance of its obligations hereunder and in connection with the transactions contemplated
hereby, including, without limitation: (i) all expenses incident to the issuance, delivery and qualification of the Securities (including
all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Common Stock; (iii) all necessary
issue, transfer and other stamp taxes in connection with the issuance and sale of the Securities; (iv) all fees and expenses of the Company’s
counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with
the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits,
schedules, consents and certificates of experts), any Prospectus, and all amendments and supplements thereto, and this Agreement; (vi)
all filing fees, reasonable attorneys’ fees and expenses incurred by the Company or the Placement Agent in connection with qualifying
or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Securities for offer and sale
under the state securities or blue sky laws or the securities laws of any other country, and, if requested by the Placement Agent, preparing
and printing a “Blue Sky Survey,” an “International Blue Sky Survey” or other memorandum, and any
supplements thereto, advising the Placement Agent of such qualifications, registrations and exemptions; provided, however, that
any such fees shall be subject to the overall expense cap set forth in Section 1(a)(ii); (vii) the filing fees incident to the review
and approval by the Financial Industry Regulatory Authority of the Placement Agent’s participation in the offering and distribution
of the Securities; (viii) the fees and expenses associated with including the Warrant Shares and the Conversion Shares on the Trading
Market; and (viii) all other fees, costs and expenses referred to in the Purchase Agreement.
Section
7. Indemnification and Contribution.
(a)
The Company agrees to indemnify and hold harmless the Placement Agent, its affiliates and each person controlling the Placement Agent
(within the meaning of Section 15 of the Securities Act), and the directors, officers, agents and employees of the Placement Agent, its
affiliates and each such controlling person (the Placement Agent, and each such entity or person. an “Indemnified Person”)
from and against any losses, claims, damages, judgments, assessments, costs and other liabilities (collectively, the “Liabilities”),
and shall reimburse each Indemnified Person for all reasonable, documented out-of-pocket fees and expenses (including the reasonable,
documented out-of-pocket fees and expenses of one counsel for all Indemnified Persons, except as otherwise expressly provided herein)
(collectively, the “Expenses”) as they are incurred by an Indemnified Person in investigating, preparing, pursuing
or defending any Actions, whether or not any Indemnified Person is a party thereto, (i) caused by, or arising out of or in connection
with, any untrue statement or alleged untrue statement of a material fact contained in the Transaction Documents or by any omission or
alleged omission to state therein a material fact necessary to make the statements therein, in light of the circumstances under which
they were made, not misleading or (ii) otherwise arising out of or in connection with advice or services rendered or to be rendered by
any Indemnified Person pursuant to this Agreement and the Transaction Documents, the transactions contemplated thereby or any Indemnified
Person’s actions or inactions in connection with any such advice, services or transactions; provided, however, that,
in the case of clause (ii) only, the Company shall not be responsible for any Liabilities or Expenses of any Indemnified Person that
are finally judicially determined to have resulted solely from such Indemnified Person’s (x) gross negligence or willful misconduct
in connection with any of the advice, actions, inactions or services referred to above or (y) use of any offering materials or information
concerning the Company in connection with the offer or sale of the Securities in the Offering which were not authorized for such use
by the Company and which use constitutes gross negligence or willful misconduct. The Company also agrees to reimburse each Indemnified
Person for all Expenses as they are incurred in connection with enforcing such Indemnified Person’s rights under this Agreement.
(b)
Upon receipt by an Indemnified Person of actual notice of an Action against such Indemnified Person with respect to which indemnity may
be sought under this Agreement, such Indemnified Person shall promptly notify the Company in writing; provided that failure by any Indemnified
Person so to notify the Company shall not relieve the Company from any liability which the Company may have on account of this indemnity
or otherwise to such Indemnified Person, except to the extent the Company shall have been prejudiced by such failure. The Company shall,
if requested by the Placement Agent, assume the defense of any such Action including the employment of counsel reasonably satisfactory
to the Placement Agent, which counsel may also be counsel to the Company. Any Indemnified Person shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Indemnified Person unless: (i) the Company has failed promptly to assume the defense and employ counsel or (ii) the named parties
to any such Action (including any impeded parties) include such Indemnified Person and the Company, and such Indemnified Person shall
have been advised in the reasonable opinion of counsel that there is an actual conflict of interest that prevents the counsel selected
by the Company from representing both the Company (or another client of such counsel) and any Indemnified Person; provided that the Company
shall not in such event be responsible hereunder for the fees and expenses of more than one firm of separate counsel for all Indemnified
Persons in connection with any Action or related Actions, in addition to any local counsel. The Company shall not be liable for any settlement
of any Action effected without its written consent (which shall not be unreasonably withheld). In addition, the Company shall not, without
the prior written consent of the Placement Agent (which shall not be unreasonably withheld), settle, compromise or consent to the entry
of any judgment in or otherwise seek to terminate any pending or threatened Action in respect of which indemnification or contribution
may be sought hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination
includes an unconditional release of each Indemnified Person from all Liabilities arising out of such Action for which indemnification
or contribution may be sought hereunder. The indemnification required hereby shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable.
(c)
In the event that the foregoing indemnity is unavailable to an Indemnified Person other than in accordance with this Agreement, the Company
shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect
(i) the relative benefits to the Company, on the one hand, and to the Placement Agent and any other Indemnified Person, on the other
hand, of the matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding clause is not permitted
by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand, and the Placement Agent
and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate,
as well as any other relevant equitable considerations; provided that in no event shall the Company contribute less than the amount necessary
to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in excess of the amount of
fees actually received by the Placement Agent pursuant to this Agreement. For purposes of this paragraph, the relative benefits to the
Company, on the one hand, and to the Placement Agent on the other hand, of the matters contemplated by this Agreement shall be deemed
to be in the same proportion as (a) the total value paid or contemplated to be paid to or received or contemplated to be received by
the Company in the transaction or transactions that are within the scope of this Agreement, whether or not any such transaction is consummated,
bears to (b) the fees paid to the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation
within the meaning of Section 11(f) of the Securities Act, as amended, shall be entitled to contribution from a party who was not guilty
of fraudulent misrepresentation.
(d)
The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or otherwise)
to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement,
the transactions contemplated thereby or any Indemnified Person’s actions or inactions in connection with any such advice, services
or transactions except for Liabilities (and related Expenses) of the Company that are finally judicially determined to have resulted
solely from such Indemnified Person’s gross negligence or willful misconduct in connection with any such advice, actions, inactions
or services.
(i)
The reimbursement, indemnity and contribution obligations of the Company set forth herein shall apply to any modification of this Agreement
and shall remain in full force and effect regardless of any termination of, or the completion of any Indemnified Person’s services
under or in connection with, this Agreement.
Section
8. Representations and Indemnities to Survive Delivery. The respective indemnities, agreements, representations, warranties and other
statements of the Company or any person controlling the Company, of its officers, and of the Placement Agent set forth in or made pursuant
to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Placement Agent,
the Company, or any of its or their partners, officers or directors or any controlling person, as the case may be, and will survive delivery
of and payment for the Securities sold hereunder and any termination of this Agreement. A successor to a Placement Agent, or to the Company,
its directors or officers or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution and
reimbursement agreements contained in this Agreement.
Section
9. Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered, e-mailed or telecopied and confirmed
to the parties hereto as follows:
If
to the Placement Agent to the address set forth above, attention: Head of Equity Capital Markets, e-mail: rothecm@roth.com
With
a copy to:
Faegre
Drinker Biddle & Reath LLP
200
Wells Fargo Center
90
S. Seventh Street
Minneapolis,
Minnesota 55402
Attention:
Jonathon R. Zimmerman and Tyler J. Vivian
E-mail:
Jonathan.zimmerman@faegredrinker.com
If
to the Company:
Biofrontera
Inc.
120
Presidential Way, Suite 330
Woburn,
Massachusetts 01801
Attention:
E. Fred Leffler, III
Email:
f.leffler@bfinc.com
With
a copy to:
McGuireWoods
LLP
1251
Avenue of the Americas, 20th Floor
New
York, New York 10020-1104
Attention:
Stephen E. Older, Esq.
Email:
solder@mcguirewoods.com
Any
party hereto may change the address for receipt of communications by giving written notice to the others.
Section
10. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees,
officers and directors and controlling persons referred to in Section 7 hereof, and to their respective successors, and personal representative,
and no other person will have any right or obligation hereunder.
Section
11. Partial Unenforceability. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not
affect the validity or enforceability of any other section, paragraph or provision hereof. If any Section, paragraph or provision of
this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.
Section
12. Governing Law Provisions. This Agreement shall be deemed to have been made and delivered in New York City and both this engagement
letter and the transactions contemplated hereby shall be governed as to validity, interpretation, construction, effect and in all other
respects by the internal laws of the State of New York, without regard to the conflict of laws principles thereof. Each of the Placement
Agent and the Company: (i) agrees that any legal suit, action or proceeding arising out of or relating to this engagement letter and/or
the transactions contemplated hereby shall be instituted exclusively in New York Supreme Court, County of New York, or in the United
States District Court for the Southern District of New York, (ii) waives any objection which it may have or hereafter to the venue of
any such suit, action or proceeding, and (iii) irrevocably consents to the jurisdiction of the New York Supreme Court, County of New
York, and the United States District Court for the Southern District of New York in any such suit, action or proceeding. Each of the
Placement Agent and the Company further agrees to accept and acknowledge service of any and all process which may be served in any such
suit, action or proceeding in the New York Supreme Court, County of New York, or in the United States District Court for the Southern
District of New York and agrees that service of process upon the Company mailed by certified mail to the Company’s address shall
be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service of process
upon the Placement Agent mailed by certified mail to the Placement Agent’s address shall be deemed in every respect effective service
process upon the Placement Agent, in any such suit, action or proceeding. Notwithstanding any provision of this engagement letter to
the contrary, the Company agrees that neither the Placement Agent nor its affiliates, and the respective officers, directors, employees,
agents and representatives of the Placement Agent, its affiliates and each other person, if any, controlling the Placement Agent or any
of its affiliates, shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection
with the engagement and transaction described herein except for any such liability for losses, claims, damages or liabilities incurred
by us that are finally judicially determined to have resulted from the willful misconduct or gross negligence of such individuals or
entities. If either party shall commence an action or proceeding to enforce any provision of this Agreement, then the prevailing party
in such action or proceeding shall be reimbursed by the other party for its reasonable attorney’s fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.
Section
13. General Provisions.
(a)
This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous
oral agreements, understandings and negotiations with respect to the subject matter hereof. Notwithstanding anything herein to the contrary,
the Engagement Agreement, dated March 24, 2023, as amended by that certain Amendment to Engagement Letter, dated October 23, 2023 (the
“Engagement Agreement”), between the Company and Roth Capital Partners, LLC shall continue to be effective and the
terms therein shall continue to survive and be enforceable by the Placement Agent in accordance with its terms, provided that, in the
event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms of this Agreement shall prevail. This
Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties
hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant
to benefit. Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation
of this Agreement.
(b)
The Company acknowledges that in connection with the offering of the Securities: (i) the Placement Agent has acted at arm’s length,
are not agents of, and owe no fiduciary duties to the Company or any other person, (ii) the Placement Agent owes the Company only those
duties and obligations set forth in this Agreement and (iii) the Placement Agent may have interests that differ from those of the Company.
The Company waives to the full extent permitted by applicable law any claims it may have against the Placement Agent arising from an
alleged breach of fiduciary duty in connection with the offering of the Securities
[The
remainder of this page has been intentionally left blank.]
If
the foregoing is in accordance with your understanding of our agreement, please sign below whereupon this instrument, along with all
counterparts hereof, shall become a binding agreement in accordance with its terms.
|
Very truly yours, |
|
|
|
|
biofrontera INC., |
|
a Delaware corporation |
|
|
|
|
By: |
/s/
Hermann Luebbert |
|
Name: |
Hermann Luebbert |
|
Title: |
CEO
and President |
The
foregoing Placement Agency Agreement is hereby confirmed and accepted as of the date first above written.
roth capital partners, LLC |
|
|
|
|
By: |
/s/
Benjamin Bowen |
|
Name: |
Benjamin Bowen, Ph.D. |
|
Title: |
Managing Director, Investment Banking |
|
EXHIBIT
A
[See
Attached.]
Exhibit 99.1
Biofrontera
Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules
| Ø | Company
closed financing of $8.0 million with an additional $8.0 million second
tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules |
| Ø | Funding
and recent restructuring of supply agreement allow Biofrontera Inc. to assume
R&D activities and to support further commercial growth |
WOBURN,
MA / ACCESSWIRE / February 23, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (“Biofrontera” or the “Company”),
a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that it has closed
on a securities purchase agreement with healthcare-focused institutional investors led by Rosalind Advisors as of February
22, 2024. Pursuant to the securities purchase agreements, the Company issued to the purchasers (a) an aggregate $8.0
million in shares of the company’s Series B-1 Convertible Preferred Stock and (b) warrants to purchase shares of the Company’s
Series B-3 Convertible Preferred Stock with an aggregate exercise price of $8.0 million exercisable until the earlier of
(i) five days after achievement of certain operational and commercial milestones, expected in Q2 of 2024, the approval
by the Company’s stockholders of an increase in authorized shares and other proposals, and the effectiveness of a registration
statement with the U.S. Securities and Exchange Commission covering the resale of the Common Stock underlying all shares preferred stock that may be issued under the securities purchase agreement or (ii) the five-year anniversary of the
issuance of the warrants.
Shares
of Series B-1 were issued at a price of $1,000.00 and Series B-3 Convertible Preferred Stock will be issued at a price of $1,000.00
per share. Conversion of all of the shares of Series B-3 Convertible Preferred Stock into shares of common stock of the Company is subject
to approval by the Company’s stockholders of an increase in the Company’s authorized shares of common stock. The Investors
may convert shares of Series B-1 Convertible Preferred Stock into an aggregate of
9,310,677 shares of common stock at a conversion price of $0.7074, subject to certain limitations on beneficial ownership.
The shares of Series B-3 Convertible Preferred Stock to be issued upon exercise of all
of the warrants are convertible into 11,309,019 shares of common stock (disregarding
any conversion or beneficial ownership limitations) at a conversion price of $0.7074. The consideration for each warrant was $0.125 per share of common stock that each share of Series B-3 Convertible
Preferred Stock may be converted into.
Biofrontera
received $8.0M as of closing and anticipates an additional $8.0M upon meeting the criteria associated with the B-3 warrants and the
subsequent exercise. These amounts are before deducting fees to the placement agents and other estimated offering expenses payable
by the Company. Roth Capital Partners acted as the exclusive agent for the private placement.
The
Company intends to use the upfront net proceeds from the private placement to fund the Company’s general business operations and
ongoing activities related to expediting the development and approval of additional indications for the Company’s lead product
Ameluz. The product is currently approved in conjunction with the BF-RhodoLED lamp series for the treatment of mild to moderate actinic
keratosis on the face and scalp (AK).
The
securities to be issued in connection with the private placement described above are being offered in a private placement under Section
4(a)(2) of the Securities Act of 1933 and Regulation D promulgated thereunder and have not been registered under the Act or applicable
state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration
statement or an applicable exemption from the registration requirements of the Securities Act of 1933 and such applicable state securities
laws. The Company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission (SEC), for purposes
of registering the resale of the common stock issued or issuable in connection with the private placement.
This
press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
For
further information, please see the Company’s current report on Form 8-K to be filed with the SEC following the closing of the transaction.
About
Actinic Keratosis
Actinic
keratosis (AK) is the most common pre-cancerous skin lesion caused by chronic sun exposure that may, if left untreated, develop into
life-threatening skin cancer called squamous cell carcinoma. AKs typically appear on sun-exposed areas such as the face, bald scalp,
arms or the back of the hands. In 2020 approximately 58 million people in the US were affected by AK and 13 million AK treatments were
performed.3
About
Biofrontera Inc.
Biofrontera
Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of products for the treatment of dermatologic conditions with
a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com
and follow Biofrontera on LinkedIn and Twitter.
Forward-Looking
Statements
Certain
statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private
Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to
the closing of the described private placement of securities . We have based these forward-looking statements on our current expectations
and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations
disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control,
including, but not limited to, the impact of any extraordinary external events; any changes in the Company’s relationship with
its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s
ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s
ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the
coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation
and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials
of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will
be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications
for marketing approvals; whether the market opportunity for Ameluz® in combination with BF- RhodoLED® is
consistent with the Company’s expectations; the Company’s ability to comply with public company requirements; the Company’s
ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that
may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned
not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s
current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in this press release except as required by law.
Contact:
Barwicki
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
SOURCE:
Biofrontera Inc.
View
the original press release on accesswire.com
v3.24.0.1
Cover
|
Feb. 19, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Feb. 19, 2024
|
Current Fiscal Year End Date |
--12-31
|
Entity File Number |
001-40943
|
Entity Registrant Name |
Biofrontera
Inc.
|
Entity Central Index Key |
0001858685
|
Entity Tax Identification Number |
47-3765675
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
120
Presidential Way
|
Entity Address, Address Line Two |
Suite
330
|
Entity Address, City or Town |
Woburn
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
01801
|
City Area Code |
(781)
|
Local Phone Number |
245-1325
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Entity Information, Former Legal or Registered Name |
Not
Applicable
|
Common Stock Par Value 0. 001 Per Share [Member] |
|
Title of 12(b) Security |
Common
stock, par value $0.001 per share
|
Trading Symbol |
BFRI
|
Security Exchange Name |
NASDAQ
|
Preferred Stock Purchase Rights [Member] |
|
Title of 12(b) Security |
Preferred
Stock Purchase Rights
|
Security Exchange Name |
NASDAQ
|
Warrants To Purchase Common Stock [Member] |
|
Title of 12(b) Security |
Warrants
to purchase common stock
|
Trading Symbol |
BFRIW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_CommonStockParValue0.001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_PreferredStockPurchaseRightsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_WarrantsToPurchaseCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
From Sep 2023 to Sep 2024